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Epilepsy is a chronic neurological disorder characterized by unpredicted recurrent 
seizures. Dysfunction of GABA-A receptors (GABA-ARs) in the brain plays a key role 
in the pathophysiology of epilepsy. Neurosteroids are powerful allosteric agonists of 
GABA-ARs and are more efficacious on extrasynaptic  subunit-containing GABA-ARs 
that mediate tonic inhibition. Endogenous neurosteroids such as allopregnanolone (AP) 
have broad-spectrum anticonvulsant activity and possess therapeutic potential for 
epilepsy. There are many synthetic neurosteroids in trials. Ganaxolone (GX) is the 3-
methylated synthetic analog of AP. Although GX was previously tested in recombinant 
GABA-ARs, its precise mechanisms of action on native neurons in the brain, including 
its ability to modulate extrasynaptic δGABA-ARs, and its interactions with other 
molecules, remain unknown.  
The main objective of this dissertation is to investigate the molecular, cell-specific, and 
phosphorylation-dependent mechanisms of action of synthetic neurosteroid GX and 
related neurosteroid agents at extrasynaptic δGABA-ARs using pharmacological, 
electrophysiological, and behavioral approaches. In addition, structure-activity 
relationships of analogs are tested in native neurons. Several GABA-AR subunits 
contain phosphorylation sites regulated by protein kinases. Therefore, this study 
examines the influences of protein kinase activity on neurosteroid actions in native 
neurons. In addition, we explore the physiological interactions between neurosteroids 
and zinc and the potential combination strategy of neurosteroids with other clinical 
GABAergic agents. 
We established concentration-response profiles of GX in two cell types: (i) -abundant 
dentate gyrus granule cells (DGGCs) and (ii) -rich CA1 pyramidal cells (CA1PCs). Our 
results show that GX and analogs are preferential allosteric modulators and direct 
activators of extrasynaptic GABA-ARs regulating network inhibition and seizures in 




protein kinase C activity-mediated. Zinc concentration-dependently blocks GX-
potentiated GABA-gated currents in DGGCs and CA1PCs. Zinc reduces antiseizure 
activity of GX by the selective blockade of extrasynaptic GABA-AR-mediated tonic 
inhibition in the hippocampus. Combination therapies of neurosteroids with clinically 
used antiepileptic drugs tiagabine and midazolam exhibit strong synergistic effects on 
antiseizure activity and hippocampal tonic inhibition. Overall, these findings signify a 
unique role for extrasynaptic δGABA-ARs as key modulators of excitability in the brain 
and provide valuable mechanistic rationales for the clinical synergistic potential of 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW
*
 
I. Introduction       
Alterations in the structure and function of neurotransmitter receptors play critical roles 
in the pathophysiology of many brain diseases. Epilepsy is one of the most widespread 
and debilitating neurological disorders that affects approximately 3.4 million people in 
the USA and 65 million people worldwide. This disorder is a chronic condition 
characterized by two or more unpredicted and unprovoked seizures occurring due to 
excessive or hypersynchronous electrical discharge of neurons in the brain (Hauser 1994; 
Thurman et al., 2011; Hesdorffer et al., 2013). Many subregions and a wide variety of 
neurotransmitters are involved in the pathology of epileptic seizures. The GABA-A 
receptor (GABA-AR), a subtype of receptor activated by the inhibitory neurotransmitter 
GABA, is a prime target for many seizure medications. While antiepileptic drugs (AEDs) 
allow for symptomatic control of seizures, epilepsy remains incurable, partially due to 
our poor understanding of the molecular and electrophysiological basis of epilepsy 
development. Advances in our understanding of the pathology of epilepsy are crucial for 
discovering effective treatments for epilepsy and related brain disorders.   
Current knowledge indicates that approximately 60% of epilepsy is idiopathic, and 40% 
stems from developmental or acquired conditions such as a stroke, traumatic brain injury, 
infections, tumor, drug withdrawal, neurotoxicity, or prolonged seizures and genetic 
defects (Eslami et al., 2015; Pitkanen et al., 2015; Vezzani et al., 2016). The underlying 
mechanisms that render a normal brain to progressively develop into a brain with 
recurring seizures are still elusive. Along with age- and gender-related factors, other 
physiological abnormalities in neurotransmitter release, functions of ion channels, 
                                                 
*Reprinted (adapted) with permission from “Genetic and molecular regulation of extrasynaptic GABA-A 
receptors in the brain: therapeutic insights for epilepsy” by S-H Chuang and DS Reddy, 2018. The journal 
of pharmacology and experimental therapeutics, 364(2): 180197, Figures 1  6, Table 1  4, Copyright ©  




synaptic connectivity, neural circuitries, or the interaction of these factors facilitate 
seizure development. The term “epileptogenesis” is used to describe the complicated 
process of the development of acquired epilepsy. Epileptogenesis denotes a plastic 
progression in which the balance of neuronal excitation/inhibition, neuronal 
interconnections, and neuronal circuits undergo gradual changes during or after a series 
of insults, and consequently, transform a normal brain into one that is hyperexcitable, 
suffers neuronal loss and damage, and, as a result, has recurrent spontaneous seizures.  
In this review, we describe briefly the emerging concepts on GABA genetics in epilepsy, 
with a special emphasis on the functional role of extrasynaptic GABA-ARs in the 
regulation of network excitability and susceptibility to brain disorders. We also highlight 
the potential therapeutic implications of modulating extrasynaptic GABA-AR-mediated 
tonic inhibition in pharmacotherapy of epilepsy, status epilepticus (SE), and other brain 
disorders. 
I.1 GABA-AR Structure and Subtypes 
Gamma-aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in 
the brain. It is a highly hydrophilic molecule and hence cannot cross the blood-brain 
barrier. GABA is synthesized in neurons and stored in synaptic vesicles. Upon neuronal 
activation, GABA is released from the vesicles into the synapse, where it can act on 
postsynaptic receptors, or diffuse into the extracellular space. GABA binds with three 
receptors: GABA-A receptor (GABA-AR), GABA-B, and GABA-C. GABA-AR plays a 
pivotal role in regulating neuronal excitability and in the pathology of epilepsy (Baulac et 
al., 2001). GABA exerts fast inhibitory actions by activating postsynaptic GABA-ARs in 
the brain, causing the influx of negatively charged chloride ions and hyperpolarization of 
neurons that serves to reduce neuronal excitability and firing. GABA-ARs are pentamers 
consisting of five subunits. Each subunit has one long extracellular N-terminus that 
interacts with a variety of drugs including benzodiazepines (BZs), barbiturates, and 




that links TM1 and TM2, one short extracellular loop that links TM2 and TM3, one long 
intracellular loop that links TM3 and TM4 and can be modulated by phosphorylation, and 
one small extracellular C-terminus. TM2 transmembrane domain of each subunits form a 
selective channel pore that is permeable for chloride ion passage (Figure 1). GABA-AR 
isoform distribution plays key roles in regulation of sedation, hypnosis, anxiolysis, 
anesthesia, and seizure protection (Table 1). 
GABA-ARs are made from a repertoire of 19 known subunits: 1-6, 1-3, 1-3, , , , , 
1-3. The most general stoichiometry of GABA-ARs contains 2 s, 2 s and 1  or 1  
subunit. GABA-AR subunits have discrete distributions among different brain regions. 
Approximately 90% of GABA-ARs are -containing, but the  subunit can substitute for 
. The  subunit has more confined expression in parts of the brain such as the 
hippocampus, cerebellum, and thalamus. GABA binding sites are located at the junction 
between subunits  and , and BZs bind at the interface between subunits  and . The 
genomic location of 19 GABA-AR subunits has been identified (Russek, 1999). The 
genes encoding subunit 2, 4, 1, and 1 cluster on chromosome 4p12; subunit 1, 6, 
2, 2, and  genes are mapped on chromosome 5q; subunit 5, 3, and 3 genes cluster 
on chromosome 15q12; subunit 3, , and  are located on chromosome Xq28; 1 and  
2 cluster on chromosome 6q15; and the 3 and  subunits are found on chromosome 







Figure 1 Schematic representation of typical GABA-AR structure and subunit 
composition. 
(A) GABA-A receptors (GABA-ARs) are heteropentamers forming a channel that is 
permeable to chloride ion passage. (B) A top view of the pentamer. GABA-ARs are made 
from a repertoire of 19 known subunits: 1-6, 1-3, 1-3, , , , , 1-3. The most 
general stoichiometry of GABA-ARs contains 2 s, 2 s and 1 ; the  subunit can be 
substituted by , , , or . Each subunit has four transmembrane domains (TM1-4). TM2 
transmembrane domains form a selective channel pore. GABA exerts fast inhibitory 
actions by activating postsynaptic GABA-ARs in the brain, causing the influx of 
negatively charged chloride ions and hyperpolarization of neurons which serves to reduce 
neuronal excitability and firing. The GABA binding sites are located at the junction 
between subunit  and , whereas benzodiazepines (BZs) bind at the interface between 
subunit  and . Barbiturates binding sites are distinct from the BZ binding site. The 
neurosteroids (NSs) have two putative binding sites including allosteric and direct 
binding sites. The allosteric binding site is located at the α subunit transmembrane 
domains, whereas the direct binding site is within the transmembrane domains of the α 
and β subunits. (C) GABA-ARs belong to Cys-loop family of ligand-gated ion channels 
that also contains nicotinic acetylcholine, glycine, and serotonin 5-HT3 receptors. Each 
subunit has one long extracellular N-terminus that interacts with a variety of drugs 
including BZs, barbiturates, and NSs; four transmembrane domains (TM1-TM4); and one 
short intracellular loop that links TM1 and TM2, one short extracellular loop that links 
TM2 and TM3, one long intracellular loop that links TM3 and TM4 and can be 






Figure 2 GABA-AR subunit family. 
(A) A dendrogram illustrating the 19 known genes encoding for the mammalian GABA-






Table 1 The pharmacological roles of select GABA-AR subunits. 
 1 2 3 4 5 2 3 2  
ANXIETY        + - 
LEARNING 
MEMORY 
    +    
-
/+ 
SEIZURE/EPILEPSY + - -  -  +   
EFFECTS OF 
BENZODIAZEPINES 
         
MOTOR 
IMPAIRMENT 
- - -  -     
SEDATION + - -  - +    
ANXIOLYSIS - + +  -     
MYORELAXATION -  +       
ANTICONVULSANT + - -  -     
EFFECTS OF 
NEUROSTEROIDS  
         
MOTOR 
IMPAIRMENT 
-         
HYPNOSIS -        + 
ANXIOLYSIS         + 
ANTICONVULSANT         + 
EFFECTS OF OTHER 
DRUGS 
         
SEDATION    +      
ANESTHESIA    +   +  - 
(Homanics et al., 1997; Mihalek et al., 1999; Rudolph et al., 1999; Low et al., 2000; McKernan et al., 2000; 
Collinson et al., 2002; Crestani et al., 2002; Blednov et al., 2003; Jurd et al., 2003; Kralic et al., 2003; 






I.2 Synaptic vs. Extrasynaptic GABA-ARs 
GABA-ARs are divided into two categories according to their localization: synaptic and 
extrasynaptic receptors. Each type of receptor possesses distinct characteristics in its 
affinity and efficacy to GABA, desensitization rate, and response to BZs and 
neurosteroids (Bianchi and Macdonald, 2002; Brown et al., 2002; Wohlfarth et al., 2002; 
Bianchi and Macdonald, 2003; Mortensen et al., 2011). Extrasynaptic GABA-ARs are 
composed of mainly -containing receptors, which have high GABA affinity but low 
efficacy, low desensitization rate, low sensitivity to BZs, and are highly potentiated by 
neurosteroids compared to synaptic GABA-ARs (Table 2). Activation of synaptic -
containing GABA-ARs and extrasynaptic -containing GABA-ARs produce phasic and 
tonic current inhibition, respectively. Rapid and transient phasic current inhibition is 
generated by presynaptic GABA release and the binding of synaptic -containing GABA-
ARs, whereas, tonic current inhibition is produced by persistent activation of perisynaptic 
or extrasynaptic -containing GABA-ARs by ambient GABA. Extrasynaptic receptors 
are only found in specific brain areas such as the hippocampus, amygdala, neocortex, 
thalamus, hypothalamus, and cerebellum (Stell et al., 2003; Jia et al., 2005; Drasbek and 
Jensen, 2006; Olmos-Serrano et al., 2010; Mortensen et al., 2011; Carver et al., 2014). 
Extrasynaptic -containing GABA-ARs are tailored to regulate neuronal excitability by 
controlling the basal tone through shunting and tonic inhibition in neurons (Coulter and 
Carlson, 2007; Carver and Reddy 2013). They are mostly insensitive to allosteric 







Table 2 Characterization of synaptic (2-containing) and extrasynaptic (-
containing) GABA-ARs in the brain. 
 
SYNAPTIC GABA-ARS EXTRASYNAPTIC GABA-ARS 
SUBUNITS Pentamer (2-containing) Pentamer (-containing) 
INHIBITION Phasic Tonic 
GABA AFFINITY Low High 
GABA EFFICACY High Low 
DESENSITIZATION Pronounced Moderate/Low 
BENZODIAZEPINES sensitive insensitive 




DISTRIBUTION Highly prevalent 
Highly specific regional (e.g.  







I.3 Distribution of GABA-AR Subtypes 
Different subtype combinations respond differently to receptor modulators and contribute 
distinct functions in each brain area. GABA-ARs have a high molecular heterogeneity 
because of the abundance of available subunits and the ways in which those subunits can 
be assembled to form the heteropentameric receptors. The composition and distribution 
of the GABA-AR isoforms are listed in Table 3. Receptors located in the synaptic sites 
are primarily made of , , and 2 subunits. 1-, 2-, 3-, and 5-containing receptors 
are generally sensitive to BZs.  subunit containing receptors constitute the majority of 
GABA-ARs. Immunohistochemistry and in situ hybridization data showed that 122 is 
the most abundant and widespread subtype accounting for ~43-60% of all GABA-ARs in 
the adult brain (McKernan and Whiting, 1996; Loup et al., 2000; Mohler et al., 2002). It 
majorly appears in the synaptic sites. 232 and 332 receptors, located mostly in the 
synaptic sites, are also highly prevalent. They represent ~15-20% and ~10-15% of all 
GABA-ARs, respectively. 4 and 4, located in the synaptic and extrasynaptic 
locations respectively, represent approximately 5%, while synaptic 51/32 and 
62/32 account for less than 5% (McKernan and Whiting, 1996; Pirker et al., 2000; 
Mohler et al., 2002). Other subtypes have more specific and confined distribution 
patterns (Figure 3).  
Receptors located in the extrasynaptic locations usually contain the  subunit rather than 
 in association with 2 or 3 and a certain isoform of  subunit. The  subunit with its 
highly specific regional and subcellular distribution is tailored to generate tonic inhibition. 
It is abundant in cerebellar and dentate gyrus granule cells (DGGCs), some cortical 
neurons, and thalamic relay cells (Wisden et al., 1992; Fritschy and Mohler, 1995; Sperk 
et al., 1997; Pirker et al., 2000; Peng et al., 2002).  
In the hippocampus, several isoforms are expressed in distinct regions and cell types. 
CA1 pyramidal neurons mainly contain 532S receptors, which are located at both 




density of  subunits, express 332S and 42/3 receptors in the synaptic and 
extrasynaptic site, respectively (Sperk et al., 1997; Peng et al., 2002). The  subunit is 
thought to be predominately co-localized and assembled with 4 and/or 6 subunit. 
α4β2/3δ or α6β2/3δ combinations exhibit the highest GABA affinity with a GABA EC50 
(concentration required to achieve half-maximal activation) in the nanomolar range. 
12 receptors are primarily present in hippocampal interneurons and show lower 
GABA potency compared to the α4β2/3δ combination. Overall, 1, 4, 2 and  subunit 
are found to be expressed in the extrasynaptic sites of hippocampus (Sun et al., 2004; 
Glykys and Mody, 2007; Mortensen et al., 2011).  
In the cerebellum, cerebellar granule cells, which contain the highest density of  subunit 
in the central nervous system (CNS), express 62/3 predominantly at extrasynaptic 
sites. 63 and 632S combinations are also found in cerebellar granule cells (Nusser 
et al., 1998; Farrant and Nusser, 2005; Zheleznova et al., 2009). Notably, 6-containing 
receptors are almost exclusively expressed in the cerebellar granule cells and, in 
combination with the  subunit, exhibit the highest GABA potency. In the thalamus, 
432S receptors are expressed at synaptic sites in the thalamic relay cells, whereas, 
43 and 43 receptors are expressed at extrasynaptic sites. In addition, 33 
receptors are also found in the thalamus.  
In the amygdala, the 2 subunit, primarily found in principal neurons, is responsible for 
the allosteric action of the BZs (Marowsky et al., 2004). The principal neurons in the 
basolateral amygdala (BLA) also contain 2 subunits which contribute to the fast synaptic 
inhibition (Esmaeili et al., 2009). The BZ-sensitive 22 subtypes are thought to be 
assembled in the principal neurons of the BLA in the synaptic site and generate phasic 
inhibition. Extrasynaptic GABA-ARs in the BLA are made up mainly of the 3, 5, and 
the  subunits, which contribute to non-desensitizing tonic current inhibition. In 
particular, the 3 subunit is strongly expressed throughout the BLA nucleus and is 




currents was observed in the BLA neurons from 3 subunit knockout mice (Farrant and 
Nusser, 2005; Marowsky et al., 2012).   
In general, receptors containing a 2 subunit in combination with α1, α2 or α3 subunits 
(12/32, 22/32 and α32/32) are the predominant synaptic receptor subtypes that 
produce phasic inhibition, whereas receptors containing α4, α5, α6 or  subunits (4, 


















Synaptic (S)  
122S S Ubiquitously express 
throughout the brain. Most 
abundant. Constitute ~43-
60% of all GABA-ARs 




Whiting 1996; Pirker 
et al., 2000; Mohler 
et al., 2002) 
132S S Widespread  2.1 BZs and zolpidem 
sensitive 
(Sieghart 1995; 
Mortensen et al., 
2011) 
232S S Widespread. Account for 
15-20% of all GABA-
ARs. Hippocampal 
pyramidal neurons, 
cerebral cortex, amygdala, 
caudate putamen 




Whiting 1996; Pirker 
et al., 2000; Mohler 
et al., 2002; 
Mortensen et al., 
2011) 
332S S Account for 10-15% of all 
GABA-ARs. Hippocampal 
dentate gyrus granule 
cells, hypothalamic nuclei, 
thalamic reticular nucleus, 
cerebral cortex 
12.5 BZs, zolpidem, and 
flumazenil sensitive 
(Sieghart 1995; 
Mohler et al., 2002; 
Mortensen et al., 
2011) 
432S S Hippocampus, thalamic 
relay cells 
2.1 Furosemide and 
Ro15-4513 sensitive 
(Brown et al., 2002; 
Mohler et al., 2002; 
Mortensen et al., 
2011) 
632S S Account for ~2% of all 
GABA-ARs. Cerebellum 
granule cells 




Brown et al., 2002; 
Mohler et al., 2002; 
Mortensen et al., 
2011) 
Extrasynaptic (E)  
12 E Hippocampal interneurons 3.7  (Sun et al; 2004; 
Glykys et al., 2007) 
3/5 E BLA principle neurons   (Marowsky et al., 
2004; Marowsky et 
al., 2012) 
33 E Thalamus, hypothalamus, 
locus coeruleus 
4.5  (Mortensen et al., 
2011) 
43 E Thalamic relay cells 0.97  (Brickley et al., 
1999; Mortensen et 
al., 2011) 
42/3 E Hippocampal dentate 
gyrus granule cells, 
thalamic relay cells, 
neostriatum 
0.97-1.7 BZs insensitive; 
Furosemide and 
THIP sensitive 
(Sperk et al., 1997; 
McKernan and 
Whiting 1996; 
Brown et al., 2002; 
Peng et al., 2002; 
Farrant and Nusser 
2005; Boehm et al., 
2006; Mortensen et 
al., 2011;) 

















62/3 E Account for ~2% of all 
GABA-ARs. Cerebellum 
granule cells 
0.17 Lacks BZ binding 
site; Furosemide and 
THIP sensitive 
(Brown et al., 2002; 
Mohler et al., 2002; 
Boehm et al., 2006) 
Synaptic (S)/ Extrasynaptic (E)  
532S S/E Account for ~4% of all 
GABA-ARs. Hippocampal 
pyramidal neurons, 
cerebral cortex, olfactory 
bulb 




Mohler et al., 2002; 
Farrant and Nusser 
2005; Mortensen et 
al., 2011) 
The GABA potency (EC50) data is obtained from recombinant HEK293 cells (Mortensen et al., 2011). BZs: 
GABA-AR allosteric agonists; Zolpidem: a full agonist at 1-containing GABA-ARs, ~10-fold lower 
affinity at 2- and 3-containing GABA-ARs; Flumazenil: a GABA-AR antagonist; Furosemide: a  









Figure 3 Extrasynaptic GABA-AR  subunit distribution. 
(A) The estimated abundance of GABA-AR subtypes in the rodent brain. (B) GABA-AR 







I.4 Neurosteroid Modulation of GABA-ARs and Tonic Inhibition 
Neurosteroids, also referred as neuroactive steroids, are steroids with rapid actions on 
neuronal excitability through modulation of membrane receptors in the CNS (Kulkarni 
and Reddy, 1995; Mellon and Griffin, 2002). The terminology on “neurosteroid” and 
“neuroactive steroid” has been described extensively in the literature (Reddy and 
Rogawski, 2012). Generally, the terms neurosteroids and neuroactive steroids are used 
interchangeably to refer to endogenous steroids with rapid membrane actions that were 
either made de novo in the brain or from peripheral sources of parent steroids that were 
metabolized in the brain (Baulieu, 1981; Paul and Purdy, 1992; Reddy, 2003ab; 2009a; 
2011; 2013b). Parent steroids or neurosteroid precursors (not the steroid metabolites) 
bind to classic steroid receptors. A brief outline of neurosteroid synthesis is described 
below. Cholesterol is first translocated across the mitochondrial membrane by the 
translocator protein 18kDa (TSPO, a key protein that controls the biosynthesis of 
neurosteroids) and converted into steroid precursor pregnenolone by the P450 side-chain 
cleavage enzyme in the inner membrane of mitochondria. Pregnenolone is subsequently 
converted into neurosteroid precursors progesterone, deoxycorticosterone, and 
testosterone, which go through two sequential A-ring reduction steps and are converted 
into three prototype endogenous neurosteroids – allopregnanolone (AP, 3α-hydroxy-5α-
pregnan-20-one), allotetrahydrodeoxycorticosterone (THDOC), and androstanediol – by 
the catalysis of two key enzymes called 5-reductase and 3-hydroxysteroid 
oxidoreductase in the brain. These three prototype neurosteroids, AP, THDOC, and 
androstanediol, are well-studied (Rupprecht, 2003; Belelli and Lambert, 2005; Reddy, 
2003ab; 2009a; 2011; Carver and Reddy, 2013; Brown et al., 2015; Porcu et al., 2016).  
THDOC potentiates both tonic current conductance and the weighted decay time of 
spontaneous inhibitory postsynaptic currents (IPSCs) directly in DGGCs and cerebellar 
granule cells (Vicini et al., 2002; Wohlfarth et al., 2002; Stell et al., 2003). AP at low 
concentrations (30 and 100 nM) potentiates the decay time of miniature IPSCs (mIPSCs) 




dissociated neurons and tonic currents in hippocampal slice allosterically and directly 
(Carver et al., 2014; Carver and Reddy, 2016). 
Neurosteroids are powerful modulators of GABA-ARs and can rapidly alter neuronal 
excitability (Reddy and Estes, 2016). Neurosteroids act at both synaptic and extrasynaptic 
GABA-ARs but they are more efficacious on extrasynaptic GABA-ARs that mediate 
tonic inhibition. At low concentrations (sub-micromolar level), neurosteroids 
allosterically potentiate GABA-AR currents, whereas at high concentrations (micromolar 
level), neurosteroids can directly activate GABA-ARs by binding directly at the 
orthosteric site (Reddy and Rogawski, 2002; Hosie et al., 2007; Reddy and Jian, 2010; 
Carver and Reddy, 2016). One recent study demonstrated a downregulation of the -
containing GABA-ARs prior to onset of epilepsy, and a reduction in neurosteroid-
induced modulation of tonic inhibition in the SE model of epilepsy, highlighting the role 
of  GABA-ARs in this disease (Joshi et al., 2017). 
Ganaxolone (GX, 3-hydroxy-3-methyl- 5-pregnan-20-one), the 3-methylated 
analog of AP, is now being assessed in advanced clinical trials for epilepsy (Pieribone et 
al., 2007; Porcu et al., 2016). Like AP, GX has been shown to modulate GABA-ARs in X. 
Laevis oocytes expressing human recombinant 112L receptors (Carter et al., 1997). 
Natural neurosteroids have low bioavailability since they can be back-converted to active 
3-ketone-containing progesterone metabolites (Rupprecht et al., 1993). The synthetic 3-
substituted GX provides a more promising pharmacokinetic profile as an AED, 
overcoming the limitations of lower bioavailability by preventing the oxidation of the 3-
hydroxyl group (Carter et al., 1997). GX possesses broad-spectrum anticonvulsant 
activity in animal seizure models (Reddy and Rogawski, 2000ab; 2010). GX is currently 
being evaluated in clinical trials for the treatment of epilepsy and related conditions 
(Nohria and Giller, 2007; Reddy and Rogawski, 2010; 2012; Bialer et al., 2015; Braat et 




Progesterone, GX, and AP have been evaluated in clinical trials for seizure conditions 
(Reddy and Estes, 2016; Younus and Reddy, 2017). GX has been evaluated in more than 
1300 subjects in various clinical studies in adults and children with epilepsy (Laxer et al., 
2000; Kerrigan et al., 2000; Reddy and Woodward, 2004; Nohria and Giller, 2007; 
Pieribone et al., 2007; Sperling et al., 2017). Progesterone was evaluated as an adjunct 
therapy in women with epilepsy (Herzog et al., 2012). The neurosteroid AP has been 
suggested as an intravenous therapy for refractory SE (Rosenthal et al., 2017) and post-
partum depression (Kanes et al., 2017). Overall, synthetic neurosteroid analogs, which 
activate both synaptic and extrasynaptic GABA-AR-mediated tonic inhibition in the brain, 
may be promising compounds for clinical development for specific seizure conditions, 
such as status epileptic and catamenial epilepsy.  
 I.5 Protein Kinase Modulation of Neurosteroid-Sensitive GABA-ARs 
Protein kinases are enzymes that can regulate the function of other proteins by 
phosphorylating hydroxyl groups on the proteins by which they act. Protein kinase 
activity influences GABA-AR surface expression, trafficking, chloride conductance, and 
sensitivity to neurosteroids. Several GABA-AR subunits contain residues that can be 
phosphorylated by protein kinases including 4, , and 2 subunits (Moss and Smart, 
1996; Brandon et al., 2000). The serine residue (Ser-443) within the intracellular domain 
of the 4 subunit is phosphorylated by protein kinase C (PKC) (Abramian et al., 2010). A 
conserved serine residue (Ser-409 or Ser-410) of the  subunit is  phosphorylated by PKC, 
protein kinase A (PKA), Ca2+/Calmodulin-dependent protein kinase II (CaMKII), and 
cGMP-dependent protein kinase. Two additional serine residues of the  subunit (Ser-408 
and Ser-383) are also phosphorylated by PKA and CaMKII, respectively (McDonald et 
al., 1998; Saliba et al., 2012). Additionally, the tyrosine residues (Tyr-365 and Tyr-367) 
and serine residue (Ser-343) of the 2 subunit are also substrates of tyrosine kinase and 
PKC, respectively (Krishek et al., 1994; Moss et al., 1995). Phosphorylation of residues 




of GABA-ARs, whereas, dephosphorylation of these subunits triggers receptor 
internalization (Kittler et al., 2005; Kittler et al., 2008; Figure 4).  
Previous studies have shown PKC activity regulates receptor function, ion conductance 
and response to receptor modulators. 10-min bath application of PKC activator phorbol 
12-myristate 13-acetate increases THDOC-potentiated, GABA-gated chloride currents 
(Leidenheimer and Chapell, 1997). Treatment with the specific PKC antagonist 
bisindolylmaleimide 15-min before and during neurosteroid administration diminishes 
the decay of IPSCs by neurosteroids (Fancsik et al., 2000).  Inhibition of either PKA or 
PKC by intracellular dialysis significantly reduces neurosteroid 5β-pregnan-3-ol-20-
one-mediated prolonged decay of mIPSCs in CA1 pyramidal neurons, whereas activation 
of PKC has no effect on neurosteroid sensitivity (Harney et al., 2003). Phosphorylation of 
the serine residue of the β subunits (Ser-383) by L-type voltage-gated Ca
2+
 channel-
activated CaMKII leads to rapid surface expression of GABA-ARs and enhanced tonic 
currents in hippocampal neurons (Saliba et al., 2012). 10-min co-treatment with PKC 
inhibitor prevents THDOC-upregulated phosphorylation of the 4 subunits and surface 
expression of 4-containing GABA-ARs (Abramian et al., 2014). Recent study 
demonstrated that continuous application of AP, but not GX, upregulates the 
phosphorylation and surface expression of the 3-containing GABA-ARs and tonic 
current potentiation, effects prevented by the application of PKC inhibitor 15-min before 






Figure 4 Modulation of extrasynaptic GABA-AR trafficking by phosphorylation. 
GABA-ARs subunits including 4, , and 2 subunit contain residues that can be 
phosphorylated by various protein kinases. Phosphorylation of residues within GABA-
ARs not only regulates receptor function but maintains their surface expression. 
Dephosphorylation of these subunits triggers receptor internalization through adaptor 
protein 2 (AP2)-clathrin complex-dependent endocytosis. Internalized receptors are 
subsequently transported to the endosomal system, where they can be either recycled to 
the surface or degraded in the lysosomes. GABA-AR trafficking is facilitated by a variety 
of protein-protein interactions. GABARAP, a GABA-AR-associated protein, interacts 
with the 2 subunit of GABA-ARs and might facilitate receptor insertion into the cell 
membrane; p130, a phospholipase, shares the same bind site on the 2 subunit with the 
GABARAP; NSF, a N-ethylmaleimide sensitive factor, interacts with GABARAP and 
p130 and plays a crucial role in intracellular transport; PLIC-1, an ubiquitin-like protein, 
increases receptor stability and enhances membrane insertion of receptors; HAP, a 
Huntingtin-associated protein, interacts with the  subunit of GABA-ARs and facilitates 
receptor recycling to the cell membrane; GODZ, a Golgi-specific DHHC zinc finger 
domain protein, mediates posttranslational palmitoylation; BIG2, a brefeldin A-inhibited 
GDP/GTP exchange factor, binds to the intracellular loop of  subunits and is involved in 





I.6 Zinc Antagonism of Neurosteroid-Sensitive GABA-ARs 
Zinc (Zn
2+
) is an essential cofactor in many cells including neurons. Zn
2+
 is the most 
abundant transition metal in the vesicles of hippocampal mossy fibers that project from 
the DG to the CA3 (Frederickson, 1989). During neuronal activity, vesicular Zn
2+ 
is 
released synaptically from certain nerve terminals in the hippocampus (Tian et al., 2010). 
Excessive release of Zn
2+
 has been shown in epilepsy, and it can decrease the threshold of 
excitability and seizures (Takeda et al., 1999; Coulter, 2000; Foresti et al., 2008). Zn
2+ 
regulation of postsynaptic targets and synaptic plasticity is shown in Figure 5. Zn
2+
 
modulates several ligand- and voltage-gated ion channels (Harrison and Gibbons 1994). 
In particular, Zn
2+
 attenuates GABAergic inhibition at mossy fiber synaptic varicosities 
that release GABA (Xie and Smart, 1991; Ruiz et al., 2004; Bitanihirwe and Cunningham, 
2009). In addition, Zn
2+
 has been shown to negatively modulate synaptic GABA-ARs and 
modify the excitability of the hippocampal network (Barberis et al., 2000). Three distinct 
Zn
2+
 binding sites mediate its inhibition of GABA-ARs: one site at the internal surface of 
the channel pore and two at the external amino-terminus of the - interfaces. The 
incorporation of the  subunit after GABA-AR co-assembly disrupts two of the Zn
2+
 
binding sites, which leads to a reduced sensitivity to Zn
2+ 
inhibition (Hosie et al., 2003). 
Thus, the sensitivity to Zn
2+
 inhibition is different between the two different GABA-AR 
subtypes (-containing and -containing) (Smart et al., 1991; Storustovu and Ebert, 2006).  
Our recent study demonstrated the -containing receptors to be more sensitive to Zn
2+
 
inhibition than -containing receptors, and Zn
2+
 selectively blocked neurosteroid-
sensitive extrasynaptic GABA-AR-mediated tonic currents in the mouse hippocampus 
dentate gyrus (Carver et al., 2016). Zn
2+ 
blocked AP potentiation of tonic currents in a 
concentration-dependent manner, while synaptic currents were unaffected. Application of 
Zn
2+ 
chelator prevented the positive shift of tonic currents by Zn
2+
, confirming the Zn
2+ 
blockade of AP-sensitive tonic currents. In the mouse kindling model of epilepsy, 
intrahippocampal infusion of Zn
2+ 
resulted in rapid epileptiform activity and prevention 
of the antiseizure activity of AP. Therefore, Zn
2+




extrasynaptic GABA-ARs in the hippocampus has direct involvement in a variety of 
brain conditions, such as seizures, epileptogenesis, epilepsy, and conditions with 





affinity for extrasynaptic δ-containing GABA-ARs, but their actions are distinctly 
opposite through the binding of different allosteric sites. Overall, Zn
2+
 hinders 
neurosteroid activation of extrasynaptic δGABA-AR-mediated tonic inhibition and their 






Figure 5 Trafficking of Zn
2+
 at the gluzinergic synapse. 
In the gluzinergic terminal, the availability of free Zn
2+
 is regulated by metallothioneins 
(MTs), the primary intracellular Zn
2+
-buffering proteins. The MT is a dumbbell-shape, 
cysteines (Cys)-rich protein comprised of two domains in which seven zinc atoms are 
tetrahedrally bound to twenty cysteines (inset, middle). The Zn
2+
 transporter (ZnT) and 
Zip proteins are also involved in the regulation of Zn
2+
 in the cytoplasm. ZnT proteins 
promote Zn
2+
 efflux and vesicular uptake to decrease the amount of intracellular Zn
2+
 
while Zip proteins facilitate the influx of extracellular Zn
2+
 into neurons and glial cells to 




 is transferred into synaptic 
vesicles through the ZnT3 proteins and stored with glutamate. During normal 
neurotransmission, Zn
2+
- and glutamate-containing vesicles fuse with cell membrane and 
co-release Zn
2+
 and glutamate into the synaptic cleft. There are a variety of postsynaptic 
targets that Zn
2+
 can act at including NMDA receptors (NMDA Rs), AMPA receptors 
(AMPA Rs), voltage-gated calcium channels (VGCCs), GABA-ARs and a number of 
other channels, transporters and receptors. Three distinct Zn
2+
 binding sites mediate its 
inhibition of extrasynaptic -containing GABA-ARs (inset, right): one site at the internal 






I.7 Genetic Regulation of GABA-ARs 
I.7.1 GABA Epilepsy Genetics 
GABA-ARs play a pivotal role in regulating neuronal inhibition in the CNS. 
Dysregulation of neuronal activity and changes in the composition and function of 
GABA-ARs contribute to the development of epilepsy. Genetic epilepsies are genetically 
driven recurrent seizures caused by mutations in genes governing excitation and 
inhibition. Mutations in GABA-AR subunit genes have been involved in the 
pathophysiology of several idiopathic generalized epilepsies. Specifically, mutations in 
the gene encoding the 1 subunit (GABRA1) and the 3 subunit (GABRB3) are mainly 
associated with Childhood Absence Epilepsy (CAE) and Juvenile Myoclonic Epilepsy 
(JME), while mutations in the gene encoding the 2 subunit (GABRG2) and the  subunit 
(GABRD) are associated with Febrile Seizures (FS), Generalized Epilepsy with Febrile 






Table 4 Summary of GABA-AR genetic epilepsies. 
 Genetic 
location 
Mutation Sample size Receptor dysfunction 
Phenotype 
OMIM# 
Child Absence Epilepsy (CAE)  
1 
(GABRA1)  
5q34 (975delC, S326fs328X) A single 
base pair deletion and premature 
stop codon in TM3  
Sporadic 1 of 
98 German IGE 
patients 
Reduced GABA current and 
surface expression 





A missense mutation in N 
terminus, causing the changes of 
arginine to tryptophan at position 
46  
1 of 72 IGE, 65 




surface expression of  subunit 
(Dibbens et al., 2009; 




15q12 Haplotype 2 promoter in exon 1a 45 CAE patients Lower transcription activity 




A  heterozygous missense 
mutation  in exon 1a in signal 
peptide, causing the changes of 
proline to serine at position 11   
4 of 48 
Remitting  CAE 
patients in a 
Mexican family 
Reduced GABA current and 
increased glycosylation 
(Tanaka et al., 2008) 
 (S15F) 
A missense mutation in signal 
peptide, causing the changes of 
serine to phenylalanine at position 
15   
1 of 48 
Remitting  CAE 
patients from 
Honduras 
Reduced GABA current and 
increased glycosylation 
(Tanaka et al., 2008) 
  (G32R  
A missense mutation  in exon 2 in 
N terminus, causing the changes of 
glycine to arginine at position 32  ) 
2 of 48 
Remitting  CAE 
patients in a 
Honduran 
family 
Reduced GABA current and 
increased glycosylation 





A  missense mutation in  N 
terminus, causing the changes of 
arginine to glutamine at position 
82  
Autosomal 
dominant  form 
in a large 
Australian 
family 
Impaired receptor trafficking 
and reduced surface expression 
(Wallace et al., 2001) 
607681 




A heterozygous missense mutation 
in TM3, causing the changes of 
alanine to aspartate at position 322  




Reduced GABA current and 
surface expression 
(Cossette et al., 2002) 
611136 
 (GABRD) 1p36.3 (R220H) 
A  missense mutation in exon 6 in 
N terminus, causing the changes of 
arginine to histidine at position 
220  
A small GEFS+ 
family 
Reduced surface expression and  
receptor mean open duration 
(Dibbens et al., 2004) 
613060 




A  missense mutation in  N 
terminus, causing the changes of 
arginine to glutamine at position 
82  
Autosomal 
dominant  form 
in a large 
Australian 
family 
Impaired receptor trafficking 
and reduced surface expression 
(Wallace et al., 2001) 
611277 
(R177G) 
A missense mutation in N 
terminus, causing the  changes of 
arginine to glycine at position 177  
1 of 47  
unrelated 
patients 
Altered GABA current and 
kinetics and impaired subunit 
folding and/or oligomerization 
(Audenaert et al., 2006) 
(K328M) 
A missense mutation in 
extracellular loop between the 
TM2 and TM3, causing the 
changes of lysine to methionine at 
position 328  
A large French 
family 
Altered GABA current and 
kinetics 




Table 4 Continued 
 Genetic 
location 
Mutation Sample size Receptor dysfunction 
Phenotype 
OMIM# 




A missense mutation in 
extracellular loop between the 
TM2 and TM3, causing the 
changes of lysine to 
methionine at position 328  
A large French 
family  with 
GEFS+ 
Altered GABA current and 
kinetics 
 (Baulac et al., 2001) 
611277 
(Q390X) 
A nonsense mutation in 
intracellular loop between the 
TM3 and TM4,  causing  a 
premature stop codon at 
position 390  
A  GEFS+ family ER  retention and abolished 
GABA sensitivity  
(Harkin et al., 2002; Kang et al., 
2010) 
(R136X) 
A nonsense mutation in N 
terminus,  causing  a premature 
stop codon at position 136  
A two-generation 
family with GEFS+ 
Reduced receptor current 
amplitudes and surface 
expression, ER retention 
(Sun et al., 2008; Johnston et 
al., 2014) 
  (W429X) 
A nonsense mutation in 
intracellular loop between the 
TM3 and TM4,  causing  a 
premature stop codon at 
position 429  
1 of 23 Chinese 
families  with 
GEFS+ 
Undetermined,  is predicted to 
translate a truncated protein 
(Sun et al., 2008; Johnston et 
al., 2014) 
 
 (GABRD) 1p36.3 (R220C) 
A  missense mutation in exon 6 
in N terminus, causing the 
changes of arginine to cysteine 
at position 220  
A small GEFS+ 
family  
Reduced GABA current and 
single channel open duration 
(Dibbens et al., 2004) 
613060 
  (E177A) 
A  missense mutation in N 
terminus, causing the changes 
of glutamate to alanine at 
position 177  
A small GEFS+ 
family 
Reduced GABA current and 
receptor expression and altered 
channel gating frequency 
(Dibbens et al., 2004) 




A nonsense mutation in N 
terminus,  causing  a premature 
stop codon at position 40  
Dizygotic twin girls 
with DS and their 
apparently healthy 





(Hirose 2006; Ishii et al., 2014) 
- 
The positions of mutations are designated in the immature peptide including the 39 amino acid signal 






Figure 6 Summary outline of the association of genetic epilepsies with GABA-AR 
subunits and other genetic factors. 
Right: GABA-AR subunits that are involved in genetic epilepsies. Mutations in each 
subunit are listed. Left: other genetic factors that are associated with genetic epilepsies. 
CACNA1H (Cav3.2): a voltage-dependent T-type calcium channel alpha1H subunit gene; 
CACNB4: a voltage-dependent L-type calcium channel beta4 subunit gene; EFHC1: a 
gene that encodes a protein with an EF-hand domains; CPA6: a gene that encodes 
carboxypeptidase A6; CASR: a gene that encodes calcium sensor receptor; SCN1A: a 
sodium voltage-gated channel alpha1A subunit gene; SCN1B: a sodium voltage-gated 
channel alpha1B subunit gene; SCN2A: a sodium voltage-gated channel alpha2A subunit 
gene; SCN2B: a sodium voltage-gated channel alpha2B subunit gene. CAE, Childhood 
Absence Epilepsy; JME, Juvenile Myoclonic Epilepsy; FS, Febrile Seizures; GEFS+, 






I.7.2 Mutations of 1 Subunit 
A heterozygous missense mutation (A322D) in the TM3 of GABRA1 was identified in 
an autosomal dominant form of JME in a French Canadian family. This mutation arises 
by the replacement of the alanine amino acid residue by a larger negatively charged 
aspartate in the helix of TM3 of the 1 subunit. In in vitro studies, HEK 293 cells 
expressing this mutant GABA-AR (1A322D22) exhibited reduced GABA-evoked 
currents, GABA sensitivity, and 1 subunit protein expression, along with altered current 
kinetics and accelerated receptor endocytosis and endoplasmic reticulum (ER)-associated 
degradation via the ubiquitin–proteasome system (Cossette et al., 2002; Gallagher et al., 
2004; Krampfl et al., 2005; Gallagher et al., 2007; Bradley et al., 2008; Ding et al., 2010). 
One study indicated that this mutant GABA-AR (1A322D22) causes a dominant 
negative effect on the composition and surface expression of wildtype (WT) GABA-ARs 
(Ding et al., 2010). Therefore, the A322D mutation in human GABRA1  results in a loss-
of-function of the receptor via several mechanisms including the alteration of receptor 
functions, a reduction in receptor surface expression, and decreased receptor lifetime on 
the cell membrane.  
A single base pair deletion (975delC) in GABRA1 was found in a patient with sporadic 
CAE among 98 unrelated idiopathic generalized epilepsy patients. This de novo mutation 
causes a frameshift and a premature stop codon (S326fs328X), leading to a truncation in 
the TM3 and ER-associated degradation. In addition, GABA-evoked currents were not 
detected in the HEK293 cells with mutant 1-containing GABA-ARs. These mutant 
receptors were not able to be incorporated into the membrane surface, highlighting the 
involvement of the 1 subunit in inserting the receptors into the cell membrane and 
overall functional integrity of GABA-AR (Maljevic et al., 2006). However, no dominant 
negative effects on the WT receptors were observed in these mutant receptors. These 
findings reveal that a single base pair deletion in GABRA1 causes a loss-of-function and 




Two other mutations in GABRA1 associated with impaired membrane delivery of the 
mature GABA-AR were also identified in a cohort of French Canadian families with 
idiopathic generalized epilepsy. A 25-bp insertion associated with intron results in the 
deletion of the TM4 and a premature stop codon (K353delins18X), and a missense 
mutation that replaces the aspartate 219 residue with an asparagine (D219N). The family 
with K353delins18X mutation displays afebrile, generalized tonic–clonic seizures, while 
the family with the D219N mutation in GABRA1 shows mainly febrile seizures and 
absence seizures (Lachance-Touchette et al., 2011). In addition, 4 novel de novo 
mutations in GABRA1 were also found in SCN1A-negative patients with DS, providing 
insight into more genetic causes for this syndrome (Carvill et al., 2014). Recently, several 
novel mutations in the extracellular N-terminus of TM1 or TM2 of GABRA1 have been 
implicated in several epileptic diseases including infantile epilepsy, West syndrome, 
Ohtahara syndrome, and early onset epileptic encephalopathy (Johannesen et al., 2016; 
Kodera et al., 2016). Mutations in GABRA1 of GABA-ARs contribute to the genetic 
etiology of both mild generalized epilepsies and severe epilepsy syndromes. 
I.7.3 Mutations of 3 Subunit 
The association of GABRB3 with idiopathic generalized epilepsies was first reported in 
1999 (Feucht et al., 1999). Urak et al. performed a mutation screening of GABRB3 of 45 
CAE patients and found 13 single nucleotide polymorphisms and 4 haplotypes in the 
haplotype 2 region of the GABRB3 promoter. Lowered transcriptional activity of this 
region is highly associated with CAE (Feucht et al., 1999; Urak et al., 2006). Thus, 
diminished expression of the GABRB3 gene could be a possible cause for the 
development of CAE.  
Missense mutations (P11S, S15F, and G32R) in GABRB3 were found in families with 
remitting CAE (Tanaka et al., 2008). P11S and S15F are heterozygous mutations in the 
exon 1a that encodes the signal peptide of the GABRB3. The P11S mutation was found 




one family from Honduras. G32R is a heterozygous mutation in the exon 2 of GABRB3 
found in four affected persons of a two-generation Honduran family. Further 
investigation revealed that G32R mutation causes a partial shift of α32L receptors to 
α3 and 3 receptors and a reduction in macroscopic current density (Gurba et al., 2012). 
HEK293T cells expressing GABA-ARs with these mutations have reduced GABA-AR 
current density attributed to hyperglycosylation in the in vitro translation and 
translocation system. Results suggest that elevated glycosylation in the mutant exon 1a 
and exon 2 may contribute to CAE by interfering with the maturation and trafficking of 
GABA-ARs and affecting receptor function. Mutation screening performed in 183 
French-Canadian individuals with idiopathic generalized epilepsy including 88 with CAE 
also found nine single nucleotide polymorphisms and the P11S missense mutation in 
GABRB3 (Lachance-Touchette et al., 2010). However, another study demonstrated that 
no mutations in the exon 1a promoter of GABRB3 were found in 780 German patients 
with idiopathic generalized epilepsy, including 250 with CAE (Hempelmann et al., 2007). 
Therefore, the association of GABRB3 with CAE is still under debate. 
I.7.4 Mutations of 2 Subunit 
The -containing GABA-ARs are the main mediators of fast inhibitory transmission 
through phasic current inhibition in the synaptic sites (Sieghart and Sperk, 2002; Farrant 
and Nusser, 2005; Olsen and Sieghart, 2009). The  subunit is required for the formation 
of the binding site for BZs. In addition, it is also important for the clustering of the 
GABA-AR subtypes in the postsynaptic sites (Essrich et al., 1998; Fang et al., 2006). 
Mutations in the gene encoding  subunit of GABA-ARs (GABRG) have been associated 
with the pathogenesis of epilepsy; mostly FS and GEFS+. The first evidence linking 
GABA-AR subunit genes with epilepsy was reported in 2001. GABRG2 was the first 
identified GABA-AR subunit gene that is involved in idiopathic generalized epilepsy 
(Baulac et al., 2001). More evidence was subsequently discovered supporting the 
association between genetic epilepsies and GABA-AR subunit genes. A missense 




by a substitution of a positively charged lysine residue for a neutral methionine (K328M) 
in the extracellular loop between the TM2 and TM3 transmembrane domains of 
GABRG2. The recombinant receptors with this mutant 2K328M subunit expressed in X. 
Laevis oocytes have significantly lower amplitudes of GABA-evoked currents, indicating 
impaired receptor function (Baulac et al., 2001). Receptors with 2K328M subunit 
expressed in cultured rat hippocampal neurons displayed accelerated decay time constant 
of mIPSCs. In addition, mutant 2K328M receptors had decreased frequency of mIPSCs 
and enhanced membrane diffusion of receptors after 1-hour exposure of elevated 
temperatures, which was not observed in WT receptors, suggesting reduced number of 
functional inhibitory synapses and compromised GABAergic transmission (Bouthour et 
al., 2012). These could be a novel mechanism involved in the pathology of FS. 
Two nonsense mutations (R136X and W429X) in GABRG2 were identified in a two-
generation family with GEFS+, and one of twenty-three Chinese families with GEFS+, 
respectively (Sun et al., 2008; Johnston et al., 2014). The R136X mutation in the 
GABRG2 reduces receptor current amplitudes and surface expression with greater 
intracellular retention when γ2R136X subunits were heterologously expressed in HEK293T 
cells with the α1 and β2 subunits since the mutant 2R136X subunit did not allow the 
assembly of functional receptors. No dominant negative suppression effects from the 
mutant γ2R136 subunits on the WT receptors were noticed. The W429X is located in the 
extracellular loop between the TM3 and TM4 transmembrane domains of GABRG2. It 
generates a premature translation termination codon and is predicted to translate a 
truncated protein. 
A novel frameshift mutation in the γ2 subunit gene (GABRG2) was also identified in a 
family with GEFS+ (Tian et al., 2013). A cytosine nucleotide deletion in the last exon of 
GABRG2 results in a γ2SS443delC subunit with a modified and elongated carboxy-terminus. 
γ2S443delC subunits, which are larger than WT γ2 subunits when translated, displayed 
higher retention in ER and lower membrane expression. Electrophysiological 




HEK293T cells, showing GABRG2 haploinsufficiency. 
Q390X, a nonsense mutation in the intracellular loop between the TM3 and TM4 
transmembrane domains of the GABRG2 was found in GEFS+, FS, and DS patients. 
This mutation introduces a premature stop codon at Q390 in the immature protein. X. 
Laevis oocytes expressing recombinant receptors with mutant γ2Q390X subunit showed 
diminished response to GABA and retention in the intracellular compartment, which are 
also found in HEK293T cells expressing receptors with mutant 2R136X subunit (Harkin et 
al., 2002). Mutant 2R136X subunits accumulated and formed high-molecular-mass 
aggregation rapidly and showed longer half-life and slower degradation compare to WT 
subunits in several cell lines including HEK293T, COS-7, and Hela cells, and cultured rat 
cortical neurons (Kang et al., 2010). The accumulation and aggregation of misfolded or 
truncated proteins are commonly observed in neurodegenerative diseases. However, 
Kang et al. showed that the aggregates are also associated with genetic epilepsies. The 
Gabrg2
+/Q390X
 knock-in mouse, developed as an animal model for severe human genetic 
epileptic encephalopathy, displayed spontaneous generalized tonic-clonic seizures and 
reduced viability. In addition, impaired inhibitory neurotransmission including reduced 
amplitude and frequency of GABAergic mIPSCs and accumulation of mutant γ2Q390X 
subunits were also found in this mouse. The aggregation of mutant γ2Q390X subunits 
initiated caspase 3 activation and cell death in the mouse cerebral cortex (Kang et al., 
2015). Their results revealed that genetic epilepsies and neurodegenerative diseases may 
share relevant pathological pathways and therapies. 
A missense mutation (R82Q) in the GABRG2 was found in an Australian family and 
results in an autosomal dominant inherited form of CAE and FS (Hancili et al., 2014; 
Wallace et al., 2001). Arginine 82, located in the high-affinity BZ-binding region, 
abolishes diazepam-potentiated currents in recombinant receptors expressed in X. Laevis 
oocytes, but does not affect Zn
2+
 sensitivity. Receptors with the mutant 2 subunit 
(332R82Q) expressed in COS-7 cells display impaired receptor trafficking, and reduced 




retention and degradation causes abnormal receptor function when 122R82Q receptors 
were expressed in HEK293T cells (Wallace., et al., 2001; Kang and Macdonald, 2004; 
Frugier et al., 2007; Huang et al., 2014). 2R82Q receptors expressed in cultured rat 
hippocampal neurons and COS-7 cells show increased clathrin-mediated dynamin-
dependent endocytosis, hindering their detection on the cell membrane (Chaumont et al., 
2013). Animal studies revealed 2SR82Q mice displayed enhanced cortical spontaneous 
single-cell activity, membrane potential shift, and variance of stimulus evoked cortical 
responses after pentylenetetrazol (PTZ) injection, supporting the focus on the cortical 
region in the pathology of absence epilepsy (Tan et al., 2007; Witsch et al., 2015). A 
splice-site mutation in intron 6 of the GABRG2 was also found in patients with idiopathic 
absence epilepsies, CAE, and FS. This mutation is predicted to translate a nonfunctinal 
protein and may be involved in the pathophysiology of CAE and FS (Kananura et al., 
2002). 
A missense mutation (R177G) in the GABRG2 was reported in patients with FS, GEFS+, 
and CAE (Audenaert et al., 2006). The mutation, located in the BZ allosteric site, 
substitutes a highly conserved arginine with glycine at position 177 in the immature 
peptide. Receptors with mutant 2LR177G subunit expressed in HEK293T cells conferred 
faster current desensitization and decreased sensitivity to diazepam. The disruption of the 
BZ-binding site could be the reason for the diminished response to BZ drugs and 
abnormal receptor function and may contribute to the disinhibition of the brain. 2LR177G 
has been demonstrated to have decreased GABA sensitivity and surface expression due to 
the retention of receptors in the ER. 2LR177G subunits also showed impaired subunit 
folding and/or oligomerization and could interrupt intra-subunit salt bridges, and thereby, 
have destabilized secondary and tertiary structure (Todd et al., 2014).  
A missense mutation (P83S) in the GABRG2 was found in patients with idiopathic 
generalized epilepsies in a French Canadian family (Lachance-Touchette et al., 2011). 
The mutation, which showed high degree of penetrance, is caused by the change of the 




binding on the extracellular ligand-binding domain. Unlike other missense mutations 
found in the GABRG2 gene, functional analysis of the receptors revealed that 2P83S 
expressed in HEK293 cells does not alter the surface expression or the receptor 
sensitivity to Zn
2+
 or BZ when co-expressed with 1 and 2 subunits. Further 
experiments are needed to elucidate whether an appreciable phenotype can be observed in 
the receptors with this mutant when assembling with other subunits.  
A nonsense mutation (Q40X) in the GABRG2 was found in dizygotic twin girls with DS 
and their phenotypically healthy father in a Japanese family (Ishii et al., 2014). The 
mutation causes premature termination codons at position 40 of the GABRG2 molecule. 
The inward currents and current density of receptors with homozygous 2Q40X mutation 
expressed in HEK293T cells in response to GABA were intermediate between WT and 
heterozygous 122Q40X GABA-ARs, showing the haploinsufficiency effects of mutant 
2Q40X. In addition, cells expressing this mutant subunit have abnormal intracellular 
trafficking and impaired axonal transport of 1 and 2 subunits.  
I.7.5 Mutations of  Subunit 
The -containing GABA-ARs primarily control the baseline neuronal network 
excitability through shunting and tonic inhibition. Mutations in the gene encoding  
subunit of GABA-ARs (GABRD) are thought to be involved in the pathology of epilepsy 
(Dibbens et al., 2004; Feng et al., 2006). To date, three point mutations (E177A, R220C, 
and R220H) of GABRD have been described in patients with idiopathic generalized 
epilepsies (a cohort study with 72 unrelated IGE, 65 unrelated GEFS+ and 66 unrelated 
FS). Two missense mutations, E177A and R220C, located in the extracellular N-terminus 
of the  subunit were identified in a small GEFS+ family (Dibbens et al., 2004). E177 is 
located immediately adjacent to one of the two cysteines that form a disulfide bond, the 
signature feature of the cys-loop family of ligand-gated ion channels, and the R220 is 
positioned between the cys-loop and the first transmembrane domain. In HEK293T cells, 




decreased GABA sensitivity and increased neuronal excitability. Further investigation 
revealed that human recombinant 42 GABA-ARs with E177A and R220H variants 
have significantly reduced receptor surface expression and altered channel gating 
frequency, resulting in impaired inhibitory neurotransmission. In addition, mutations in 
the main cytoplasmic loop of the  subunit result in interrupted receptor trafficking and 
decreased surface expression in recombinant HEK 293 cells (Bracamontes et al., 2014). 
Since -containing GABA-ARs localize exclusively to extrasynaptic membranes and 
control tonic inhibition by continuously regulating the basal tone of inhibition when 
activated by GABA, alteration of features such as gating frequency or GABA sensitivity 
caused by mutations in  subunit genes may contribute to the idiopathic generalized 
epilepsies. 
I.7.6 Other GABA Receptor Subunit Mutations 
A mutation in GABRA6 (R46W) was found in a patient with CAE (Dibbens et al., 2009; 
Hernandez et al., 2011). This mutation, caused by the substitution of arginine to 
tryptophan at position 46, is located in the N-terminal extracellular domain of the 6 
subunit. Notably, R46 is a highly conserved residue identified from humans to D. 
melanogaster and C. elegans. R46W impaired receptor assembly/trafficking and gating in 
both 6R46W22L and 6R46W2 recombinant receptors expressed in X. Laevis oocytes. 
Surface expression of  subunits was also decreased in R46W, showing a similar trend 
with a study reported early that a dramatic decrease of cerebellar  subunit protein in 6 
knockout mice (Jones et al., 1997). These results suggest that mutations in GABRA6 
could lead to disinhibition and elevated susceptibility to genetic epilepsies due to 
compromised receptor function and membrane expression.  
In the past decades, no genetic studies demonstrated that mutations in GABRB2 are 
associated with genetic epilepsies. Until recently, Srivastava and colleagues reported a 
case study in which a de novo heterozygous missense mutation of GABRB2 was found in 




suggests the need for further investigation into the role of GABRB2 in the pathology of 
epilepsy and other neurological disorders. 
I.8 Insights from Transgenic Models on Tonic Inhibition 
In order to elucidate the distinctive pharmacological and functional properties and the 
role of the  subunit in brain disorders, a strain of mice globally lacking the  subunit 
(KO) of GABA-ARs was introduced in 1999 (Mihalek et al., 1999). Initial 
pharmacological and behavioral characterizations revealed the KO mice have 
significantly lower binding affinity for muscimol, a GABA binding agonist with high 
affinity to -containing GABA-ARs, and faster decay of mIPSCs and inhibitory 
postsynaptic potentials than that of WTs. In addition, KO mice show significantly 
decreased sleep time in response to alphaxolone, a neurosteroid and general anesthetic, 
diminished sensitivity to anxiolytic drugs examined by elevated plus-maze assay, 
diminished GX facilitated exacerbation of PTZ-induced absence seizure, and higher 
vulnerability to the chemoconvulsants seizures caused by GABA-AR antagonists. Their 
results suggest that deficiency of the  subunit of the GABA-ARs leads to a significant 
attenuation in the sensitivity to behavioral actions of neurosteroids, which may contribute 
to a higher degree of seizure susceptibility (Mihalek et al., 1999; Spigelman et al., 2002; 
Porcello et al., 2003; Spigelman et al., 2003; Chandra et al., 2010).  
The -specific selectivity for neurosteroid modulation is further confirmed by 
electrophysiological studies demonstrating suppressed responses to THDOC modulation 
such as decreased spontaneous IPSCs in cerebellar granule cells and decreased tonic 
conductance in DGGCs in the KO mouse model (Vicini et al., 2002; Wohlfarth et al., 
2002; Stell et al., 2003). In addition, attenuated response to AP potentiation of 
GABAergic and tonic currents is also evident in mice bearing a targeted deletion of the  
subunit, underscoring the role of -containing GABA-ARs for neurosteroid activity 
(Carver et al., 2014; Carver and Reddy, 2016). Reduced response to gaboxadol-induced 




containing GABA-ARs in the action of gaboxadol, a preferential agonist of -containing 
GABA-ARs at low concentrations (Boehm et al., 2006; Meera et al., 2011).  
In the composition of the receptor subunits, deletion of the  subunit accompanied the 
decreased expression of the 4 subunit and the increased expression of the 2 subunit in 
brain regions that normally contained the  subunit such as hippocampus and thalamus 
(Korpi et al., 2002; Peng et al., 2002). The results from electrophysiology, animal 
knockout models, and immunohistochemistry specific to DGGCs indicate that 42 
GABA-ARs are the major receptors located in extrasynaptic sites and responsible for 
tonic current inhibition in DGGCs (Sun et al., 2004; Chandra et al., 2006; Herd et al., 
2008). The α5 subunit contributes to the remaining tonic currents in DGGCs (Glykys et 
al., 2008; Carver and Reddy, 2013). The -containing GABA-ARs are highly sensitive to 
Zn
2+
 and the Zn
2+
-reduced decay time and amplitude of evoked IPSCs in DGGCs from 
WT is lacking in KO mice. Recently, we have uncovered that Zn
2+
 showed a 
concentration-dependent blockade of AP-potentiated tonic currents in DGGCs. Moreover, 
Zn
2+ 
inhibition of AP-sensitive tonic currents is absent in KO mice (Wei et al., 2003; 
Carver et al., 2016). Animal studies further revealed that Zn
2+ 
prevents the antiseizure 
activity of AP in epileptic mice, suggesting that Zn
2+
 blockade of neurosteroid-sensitive, 
extrasynaptic -containing GABA-ARs in the hippocampus possesses implications in a 
variety of neuronal hyperexcitability disorders like SE and epilepsy. 
I.9 Therapeutic Insights of Tonic Inhibition in Epilepsy 
Extrasynaptic GABA-ARs are involved in the pathophysiology of certain brain 
conditions, such as catamenial epilepsy, SE, and other neuroendocrine disorders (Belelli 
and Lambert 2005; Brickley and Mody, 2012; Reddy, 2013ab; 2016a). Consequently, 
these receptors are emerging as novel targets for excitability disorders (Reddy and Estes, 
2016). Substantial evidence suggests that neurosteroid-sensitive, extrasynaptic GABA-
ARs play a critical role in the pathophysiology of catamenial epilepsy, a menstrual cycle-




and Rogawski, 2001; 2012; Reddy et al., 2001; 2012; Wu et al., 2013). Although this 
condition has been documented for millennia, there is currently no effective treatment for 
catamenial seizures, leaving many women and their families desperate for answers. 
Recently, a catamenial-like seizure exacerbation has been clearly demonstrated in mice 
with targeted ablation of extrasynaptic δGABA-ARs in the brain (Clossen and Reddy, 
2017). This has substantially bolstered the role of tonic inhibition in catamenial epilepsy 
(Reddy, 2016a). In essence, extrasynaptic δGABA-ARs are strikingly upregulated during 
perimenstrual-like neuroendocrine milieu (Gangisetty and Reddy, 2010; Carver et al., 
2014). Consequently, there is greater antiseizure efficacy of neurosteroids in catamenial 
models because δGABA-ARs confer enhanced neurosteroid sensitivity and greater 
seizure protection. Therefore, this molecular mechanism of tonic inhibition as the major 
regulator of the catamenial seizures is providing a strong platform for “neurosteroid 
replacement therapy,” a pulse therapy with low doses of synthetic neurosteroid agents 
that may effectively control catamenial seizures without hormonal side effects (Reddy 
and Rogawski, 2009).  
Neurosteroid levels are reduced during SE, a neurological emergency characterized by 
continuous seizure activity or multiple seizures without regaining consciousness for more 
than 30 minutes (Meletti et al., 2017). BZs such as lorazepam and MDZ are the primary 
anticonvulsants for SE, but some patients do not respond to these treatments, a condition 
referred as refractory SE (Reddy and Reddy, 2015).  BZs target synaptic GABA-ARs, but 
have little effect on extrasynaptic isoforms which are responsible for tonic inhibition 
(Reddy et al., 2015). There are many theories but functional inactivation of synaptic 
GABA-ARs via active internalization appears a lead physiological mechanism by which 
BZ resistance emerges in SE (Naylor et al., 2005; Reddy and Reddy, 2015). Therefore, 
neurosteroid agents such as AP and its synthetic analogs, which potentiate both phasic 
and tonic current, have been proposed as better anticonvulsants for SE (Briyal and Reddy, 
2008; Reddy, 2009b; Rogawski et al., 2013). Clinical evaluation of AP is in progress to 




Synthetic neurosteroids are proposed as novel anticonvulsant antidotes for chemical 
intoxication caused by organophosphate (OP) pesticides and nerve agents like sarin and 
soman (Reddy, 2016c). BZs, such as diazepam, are the current anticonvulsants of choice 
for controlling nerve agent–induced seizures, SE, and brain injury. BZs can control acute 
seizures when given early, but they are ineffective for delayed treatment of SE after nerve 
agent exposure (Reddy and Reddy, 2015). Neurosteroid-sensitive extrasynaptic GABA-
ARs are minimally impacted by OP intoxication. Thus, anticonvulsant neurosteroids may 
produce more effective protection than BZs against a broad spectrum of chemical agents, 
even when given late after nerve agent exposure, because neurosteroids can activate both 
synaptic and extrasynaptic GABA-ARs and thereby can produce maximal inhibition 
(Carver and Reddy, 2016). An intramuscular GX product is being developed as 
anticonvulsant antidote for nerve agents (patent #WO2016036724A1). A neurosteroid 
therapy with a synthetic neurosteroid such as GX has been found to more protective than 
MDZ for controlling persistent SE and neuronal damage caused by OP pesticides and 
nerve agents (Reddy, 2016c).  Although neurosteroids show great promise in the 
treatment of SE, none are currently approved by the FDA for clinical use. 
Some endogenous neurosteroids, such as dehydroepiandrosterone sulfate (DHEAS), are 
negative modulators of GABA-ARs and can cause proconvulsant actions (Majewska et 
al., 1990; Reddy and Kulkarni, 1998). It is likely that such actions have clinical 
implications in certain physiological and pathological conditions (Galimberti et al., 2005; 
Reddy, 2006; 2009; Pack et al., 2011). It is hypothesized that the increase in the 
frequency of onset of seizures during the process of adrenarche, which is associated with 
a massive increase in DHEAS production, is caused by DHEAS’s ability to block 
GABA-ARs. However, it remains unclear if DHEAS can negatively modulate 
extrasynaptic GABA-ARs in the brain. In addition, there are developmental changes in 
hippocampal extrasynaptic GABA-ARs during puberty with significant impact on 








The main objective of this dissertation is to investigate the molecular, cell-specific, and 
phosphorylation-dependent mechanisms of action of the synthetic neurosteroid GX and 
related neurosteroid agents at extrasynaptic GABA-ARs. We use a combination of 
pharmacological, electrophysiological, and behavioral approaches to address the 
proposed questions. In addition, structure-activity relationships of synthetic analogs are 
tested in native neurons. This study also aims to examine the influence of protein kinase 
activity on the neurosteroid mechanism of action in native neurons. We also explore the 
physiological interaction between neurosteroids and Zn
2+
 at extrasynaptic GABA-ARs 
as well as the combination potential of GX with other AEDs for epilepsy.  
II.1 Specific Aim 1  
The first specific aim investigates the mechanisms of action and structure-activity 
relationships of GX and related neurosteroid analogs on extrasynaptic GABA-AR-
mediated tonic inhibition and seizure protection. 
The GABA-ARs regulate fast inhibitory transmission in the brain. These chloride 
channels are composed of a pentamer of subunits, of which there are 19 subtypes (1-6, 
1-3, 1-3, , , , , 1-3). There are two classes of GABA-ARs in the hippocampus, 
categorized based on their localization (Chuang and Reddy, 2018a). Synaptic receptors 
(-containing) are responsible for phasic inhibition via synaptic neurotransmission, 
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whereas extrasynaptic receptors (4/-containing in dentate gyrus, 5/2-containing in 
CA1) mediate tonic inhibition through high affinity and low-efficacy binding of ambient 
GABA. Endogenous neurosteroids are potent allosteric agonists of GABA-ARs. AP is an 
endogenous neurosteroid with potent antiseizure effects mediated by GABA-ARs (Reddy 
et al., 2014; Clossen and Reddy, 2017a). Neurosteroids have a greater sensitivity for 
GABA-ARs, which are highly expressed in the dentate gyrus (Brown et al., 2002; 
Bianchi and Macdonald, 2003; Carver and Reddy, 2013). Natural neurosteroids have 
several limitations for therapeutic use, including low bioavailability, ultra-short t1/2, and 
hormonal side effects due to steroid metabolites (Rupprecht et al., 1993). Therefore, 
synthetic analogs have been prepared to surpass these limitations (Reddy and Estes, 
2016). GX is the 3-methylated analog of AP, first characterized in 1997 with 
recombinant 112L receptors expressed in Xenopus oocytes (Carter et al., 1997). GX 
was shown to have comparable modulatory activity to that of AP. The synthetic 3-
substitution provides a more favorable pharmacokinetic profile as an AED, overcoming 
the limitations of lower bioavailability and short t1/2 by preventing the oxidation of the 
3-hydroxyl group (Carter et al., 1997). GX has broad-spectrum anticonvulsant activity 
in animal seizure models, and is currently being evaluated in clinical trials for the 
treatment of epilepsy including partial-onset seizures, infantile spasms, catamenial 
epilepsy, genetic seizure conditions, and chemical neurotoxicity (Kerrigan et al., 2000; 
Laxer et al., 2000; Nohria and Giller, 2007; Pieribone et al., 2007; Reddy and Rogawski, 
2012; Bialer et al., 2015; Braat et al., 2015; Reddy, 2016a; Clossen and Reddy, 2017b; 
Sperling et al., 2017; Younus and Reddy, 2018). Surprisingly, there is limited literature 
investigating the mechanism of action of GX in the brain. 
Phosphorylation status of GABA-ARs influences surface expression, chloride 
conductance, and sensitivity to neurosteroids. Several GABA-AR subunits contain 
residues that can be phosphorylated by protein kinases (Moss and Smart, 1996; Brandon 
et al., 2000; Chuang and Reddy, 2018a). Conserved serine residues (Ser-409 or Ser-410) 




protein kinase. Two additional serine residues of the  subunits (Ser-408 and Ser-383) are 
phosphorylated by PKA and CaMKII, respectively (McDonald et al., 1998; Saliba et al., 
2012). Additionally, the serine residues (Ser-443) within the intracellular domain of the 
4 subunit, and the Ser-408 and Ser-409 in 3 subunits are phosphorylated by PKC 
(Leidenheimer and Chapell, 1997; Fancsik et al., 2000; Harney et al., 2003; Abramian et 
al., 2010; Abramian et al., 2014; Adams et al., 2015). However, the extent of functional 
impact of PKC activity on the neurosteroid potentiation of extrasynaptic GABA-AR-
mediated tonic inhibition remains unclear. 
In this aim, we investigate the molecular mechanisms of GX modulation of synaptic and 
extrasynaptic GABA-ARs in a cell-specific and phosphorylation-dependent pathway as 
well as the structure-activity relationships of GX and related neurosteroid analogs on 
extrasynaptic GABA-AR-mediated tonic inhibition and seizure protection. 
II.2 Specific Aim 2 
The second specific aim investigates the influence of Zn
2+
 on neurosteroid activation of 
extrasynaptic GABA-AR-mediated tonic inhibition and seizure protection. 
The hippocampus is a key region associated with the pathophysiology of epilepsy (Jutila 
et al., 2002). There are two distinct categories of GABA-ARs in the hippocampus. 
Synaptic receptors and extrasynaptic receptors exhibit different characteristics in their 
affinity and efficacy to GABA, desensitization rate, and drug sensitivity (Bianchi and 
Macdonald, 2002; 2003; Brown et al., 2002; Wohlfarth et al., 2002; Mortensen et al., 
2011). Synaptic receptors, mainly -containing receptors, produce rapid and transient 
phasic currents in response to presynaptic release of GABA (~1 mM), whereas 
extrasynaptic receptors, mostly -containing receptors in dentate gyrus and 532 
receptors in CA1, generate persistent, non-desensitizing tonic currents by ambient GABA 
(~0.3  2 M) (Mody et al., 1994; Brickley et al., 1996; Farrant and Nusser, 2005). Tonic 




channel conductance in neurons expressing -containing receptors. Hippocampus dentate 
gyrus granule cells (DGGCs), which express high density of  subunit-containing 
extrasynaptic receptors, promote tonic inhibition and thereby regulate network 
excitability (Coulter and Carlson, 2007; Glykys et al., 2008). GABA-ARs are modulated 





 is the second most abundant trace metal in many cells and neurons in the brain. It 
regulates cellular functions such as gene expression, epigenetic enzymatic activity, 
protein structural stability, and neuronal plasticity. Zn
2+
 is particularly abundant in the 
cortex and limbic system, including hippocampus and amygdala (Frederickson, 1989; 
Frederickson et al., 2000; 2005; Gower-Winter and Levenson, 2012; Szewczyk, 2013). 
Zn
2+
 homeostasis in the brain is tightly controlled and primarily regulated by Zn
2+
 
transporters and binding proteins. High level of “chelatable” Zn
2+
 is sequestered in the 
synaptic vesicles of glutamatergic neurons through Zn
2+
 transporter protein ZnT3. Other 
transporters like ZIP proteins promote the efflux of vesicular Zn
2+
 and increase the 
concentration of cytoplasmic Zn
2+
 (Cole et al., 1999; Kambe et al., 2004; Lee et al., 
2011). Zn
2+ 
is synaptically co-released with glutamate from presynaptic vesicles of the 
hippocampal mossy fibers, the axons of DGGCs (Frederickson et al., 1983; Assaf and 
Chung, 1984; Molnar and Nadler, 2001; Paoletti et al., 2009). Zn
2+
 has been shown to 
modulate both excitatory and inhibitory transmission (Westbrook and Mayer, 1987; 
Harrison and Gibbons, 1994; Vogt et al., 2000). Zn
2+
 inhibits GABA-ARs and has 
distinct sensitivities at different receptor subtypes partly due to the accessibility of Zn
2+
 
binding sites (Smart et al., 1991; Barberis et al., 2000; Ruiz et al., 2004). The -
containing extrasynaptic receptors exhibit greater sensitivity to Zn
2+
 blockade than -
containing synaptic receptors (Hosie et al., 2003). Alterations in Zn
2+
 homeostasis have 
implications in several neurological disorders (Frederickson et al., 2005; Bitanihirwe and 
Cunningham, 2009; Qian et al., 2011; Szewczyk, 2013; Prakash et al., 2015). Aberrant 
Zn
2+
-rich mossy fiber sprouting is a classical feature in limbic epileptogenesis (Cavazos 
et al., 1991). Excessive release of Zn
2+




circuits and plays an important role in the pathophysiology of epilepsy (Takeda et al., 
1999; Coulter, 2000; Foresti et al., 2008; Elsas et al., 2009).  
AP and related neurosteroids are endogenous modulators of neuronal excitability and 
seizure susceptibility (Chuang and Reddy, 2018ab; Younus and Reddy, 2018). 
Neurosteroids modulate GABA-ARs primarily via allosteric potentiation of GABA at 
nanomolar concentrations and through direct activation of the channel at micromolar 
concentrations (Hosie et al., 2007). AP has powerful antiseizure activity (Kokate et al., 
1996; Kaminski et al., 2003; Kaminski et al., 2004; Carver et al., 2016; Reddy and Estes, 
2016). GX, a synthetic analog of AP, is designed to treat epilepsy and related seizure 
conditions. GX produces robust positive allosteric modulation of GABA-ARs, with 
preferential sensitivity at  subunit-containing extrasynaptic receptors (Chuang and 
Reddy, 2018b). GX has a more favorable biopharmaceutical profile than AP due to its 
higher bioavailability and less hormonal side effects (Carter et al., 1997; Reddy and 
Woodward, 2004; Carver and Reddy, 2016). GX produces powerful antiseizure activity 
in a wide range of experimental models, and is being evaluated in clinical trials for 
epilepsy (Kerrigan et al., 2000; Laxer et al., 2000; Nohria and Giller, 2007; Pieribone et 
al., 2007; Reddy and Rogawski, 2012; Bialer et al., 2015; Braat et al., 2015; Sperling et 
al., 2017). Recently, Zn
2+
 has been shown to selectively block neurosteroid-sensitive, 
extrasynaptic GABA-ARs in the hippocampus (Carver et al, 2016). Therefore, it is 
likely that Zn
2+
 may exert antagonistic effects on GX modulation of tonic inhibition and 
seizure protection. 
In this aim, we investigate the pharmacodynamic interactions of Zn
2+
 and GX at 
extrasynaptic GABA-ARs and its functional relevance on the anticonvulsant activity of 
GX in the kindling model.  Our results demonstrate that Zn
2+
 diminishes the antiseizure 





II.3 Specific Aim 3 
The third specific aim investigates the combination efficacy of neurosteroids AP and GX 
with the GABA-reuptake inhibitor tiagabine (TG) or the benzodiazepine midazolam 
(MDZ) on tonic inhibition in dentate gyrus granule cells (DGGCs) and seizure protection 
in the hippocampus kindling and 6-Hz seizure models. 
Antiepileptic drugs (AEDs) are the mainstay for the treatment of epilepsy, a chronic 
neurological disorder that affects nearly 65 million people worldwide (Thurman et al., 
2011; Hesdorffer et al., 2013). AEDs are the most effective interventions to suppress the 
occurrence of seizures; however, approximately 30% of epilepsy patients are 
unresponsive to current AEDs when used in monotherapy. Consequently, a 
polypharmacy with combination of two or more AEDs is used to improve seizure control 
in persons with refractory epilepsy. Drugs given in combination may produce effects that 
are additive or synergistic that is estimated using isobolograms (Tallarida, 2006), 
including select AED combinations (Luszczki and Czuczwar, 2004; Kwan and Brodie, 
2006; Luszczki, 2008a; b). Neurosteroids are developed as novel AEDs for epilepsy 
(Reddy and Estes, 2016). Combination of a neurosteroid with GABAergic AED may 
enhance seizure control in refractory epilepsy.  
GABA-ARs are the prime targets of AEDs such as benzodiazepines, neurosteroids and 
TG. There are two subtypes of GABA-ARs in the brain, namely synaptic and 
extrasynaptic receptors (Chuang and Reddy, 2018a). Synaptic GABA-ARs generate 
transient inhibitory postsynaptic current, whereas extrasynaptic GABA-ARs generate a 
tonic inhibitory current that regulates neuronal network excitability. Extrasynaptic 
GABA-ARs typically contain either  or α5 subunits, in combination with β2 or β3 
subunits and elicit the basal inhibitory tone referred as tonic inhibition (Bianchi and 
Macdonald, 2003; Coulter and Carlson, 2007; Glykys et al., 2008). Extrasynaptic 
GABA-ARs are expressed in a cell-type specific fashion in key brain areas such as 




hippocampus is linked to epilepsy pathology (Jutila et al., 2002; Mortensen et al., 2011). 
Tonic inhibition plays a critical role in epilepsy (Carver et al., 2014; Reddy, 2018). 
Neurosteroids such as AP are potent allosteric agonists of GABA-ARs, especially 
extrasynaptic GABA-ARs (Chuang and Reddy, 2018a). AP has been shown to have 
robust anticonvulsant activity (Rupprecht, 2003; Belelli and Lambert, 2005; Carver and 
Reddy, 2013; Brown et al., 2015; Porcu et al., 2016; Chuang and Reddy, 2018b). GX, a 
synthetic analog of AP, is a broad-spectrum anticonvulsant agent with greater 
bioavailability and reduced side effects compared to AP. Like AP, GX is a powerful 
allosteric modulator of synaptic and extrasynaptic GABA-ARs (Carter et al., 1997; 
Chuang and Reddy, 2018b). GX is undergoing clinical trials for refractory epilepsy, 
pediatric genetic epilepsies, and status epilepticus (Nohria and Giller, 2007; Pieribone et 
al., 2007; Reddy and Rogawski, 2010; 2012; Porcu et al., 2016; Ligsay et al., 2017). 
However, the antiepileptic potential of GX or other neurosteroids in combination with 
current AEDs has not yet been investigated. It is postulated that a combination therapy 
utilizing pair compounds with distinct GABAergic mechanisms might provide additive or 
synergistic therapeutic efficacy at doses that would minimize or eliminate unwanted side 
effects.  
TG is an adjunct AED for partial seizures (Goldenberg, 2010). TG, a GABA-reuptake 
inhibitor, increases GABA level in the synaptic cleft by selective blockade of the GABA 
transporter GAT-1 (Adkins and Noble, 1998; Meldrum and Chapman, 1999). The major 
limitations of TG include lack of robust antiseizure efficacy and adverse effects such 
dizziness nervousness, seizures, and tremors. It is suggested that a combination treatment 
of TG with neurosteroids might be a rational strategy to design a robust anticonvulsant 
drug regimen. To evaluate the effect of neurosteroids and TG combinations, we utilized 
the isobolographic analysis, a well-accepted approach for the assessment of drug 
interactions (Grabovsky and Tallarida, 2004; Luszczki, 2008a; b). It typically includes 
two types: type I is used to evaluate drugs that are fully active, while type II is used when 
one of the drugs tested has no effects (Berenbaum 1989). Drug combination analysis with 




drugs tested as synergistic, additive or antagonistic (Grabovsky and Tallarida 2004; 
Tallarida 2006; 2007).  
In this aim, we sought to investigate the combination interactions between neurosteroids 
and TG or neurosteroid and MDZ on extrasynaptic tonic inhibition in the hippocampus 
and seizure protection in the hippocampus kindling and 6-Hz seizure models. Our 
isobolographic studies demonstrate a synergistic anticonvulsant effect of neurosteroid  
TG combinations, and as well as neurosteroid  MDZ regimens, indicating a role for 









III.1 Experimental Animals 
Young adult (2  3 months-old) male C57BL/6 mice were used in the study. Experiments 
were conducted in wildtype (WT) and GABA-AR  subunit knockout (Gabrd
-/-
, KO) 
mice (Mihalek et al., 1999) that were maintained on a hybrid C57BL/6-129SV genetic 
background. Four mice were housed per cage under standard laboratory conditions with a 
12 h light/dark cycle. The animals were cared for in compliance with the guidelines in the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. Animal 
procedures were conducted in compliance with a protocol approved by the Texas A&M 
Institutional Animal Care and Use Committee. 
III.2 Electrophysiology Studies 
III.2.1 Hippocampal Slice Preparation  
Patch-clamp electrophysiological studies were conducted in acutely dissociated neurons 
and slices using established methods as described previously (Reddy and Jian, 2010; 
Carver and Reddy, 2016). Adult male mouse was anesthetized with isoflurane and the 
brain was rapidly removed and placed in ice-cold artificial cerebrospinal fluid (aCSF) 
buffer. Transverse slices (320 μm thickness) of the hippocampus were obtained with a 
Vibratome in 3.5˚C aCSF (model 1500 with 900 Refrigeration System; Leica 
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Microsystems, Inc., Bannockburn, IL). The aCSF buffer for slice cutting was composed 
of (in mM): 0.3 kynurenic acid (Tocris Bioscience, Bristol, UK), 126 NaCl, 3 KCl, 0.5 
CaCl2, 5 MgCl2, 26 NaHCO3, 1.25 NaH2PO4, 11 glucose (pH adjusted to 7.35  7.40 
with 95% O2  5% CO2, 305  315 mOsm/kg).  
III.2.2 Dissociation of Neurons  
Hippocampus CA1 and DG neurons were acutely dissociated by the standard enzymatic 
technique as described previously (Kay and Wong, 1986; Reddy and Jian, 2010). The 
hippocampal CA1 or DG region was microdissected under a microscope (model SMZ 
647; Nikon, Tokyo, Japan) and incubated in aCSF for 1 h at 28°C. The isolated CA1 and 
DG slices were transferred into an enzymatic solution containing aCSF with protease 
XXIII (3 mg/ml, Sigma-Aldrich, St. Louis, MO). Next, the slices were incubated for 
precisely 23 to 25 min at 28°C, rinsed twice with aCSF, and gently triturated through 
three fire-polished Pasteur pipettes to yield single cells. For each batch, slices were 
triturated six to eight times with each pipette in approximately 1 ml of aCSF. Then, the 
solution was allowed to settle for 1 min, and the suspension of freshly isolated cells was 
plated onto the recording chamber (Warner Instruments, Hamden, CT).  
III.2.3 Recording of GABA-Gated Currents 
Whole-cell patch-clamp configuration was used for electrophysiological recordings in 
dissociated cells (Reddy and Jian, 2010). Experiments were performed at room 
temperature (22  24 °C). The recording chamber was fixed into the stage of an inverted 
microscope with phase-contrast and differential interference contrast optics (model IX71; 
Olympus, Tokyo, Japan). The physiological bath solution for the recording of dissociated 
neurons was composed of (in mM): 140 NaCl, 3 KCl, 10 HEPES, 2 MgCl2, 2 CaCl2, and 
16 glucose (pH adjusted to 7.4 with NaOH, osmolarity, 315 – 325 mOsm/kg). Cells were 
visualized and images were acquired through video camera CCD-100 (Dage-MTI, 




pipettes were pulled from capillary glass tubes (King Precision Glass, Claremont, CA) 
using a P-97 Flaming-Brown horizontal puller (Sutter Instrument Company, Novato, CA). 
The pipette tip resistances were 4 to 6 M for recording. The recording pipettes were 
filled with a cesium pipette solution containing (in mM): 124 CsCl, 20 
tetraethylammonium, 2 MgCl2, 10 EGTA, 10 HEPES, 0.1 GTP, 4 ATP (pH adjust to 7.2 
with CsOH, osmolarity, 295 – 305 mOsm/kg). Currents were recorded using an Axopatch 
200B amplifier (Molecular Devices, Sunnyvale, CA). The membrane capacitance, series 
resistance, and input resistance of the recordings were monitored by applying a 5-mV 
(100-ms) depolarizing voltage step from a holding potential of 70 mV for dissociated 
cells. Signals were low-pass filtered at 2 kHz and digitized at 10 kHz with Digidata 
1440A system. The current values were normalized to cell capacitance (an index of cell 
size) and expressed as current density (pA/pF). Fractional potentiation generated by 
allosteric modulator was expressed as IA/IGABA, where IGABA is the GABA peak current 
amplitude and IA is the peak current response of the co-application of GABA and the 
allosteric drug (0.05 to 1 M). GABA at 3 M produced 10% of the maximal current 
(EC10), as described previously in dissociated murine CA1PCs (Reddy and Jian, 2010) 
and DGGCs (Wu et al., 2013; Carver and Reddy, 2016). The concentration-response 
relationship was fitted by the nonlinear Hill function to derive the EC50, which is the 
concentration of test drug required to generate 50% of maximal efficacy. For whole cell 
current from isolated single cells, current response was expressed as the percentage of 
potentiation produced by GABA or GABA + GX. For fast application of test drugs, the 
perfusion pipette was positioned < 200 µm away from the cell in the chamber. GABA, 
GX, and Zn
2+
 (1  30 μM) were applied using a multi-channel perfusion system 
(Automate Scientific, Berkeley, CA). A two-minute wash with bath solution was 
instituted after each drug trial in order to prevent receptor desensitization. 
III.2.4 Slice Patch-Clamp Electrophysiology 
Electrophysiological recordings in hippocampal slices were performed in the whole-cell 




Hippocampal neurons were visually identified with an Olympus BX51 microscope 
equipped with a 40x water-immersion objective, infrared-differential interference 
contrast optics, and video camera. Hippocampal slices (320 µm) were maintained in 
continuously oxygenated aCSF at 28°C in a holding chamber for 60 min, and 
experiments were performed at room temperature (22  24 °C) as described by other 
groups (Vicini et al., 2002; Scimemi et al., 2006; Nani et al., 2013; Gong and Smith, 
2014). The physiological bath solution for whole-cell recording from slice was composed 
of (in mM): 124 NaCl, 3 KCl, 1.5 MgSO4, 2.4 CaCl2, 1.25 NaH2PO4, 26 NaHCO3 and 10 
glucose (pH adjusted to 7.4 with NaOH, osmolarity, 295  305 mOsm/kg). The pipette 
tip resistances were 5 to 7 M for slice recordings, and were filled with a cesium pipette 
solution containing (in mM): 124 CsCl, 20 tetraethylammonium-chloride, 2 MgCl2, 10 
EGTA, 10 HEPES, 0.1 GTP, 4 ATP, and 5 lidocaine N-ethyl bromide (QX-314), (pH 
adjusted to 7.2 with CsOH, osmolarity, 295–305 mOsm/kg). Currents were recorded 
using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA). The membrane 
capacitance, series resistance, and input resistance of the recordings were monitored by 
applying a 5-mV (100-ms) depolarizing voltage step from a holding potential of 65 mV 
for slice recordings. Signals were low-pass filtered at 2 kHz and digitized at 10 kHz with 
Digidata 1440A system.  
III.2.5 Tonic Current Recording and Analysis 
Tonic and phasic currents of GABA-ARs were recorded in the presence of tetrodotoxin 
(TTX, 0.5 M, Na
+
 channel blocker and inhibition of action potential-evoked 
neurotransmitter release), D,L-2-amino-5-phosphonovaleric acid (APV, 40 M, N-
methyl-D-aspartate channel blocker), and 6,7-dinitroquinoxaline-2,3-dione (DNQX, 10 
M, non-N-methyl-D-aspartate glutamate receptor blocker). The competitive antagonist 
gabazine (SR-95531, 50 M) was added to perfusion at the conclusion of slice recordings 
to confirm block of GABAergic currents. Drugs were delivered to the bath chamber using 




was maintained at 2 ml/min. Drugs were allowed 2  4 min to perfuse into the bath 
chamber and slice before measurements were obtained. Four to six mice were used to 
obtain adequate sample size for recording of tonic currents. 
Off-line current analysis was performed with pClamp 10.2 software (Molecular Devices, 
Sunnyvale CA) and in-house software. To study the tonic inhibitory currents, transient 
events were manually removed from the current trace, so that the recording consisted 
only of the holding current in the voltage-clamp mode (Wu et al., 2013). Averaged 
amplitude of tonic current shift in conductance and root-mean-square (RMS) noise 
amplitude were measured. The tonic current response was expressed as the differences in 
holding current before and after application of gabazine (50 µM) or Zn
2+
 (0.1  10 mM). 
IRMS is the noise conductance from chloride ions passing through the opened channels 
and in proportion to the chloride driving force. Tonic current was measured and averaged 
in 100 ms per epoch with 1 sec interval between epochs for 30 epochs. The 
measurements were taken 30 s before and 2  3 min after application of a drug. IRMS was 
studied in 50 ms each epoch with 500 ms interval between epochs for 30 epochs before 
and after drug application in each cell. To assess the effects of a drug on IRMS in an 
individual neuron, the distribution of IRMS in 30 epochs before the application of a drug 
(during the baseline period) was compared with that after drug application by a Student’s 
independent t-test. To compare data obtained from a group of neurons, IRMS values in 
individual epochs before and after drug application were averaged. Changes in IRMS are 
expressed in pA of current. Currents for a single cell were normalized to membrane 
capacitance (pA/pF) as tonic current density. Concentration-response curves were 
subjected to non-linear, logistic fitting. A curve fitting was applied for concentration-
responses that achieved a plateau at maximal levels. 
III.2.6 Miniature Postsynaptic Current Recording and Analysis 
Synaptic currents were recorded and analyzed as previously described (Carver et al., 




The amplitude and kinetics of mIPSCs were measured using MiniAnalysis software 
(Synaptosoft, NJ), with the threshold for detection set at least three times the baseline 
RMS noise. The characteristics of amplitude, frequency, rise time, and decay time 
constants of the mIPSCs were determined and compared between groups. The decay of 
averaged mIPSC within DGGCs was best fit with a double exponent time constant (Stell 
et al., 2003). Nonoverlapping events with single peaks were used to create an ensemble 
average mIPSC. A mean weighted decay time constant was determined from 
biexponential fitting function I(t) = A1 x e
(-t/τ1) 
+ A2 x e
(-t/τ2)
 as τw = (A1 x τ1 + A2 x τ2) / 
(A1 + A2).   
III.3 Seizure Models 
III.3.1 Hippocampus Kindling Model  
A hippocampus kindling model was used in seizure experiments (Reddy and Mohan, 
2011; Reddy et al., 2015). Mice were anesthetized by intraperitoneal injection of 
ketamine (100 mg/kg) and xylazine (10 mg/kg). A bipolar electrode fixed to a guide 
cannula (Plastics One) was stereotaxically implanted in the right ventral hippocampus 
(2.9 mm posterior, 3.0 mm lateral, and 3.0 mm below dura). After postoperative recovery, 
animals were subjected to kindling stimulation (Reddy and Mohan, 2011). The 
electrographic afterdischarge (AD) threshold was determined by application of 1 ms 
biphasic rectangular pulses at 60 Hz for 1 s, in increments of 25 A using an isolated 
pulse stimulator (A-M Systems). AD duration was the total duration of electrographic 
spike activity (amplitude >2X baseline) occurring in a rhythmic pattern at a frequency > 
1 Hz. Mice were stimulated at 125% AD threshold once per day until Stage 5 seizures 
were elicited on 3 consecutive days, considered the fully kindled state. The electrographic 
activity was recorded using Axoscope 8.0 software with Digidata 1322A interface 
(Molecular Devices) through a Grass CP511 preamplifier (Astro-Med). Behavioral 
seizures were rated according to Racine’s scale as modified for mouse (Racine, 1972)  




chewing and head nodding; stage 3= forelimb clonus; stage 4= bilateral forelimb clonus 
and rearing; stage 5= bilateral forelimb clonus/ rearing and falling. One week after 
kindling, ZnCl2 (10   300 M) was dissolved in sterile saline and microinfused in 5 l 
volume directly into the hippocampus using a perfusion pump at 0.2 l/min. Mice were 
monitored for seizures and electrographic activity for at least 10 min. GX (s.c.) was 
administered 15 min after infusion of Zn
2+
. AP and GX were made in 20% -cyclodextrin 
solution for in vivo study. Drugs were given subcutaneously in a volume equivalent to 
1% of the body weight of the animals 15-min before kindling stimulations. Mice were 
scored for protection based on the behavioral motor seizures and AD duration after each 
kindling session. 
III.3.2 Six-Hertz Seizure Model  
The 6-Hz mouse model of partial seizures was used as previously described (Reddy et al., 
2015). Mice were electrically stimulated via cornea for 0.2-millisecond-duration 
monopolar low-frequency rectangular pulses at 6-Hz for 3 seconds (World Precision 
Instruments, Sarasota, FL). Current value causing seizures in 50% of animals was 
determined by administering different current intensities in the range of 6 – 44 mA to a 
group of control animals. Current intensity at 38 mA was determined to elicit seizures in 
100% population of male mice and delivered as the standardized intensity for the in vivo 
studies of combination therapy. The ocular anesthetic tetracaine (0.5%) drops were 
applied to each eye 10 minutes before stimulation. The corneal electrodes were wetted 
with 0.9% saline solution immediately prior to stimulation. Animals were manually 
restrained for stimulation and immediately released into a chamber for behavioral 
observation. Test drugs were administered 15 min before stimulation. The duration of 
seizure activity ranged from 20 to 60 seconds in untreated, control mice. Animals were 
considered to be protected if they resumed normal exploratory behavior within 10 





III.4 Zinc Administration 
Zinc doses were given acutely via intrahippocampal microinfusion in mice, as previously 
described (Carver et al., 2016). The sterile saline was used as a control. Apart from a 
bipolar electrode in the hippocampus, a 26 gauge guide cannula (Plastics One) was 
stereotaxically implanted into the left ventral hippocampus (2.9 mm posterior, 3.0 mm 
lateral, and 3.0 mm below dura). After a period of at least 1 week of recovery, dual-
implanted animals were subjected to kindling. Zinc was dissolved in sterile saline. Mice 
received zinc doses (10  300 M) by slow intrahippocampal microinfusion 10 min prior 
to GX administration and 25 min before kindling stimulations. The efficiency of zinc 
delivery was confirmed by the correct placement of the guide cannula by histology 
(Carver et al., 2016).  
III.5 Isobolographic Analysis of Drug  Drug Interactions. 
Interactions between neurosteroids and TG or MDZ against 6-Hz-induced seizures were 
examined using established methodology as described previously (Łuszczki 2008a, b). 
Briefly, the median effective dose (ED50) of each drug administered alone in the 6-Hz 
seizure model was first determined by using log-probit linear regression analysis 
(Litchfield and Wilcoxon, 1949). Next, the theoretical additive ED50 add values ± standard 
error of mean (SEM) for the mixtures of tested drugs at three fixed ratio of 1:1, 1:3, and 
3:1 (the most commonly used drug-dose ratio combinations for the evaluation of drug 
interactions) were calculated. The ED50 add value is a total additive dose of the two drugs 
in the mixture, exerting theoretically a 50% protection against 6-Hz-induced seizures. 
The ED50 mix values are experimentally determined total doses of a mixture of two tested 
drugs administered at a fixed-ratio combination sufficient for 50% protection against 6-
Hz-induced seizures and were derived from the seizure protection exerted by each 
mixture at 1:3, 1:1 and 3:1 (Fig. 29F; Table 9).  
For the analysis of electrophysiological tonic currents, the isobologram method was 




inhibition. We utilized the EF2-fold values that represent the effective functional 
concentration of drug (nM) required to double the basal tonic response in DGGCs. 
Briefly, the EF2-fold values of tested drugs were deduced from their concentration-
response curves. The theoretical EF2-fold (EF2-fold add) values for mixtures were calculated 
and tested in DGGCs to quantify the contribution of each drug to the overall effects. The 
experimental EF2-fold (EF2-fold mix) values were derived from the tonic current modulation 
of each mixture. The isobolograms were plotted and the theoretical and experimental-
determined EF2-fold values of mixtures were compared (Fig. 27 – 28; Table 8). 
In the present study, the isobolographic analysis was performed to ascertain the effect of 
combination, which is based on the concept of “dose equivalence”. This isobologram 
method is the ‘gold standard’ for the evaluation of interactions between drugs, which 
allows their stratification as supra-additive (synergistic), additive, and sub-additive 
(antagonistic) drugs (Tallarida, 2006). In isobolography, it is accepted that half of the 
ED50 dose of a first drug plus half of the ED50 dose of a second drug, should be as 
therapeutically effective as a full dose of each drug administered separately. This concept 
of adding fractions of the effective doses of AEDs is the fundamental rule underlying the 
isobolographic analysis (Loewe, 1953; Berenbaum, 1989; Tallarida, 2000).  The 
interaction of two or more drugs to produce a combined effect is described by the 
interaction index I (Berenbaum 1977). 
I = D1/M1 + D2/M2   ---------- (1) 
where, D1 and D2 are concentrations of drug 1 and 2 that produce a certain effect if 
applied together; M1 and M2 are the median concentrations that produce the same effect 
when given alone. Consequently, for deriving the 50 % seizure protection, then equation 
1 can be expressed as: 




Here, ED50,1 and ED50,2 are the ED50 values of drug 1 and drug 2 alone. D1 and D2 are 
the doses of drug 1 and 2, respectively, which also produce 50 % protection when given 
together. This general method has been developed based on the analysis of each drug 
alone and the simulation of the combined action response, based on the Loewe additivity 
theory (Loewe, 1953). For drugs showing an interaction, equation (1) is adapted and 
advanced into defining a combination index (CI), indicating type and amount of 
interaction between two drugs with target experimental outcome (Chou and Talalay, 
1983). 
CI = D1/M1 + D2/M2   -- (3) > 1 for antagonism; = 1 for additivity; and < 1 for synergy  
The CI can take values between 1 and infinity for antagonism, and runs between 0 and 1 
for synergy. The interaction index underlies one of the most widely used graphical 
representations of drug synergism and antagonism, the isobologram (Figure 7). The 
isobolograph illustrates typical subadditive (antagonistic) and superadditive (synergistic) 
isoboles. The doses of drugs A and B give abscissa and ordinate, respectively, and the 
effect of drug combinations is plotted as graph (Figure 7). The effects of each drug alone 
(ED50) can be read from the axes. The isobologram shows an effect, such as 
anticonvulsant ED50 and which drug concentration is needed to achieve this effect. 
Overall, to simplify the notation of interactions in isobolography, the drug doses were 
administered in fixed ratio combinations (1:3, 1:1, and 3:1) and reflect fractions of ED50 
values denoted for the drugs used separately. The isobologram-based CI calculations 






Figure 7 Isobologram-based characterization of drug combinations.     
The X and Y axis units are the doses of drugs A and B. The solid black line connects 
doses that produce the same effect of certain examined response (ED50 line), such as 
seizure protection. From additivity (A), the combination of drug A with drug B would 
produce 50% protection (point A). If, 50% protection is achieved at lower doses of the 
two drugs, the drugs would exhibit synergism (point B). If the observed effect by the 
combination is less than 50%, drug A and B would interact in an antagonistic way (point 
C). The dashed lines are drawn to enhance the recognition of symmetry for additive 
isobole responses. In practical terms, fixed drug dose ratios are tested in the standard 






III.6 Drugs and Reagents 
All chemicals utilized in electrophysiology experiments were acquired from Sigma-
Aldrich unless otherwise specified. AP and GX were prepared as 2 mM stock solutions in 
dimethyl sulfoxide for electrophysiology experiments. Stock solutions were diluted in the 
external perfusion solution to the desired concentration for electrophysiological use. The 
concentration of dimethyl sulfoxide in final solution was less than 1%. AP was purchased 
from Steraloids (Newport, RI), and GX, kynurenic acid, and GF 109203X were 
purchased from Tocris. 21-OH-GX was synthesized in the laboratory. TTX was acquired 
from Calbiochem (Billerica, MA). Midazolam was purchased from Akorn (Lake Forest, 
IL). 
III.7 Statistical Analysis 
Data were expressed as the mean ± standard error of mean (SEM). In slice 
electrophysiology studies, concentration-response curves were subjected to non-linear, 
logistic fitting. A curve fitting was applied for concentration-responses that achieved a 
plateau at maximal levels. Comparisons of statistical significance of data were made 
using a Student’s t-test. Comparisons of cumulative probability distributions were made 
using the Kolmogorov-Smirnov test. Results were considered significant if the two-tailed 
p values were < 0.05. In pharmacological studies, the percent protection of mice against 
6-Hz-induced seizures and subsequently, dose-response relationship lines were fitted 
using log-probit linear regression analysis according to Litchfield and Wilcoxon 
(Litchfield and Wilcoxon, 1949). The ED50 values with their 95% confidence limits were 
calculated by computer-assisted log-probit analysis according to Litchfield and Wilcoxon 
procedure. First, the dose-response relationships of test drugs for target outcomes were 
subjected to the test for parallelism, an essential condition for characterizing AED 
interactions with isobolography. Since the dose-response relationship for GX and TG 
were parallel in this study, the type I isobolographic analysis for parallel dose-response 




performed by the use of Student’s t-test in order to detect the differences between the 
experimentally derived (ED50 mix) and theoretical additive (ED50 add) values (Tallarida, 
2000; Łuszczki, 2008a, b). Comparison of the differences in seizure stage between 
groups was made with the nonparametric Kruskal-Wallis test followed by the Mann-
Whitney U-test. The differences in means of the AD duration and the percentage 
inhibition of seizure stage between groups were compared with one-way analysis of 
variance, followed by Student’s t-test and Wilcoxon signed ranks test, respectively. For 
patch-clamp data with small sample size, nonparametric tests were used to check the 
statistical significance especially when the data points were not normally distributed. The 








IV.1 3-Methyl-Neurosteroid Analogs are Preferential Positive Allosteric 
Modulators and Direct Activators of Extrasynaptic GABA-ARs in the 
Hippocampus Dentate Gyrus Subfield 
IV.1.1 Allosteric Activation of GABA-Gated Currents by GX in Acutely Dissociated 
Hippocampal Neurons 
The chemical structures of the neurosteroid AP and its 3-methyl analogs GX and 21-
OH-GX are shown in Figure 8. To determine the modulatory effects of GX on whole-cell 
GABA-gated currents, we studied native neurons using patch-clamp electrophysiology. 
To examine the effects of subunit composition on GABA-AR function, concentration-
response profiles of GX were compiled in two cell types: -containing dentate gyrus 
granule cells (DGGCs) and -containing CA1 pyramidal cells (CA1PCs). GABA-AR 
currents were recorded from acutely dissociated, voltage-clamped DGGCs or CA1PCs 
from adult male mice in whole-cell mode. We utilized 3 M GABA, which was within 
the range of EC10 response for both DGGCs (Wu et al., 2013; Carver and Reddy, 2016) 
and CA1PCs (Reddy and Jian, 2010), to determine a baseline response and allosteric 
activation by tested compounds. We confirmed the EC10 value of GABA in DGGCs 
(Figure 9C). Increasing concentrations of GX were co-applied with 3 M GABA to 
obtain the fractional potentiation of GABAergic currents mediated by GX. Both cell 
                                                 
†† Reprinted with permission from “3β-methyl-neurosteroid analogs are preferential positive allosteric 
modulators and direct activators of extrasynaptic δ-subunit γ-aminobutyric acid type A receptors in the 
hippocampus dentate gyrus subfield.” by S-H Chuang and DS Reddy, 2018. The journal of pharmacology 
and experimental therapeutics, 365(3): 583601, Figures 1  13, Table 1  2, Copyright ©  2018 by The 
American Society for Pharmacology and Experimental Therapeutics. All rights reserved. 
‡‡Reprinted with permission from “Zinc reduces antiseizure activity of neurosteroids by selective blockade 
of extrasynaptic GABA-A receptor-mediated tonic inhibition in the hippocampus” by S-H Chuang and DS 
Reddy, 2019. Neuropharmacology, 148: 244256, Figures 1  7, Table 1, Copyright ©  2018 Elsevier Ltd. 




types responded to GX in a concentration-dependent manner (Figure 9A). Concentration-
response plots were generated for DGGCs and CA1PCs to determine allosteric 
potentiation by GX (0.05 – 1 M) (Figure 9B). Due to the lack of a response plateau, a 
nonlinear curve could not be fit to the data for either DGGCs or CA1PCs. Based on 
previous structure-activity data, 1 M GX-mediated current was denoted as the 
constrained maximum efficacy response for allosterically modulated activity. Higher 
micromolar concentrations of neurosteroids directly activate receptors and exhibit a 
biphasic modality at a separate neurosteroid binding site (Puia et al., 1990; Carver and 
Reddy, 2013). As shown in Figure 9B, GX (0.1 M) potentiated GABA-gated currents 
significantly higher in DGGCs than CA1PCs (n = 8 – 9 cells per group, p = 0.038). GX at 
0.3 and 0.5 M concentrations also showed markedly higher GABA-gated currents in 
DGGCs than CA1PCs (n = 6 – 10 cells per group, p = 0.05). In maximal efficacy 
estimation for allosteric potentiation, GX (1 M) displayed significantly greater GABA-
gated currents in DGGCs (5-fold potentiation) than CA1PCs (2-fold potentiation; n = 7 
cells per group, p < 0.05). To confirm the contributory role of the  subunit for enhanced 
allosteric potentiation of GX in DGGCs, we studied GX allosteric activation of GABA-
gated currents in DGGCs from KO mice, which lack -containing receptors (Mihalek et 
al., 1999; Carver and Reddy, 2016). GX-potentiated GABAergic currents (1 M) were 
significantly reduced in KO DGGCs than WT DGGCs (Figure 8A, 8B; n = 5 – 6 cells 
per group, p = 0.038). These findings suggest that GX has higher sensitivity at neurons 







Figure 8 Chemical structures of the neurosteroid AP and its 3-methyl analogs. 






Figure 9 GX allosteric activation of GABA-gated currents in acutely dissociated 
neurons. 
GX (1 M) displayed significantly greater GABA-gated chloride currents in WT DGGCs 
(5.1 ± 0.9 fold-potentiation) than CA1PCs (2.0 ± 0.5 fold-potentiation). However, GX-
potentiated GABAergic currents were significantly reduced in KO DGGCs. (A) 
Representative whole-cell current recordings of DGGCs and CA1PCs. Neurons displayed 
concentration-dependent responses to GX potentiation of 3 M GABA (EC10). (B) 
Concentration-response of GX-modulated allosteric potentiation of chloride currents in 
DGGCs and CA1PCs from WT or  subunit knockout (Gabrd
-/-
, ) mice. (C) 
Concentration-response profile of GABA-potentiated current density (pA/pF). GABA 
EC10 = 3 M. Each point represents mean ± SEM of data from 5 to 10 cells. *p < 0.05 vs. 
CA1PCs; 
#




IV.1.2 GX Modulation of Inhibition via GABA-ARs 
To verify the target specificity of GX inhibitory activity in native DGGCs, we studied the 
blockade of GABAergic currents with specific GABA-AR antagonists. At 10 M, the 
competitive antagonists bicuculline (BIC) or gabazine (GBZ) completely blocked whole-
cell GABA-gated current potentiation by GX (n = 4 – 5 cells per group, p < 0.05; Figure 
10A, 10B). When the antagonists were removed by washing, the GX-potentiated GABA-
gated currents returned to the same level as before the application of antagonists. These 







Figure 10 GX-activated chloride currents are blocked by GABA-AR antagonists. 
(A) Representative recording and fractional block of currents by bicuculline (BIC, 10 M) 
in DGGCs. (B) Representative recording and fractional block of currents by gabazine 
(GBZ, 10 M) in DGGCs. Each bar represents mean  SEM of data from 4 to 5 cells. *p 
< 0.05 vs. control.  
 
IV.1.3 Direct Activation of GABA-Gated Currents by GX in Acutely Dissociated 
Hippocampal Neurons 
Neurosteroids have been shown to directly activate GABA-AR chloride channels at 
concentrations exceeding 1 M (Puia et al., 1990; Reddy and Rogawski, 2002). This 
direct activation may occur in the absence of GABA, but when GABA is present, the 
potentiating effects of neurosteroids are enhanced. Therefore, we examined direct 




Cells were voltage-clamped in the same preparation denoted in Figure 9. Increasing 
concentrations of GX (1 – 100 M, no GABA) were applied by rapid perfusion to the cell 
until saturation of the inward current response was observed (Figure 11A). 
Concentration-response curves were derived for DGGCs and CA1PCs (Figure 11B). GX 
evoked significantly greater inward currents in DGGCs than CA1PCs. At each 
concentration tested, GX potentiated-GABAergic currents were significantly higher in 
DGGCs (2.07 ± 0.66 fold of 3 M GABA response at 1 M; 3.08 ± 0.37 fold at 3 M; 
5.20 ± 0.70 fold at 10 M; 6.01 ± 0.84 fold at 30 M; and 6.34 ± 0. 24 fold at 100 M) 
than CA1PCs (0.36 ± 0.09 fold of 3 M GABA response at 1 M; 0.83 ± 0.20 fold at 3 
M; 1.55 ± 0.27 fold at 10 M; 2.05 ± 0.36 fold at 30 M; and 2.67 ± 0. 62 fold at 100 
M). Such greater currents in response to high GX (1 – 100 M) are mostly due to 
abundance of GABA-ARs in DGGCs. Next, we compared the efficacy and potency of 
GX with AP for direct activation of GABAergic inward currents (Figure 11A, 11B). 
Table 5 shows the summary data on the efficacy and potency of GX and AP for allosteric 
and direct-gating effects at GABA-ARs in DGGCs. In allosteric activation, GX appears 
to be similar in potency and efficacy with that of AP. AP at 1 M caused 4.3-fold 
potentiation (EF(2-fold GABA)= 474 nM), which is not significantly different from GX-
potentiated currents (5.1-fold; EF(2-fold GABA)= 389 nM). In direct-gating effects, GX 
exhibited 1.5 to 2- fold higher efficacy than AP in DGGCs. Other parameters could not 
be derived because concentration responses were largely saturated at concentrations  10 
M. Overall, GX has greater efficacy than AP for direct activation of inward currents at 






Figure 11 GX direct activation of GABA-ARs in acutely dissociated neurons. 
GX and AP directly activated chloride currents in a concentration-dependent manner in 
hippocampal neurons. GX evoked significantly greater inward currents in DGGCs than 
CA1PCs. (A) Representative whole-cell current recordings of GX and AP in DGGCs and 
GX in CA1PCs. (B) Concentration-response curves for direct activation of inward 
currents by GX or AP alone in DGGCs and CA1PCs. Each point represents mean  SEM 
of data from 4 to 13 cells. *p < 0.05 vs. CA1PCs. Other derivative parameters are listed 




Table 5 Comparative efficacy of GX and AP for allosteric and direct-gating effect at 
GABA-ARs in DGGCs. 
 
Compound 
GABA-gated whole-cell current Tonic current 
Allosteric effect Direct effect 

















AP 474 273.5 100.6 80 
GX 389 336.1 64.0 290 
GABAd - 1426.3 19.6 - 
aEF values represent the effective functional concentration of drug (nM) required to double the 3 M 
GABA (EC10) response. 
 
bE30 μM values represent the mean tonic current responses of drug at 30 μM concentration.  
cE1 μM values represent the mean tonic current responses of drug at 1 μM concentration co-applied with 1 
μM GABA. GABA 1 μM tonic current response: 0.66 ± 0.22 pA/pF, 19.6 pA. 
dGABA EC50: 18.6 M. EC50 values represent the concentration required to produce half of its own 






IV.1.4 Allosteric Potentiation of Extrasynaptic GABA-AR-Mediated Tonic 
Currents by GX in Hippocampus Slices 
To ascertain the functional role of GX in potentiating extrasynaptic -containing GABA-
ARs within the hippocampus, we explored the tonic current levels in WT and  
DGGCs in slice recordings. We used voltage-clamp electrophysiology to record 
enhancement of GABAergic tonic currents by GX in the presence of the NMDA receptor 
antagonist (APV, 40 M), the AMPA receptor antagonist (DNQX, 10 M), and the 
sodium channel blocker (TTX, 0.5 M). Baseline tonic currents were derived in a bath 
perfusion with 1 M GABA. GX (0.1 – 1 M) was co-applied with 1 M GABA in tonic 
current recordings (Figure 12A, 12B). At the end of each recording, 50 M GBZ was 
perfused in order to determine the total tonic current shift. Tonic current of each cell was 
normalized to the cell capacitance as a measure of current density (pA/pF). RMS (root-
mean-square) noise was determined for each recording as previously specified (see 
Methods) (Figure 12C). WT DGGCs displayed concentration-dependent sensitivity to 
GX-mediated enhancement of tonic currents (1.08 ± 0.17 pA/pF at 0.1 M; 1.61 ± 0.18 
pA/pF at 0.3 M; and 2.48 ± 0.49 pA/pF at 1 M). However, the  DGGCs exhibited 
completely attenuated tonic current response at all concentrations of GX tested (0.40 ± 
0.12 pA/pF at 0.1 M; 0.16 ± 0.04 pA/pF at 0.3 M; and 0.37 ± 0.10 pA/pF at 1 M). 
WT DGGCs also showed greater concentration-dependent potentiation of GX-mediated 
RMS conductance than  neurons (Figure 12C). At 0.3 and 1 M GX, RMS channel 
conductance was significantly higher in WT DGGCs compared to  neurons, 
indicating greater enhancement in chloride conductance by GX in WT DGGCs. Overall, 
these results indicate that the  subunit plays an obligatory role in GX potentiation of 






Figure 12 GX allosteric potentiation of GABA-AR-mediated tonic currents and 
RMS channel conductance are attenuated in DGGCs from KO mice. 
(A) Representative whole-cell current recordings of DGGCs from WT or  mice. 




 grey dashed lines) was achieved 
relative to complete block by gabazine (GBZ) at 50M. (B) Concentration-response 
curves for allosteric activation of normalized tonic current density (pA/pF) by GX in 
DGGCs from WT or  mice. *p < 0.05 vs. WT. (C) IRMS channel conductance (pA) of 
GX modulation in DGGCs from WT or  mice. Each point or bar represents mean  
SEM. *p < 0.05 vs. GABA; 
#





IV.1.5 Direct Activation of Extrasynaptic GABA-AR -Mediated Tonic Currents by 
GX in Hippocampus Slices 
To further explore the functional role of the  subunit in GX activation of GABA-ARs, 
we examined direct activation of extrasynaptic tonic currents in DGGCs from WT and 
 slices. Voltage-clamp electrophysiology was used to record GABA-AR-mediated 
potentiation of tonic currents by GX in the absence of GABA application. GX (0.1 M – 
3 M) was applied in slice recordings (Figure 13A – 13C). 50 M GBZ was added at the 
end of each recording to confirm the total tonic current shift. Current density (pA/pF) was 
obtained by normalizing the tonic current shift with the cell capacitance of each cell. GX 
(0.1 – 3 M) directly activated GABA-AR-mediated tonic currents without exogenous 
GABA application in WT DGGCs in a concentration-dependent manner (0.51 ± 0.09 
pA/pF at 0.1 M; 0.54 ± 0.10 pA/pF at 0.3 M; 1.50 ± 0.28 pA/pF at 1 M; and 2.05 ± 
0.18 pA/pF at 3 M). However, in  DGGCs, GX tonic current responses were 
completely diminished at 0.1, 0.3, and 1 M (0.26 ± 0.07 pA/pF at 0.1 M; 0.31 ± 0.07 
pA/pF at 0.3 M; and 0.30 ± 0.06 pA/pF at 1 M). At 3 M, GX (0.82 ± 0.20 pA/pF) 
slightly potentiated tonic current response in  DGGCs, possibly eliciting a non -
mediated response. These results demonstrate that GX potentiation of tonic currents is 






Figure 13 GX direct activation of GABA-AR-mediated tonic currents is attenuated 
in DGGCs from KO mice. 
(A) Representative whole-cell current recordings of DGGCs from WT or  mice. 




 grey dashed lines) was achieved 
relative to complete block by gabazine (GBZ) at 50 M. Concentration-response curves 
for direct activation of tonic currents (pA, B) and normalized tonic current density (pA/pF, 
C) by GX in DGGCs from WT or  mice. Each point represents mean  SEM. *p < 





IV.1.6 GX Modulation of Phasic Currents in DGGCs from WT and KO Mice 
The miniature inhibitory postsynaptic currents (mIPSCs) predominantly reflect the 
activation of synaptic GABA-ARs. To determine the effects of GX on synaptic GABA-
AR-mediated phasic currents, the mIPSCs were isolated in the presence of the NMDA 
receptor antagonist (APV, 40 M), the AMPA receptor antagonist (DNQX, 10 M), and 
the sodium channel blocker (TTX, 0.5 M). First, we recorded the endogenous mIPSCs 
of WT and  DGGCs. The average amplitude, frequency, 10-90% rise time, and 
decay time constant of mIPSCs from WT and  DGGCs are displayed in Figure 14. 
Representative traces and ensemble average mIPSCs from WT and  DGGCs are 
shown in Figure 14A, 14B. The average mIPSC from each cell was best fit with a double-
exponential decay curve, depicted as 1 and 2. A mean weighted decay constant w was 
also derived from 1 and 2 (see Materials and Methods). The average amplitude and rise 
time of mIPSCs were not different between WT and  mice (Figure 14C). However, 
the mean weighted decay time (τw) of mIPSCs in  neurons (n = 10, 28.2 ± 1.2 ms) 
was significantly faster than in WT neurons (n = 9, 34.8 ± 2.4 ms), signifying that 
changes in receptor subunit composition can alter the channel kinetics. Furthermore, the 
frequency of mIPSCs in  DGGCs was modestly smaller than in WT DGGCs (n = 10-
12 cells per group, p = 0.06), showing a small reduction in the functional number of 
GABAergic synapse release sites and the rate of presynaptic release in  neurons 
(Cherubini and Conti, 2001). Overall, these findings are similar and consistent with the 






Figure 14 Alterations in mIPSCs kinetics in KO mice. 
(A) Representative traces of endogenous phasic currents by patch-clamping recording 
from WT or  DGGCs. (B) Averaged mIPSC events in the WT (solid line) or  
(dashed line) DGGCs. (C) The bar graphs represent: amplitude, frequency, rise time (10 – 
90%), decay τ1, decay τ2, and mean weighted decay (τw) of mIPSCs in DGGCs from WT 





Next, we analyzed the potentiation of synaptic GABA-AR-mediated mIPSCs by bath 
application of GX (0.1 – 1 M) with GABA (1 M) in WT DGGCs. To determine 
whether the GX-mediated changes to synaptic activity are related to  subunit expression, 
we also recorded mIPSCs in DGGCs from  mice (Figure 15). Representative traces 
and ensemble average mIPSCs for each drug concentration and condition are shown in 
Figure 15A, 15B. GX has no significant effect on frequency or rise time of mIPSCs 
(Figure 15D). However, the cumulative probability of amplitude and the mean peak 
amplitude were strongly enhanced by GX (1 M) in WT DGGCs but not in  DGGCs 
(Figure 15C). Concentration-dependent potentiation of amplitude of mIPSCs by GX was 
evident in WT neurons but not in  DGGCs. In addition, GX prolonged the decay 
time constant 2 and the mean weighted decay time τw of mIPSCs in a concentration-
dependent manner in both WT and  neurons. However, GX prolonged 2 and τw 
decay time constants of mIPSCs to a significantly greater degree in WT DGGCs 
compared to KO DGGCs (2: p = 0.014 at 0.1 M; p = 0.015 at 0.3 M; and p = 0.049 
at 1 M; w: p = 0.007 at 0.1 M; p = 0.030 at 0.3 M; and p = 0.066 at 1 M, WT vs. 
). These results suggest that -containing GABA-ARs highly contribute to GX-
potentiated amplitude of mIPSCs, which reflects its influence on postsynaptic receptor 
density and dendritic property, and play a pivotal role in the GX-potentiated kinetics of 





Figure 15 GX concentration-dependent potentiation of mIPSCs is attenuated in 
DGGCs from KO mice. 
(A) Representative traces of phasic currents by patch-clamping recording from WT or 
 DGGCs in the presence of 1 M GABA, 1 M GABA+0.1 M GX, 1 M 
GABA+0.3 M GX, and 1 M GABA+1 M GX. (B) Averaged mIPSC events recorded 
from WT (B, left)  or  (B, right) DGGCs in the presence of 1 M GABA (solid line) 
or 1 M GABA co-applied with 1 M GX (dashed line). Cumulative probability curves 
for WT (C, left) or  (C, right) mIPSC amplitude, plotted from all events. The 
Kolmogorov–Smirnov test was used to compare mIPSCs before and after application of 
GX in DGGCs. (C, insets) Mean peak amplitude of mIPSCs in WT (left) or  (right) 
DGGCs in the presence of 1 M GABA or 1 M GABA co-applied with 1 M GX. 
*p<0.05 vs. GABA alone (n = 14 – 19 cells per drug concentration). (D) Summary 
graphs of concentration-response relationship for amplitude, frequency, rise time (10-
90%), decay τ1, decay τ2, and mean weighted decay time (τw) of GX modulation in 
DGGCs from WT or  mice. Each point represents mean  SEM. *p < 0.05; **p < 
0.01; ***p < 0.001 vs. GABA; 
#











IV.1.7 Inhibition of Protein Kinase C Prevents Allosteric Potentiation of Tonic 
Currents by GX and AP in Hippocampus Slices 
Protein kinase C (PKC) activity may affect neurosteroid modulation of GABA-AR 
function (Fancsik et al., 2000; Harney et al., 2003; Adams et al., 2015). We hypothesize 
that the PKC inhibitor (PKCi) may also influence the extent of neurosteroid-potentiated 
tonic inhibition. To explore the effects of PKC activity on GX allosteric potentiation of 
tonic currents, the PKC inhibitor GF109203X (1 M) was applied to the bath solution for 
15 or 30 minutes before the perfusion of GABA and the application was continued during 
GABA or neurosteroid perfusion. To compare the mechanism of action of GX with AP, 
we also examined the influence of PKC inhibitor on AP-potentiated tonic currents. The 
experimental protocol is shown in Figure 16A. Pretreatment of PKC inhibitor for 15 or 
30 min prior the application of GABA reduced GABA-evoked tonic current density from 
0.62 ± 0.08 pA/pF to 0.11 ± 0.04 pA/pF and 0.13 ± 0.05, respectively (n = 5 cells per 
group; Figure 16F). The PKC inhibitor attenuated the allosteric potentiation of AP and 
GX in a time-dependent manner (Figure 16B – 16F). Pretreatment of PKC inhibitor for 
15 or 30 min prior to the application of GABA reduced the tonic current density 
potentiated by AP from 1.80 ± 0.18 pA/pF to 1.07 ± 0.32 pA/pF and 0.15 ± 0.03, 
respectively (n = 6 – 9 cells per group, 40.6 ± 17.8% decrease, p = 0.082 and 91.9 ± 1.8% 
decrease, p = 0.00001, respectively; Figure 16D, 16F). Pretreatment of PKC inhibitor for 
15 or 30 min prior to the application of GABA also significantly attenuated the tonic 
current density potentiated by GX from 1.61 ± 0.18 pA/pF to 0.66± 0.23 pA/pF and 0.49 
± 0.15 pA/pF, respectively (n = 6 – 7 cells per group, 59.2 ± 14.4% decrease, p = 0.009 
and 69.8 ± 9.4% decrease, p = 0.001, respectively; Figure 16E, 16F). These results 
demonstrate that both AP and GX potentiation of tonic current are regulated by the extent 






Figure 16 PKC inhibitor (PKCi) prevents neurosteroid potentiation of tonic 
currents in DGGCs. 
(A) Scheme demonstrating experimental protocol. PKCi GX109203X (GFX, 1 M) was 
applied to the bath solution for 15 or 30 minutes before the GABA application and the 
PKCi application was continued during GABA, neurosteroid, and gabazine (GBZ) 
perfusion. Representative whole-cell current recordings of DGGCs in the presence of 
GABA + AP (B) or GABA + GX (C) and GBZ with or without PKCi application. 
Qualification of tonic current shift was achieved relative to complete block by GBZ at 50 
M. (D, E) PKCi attenuation of AP- or GX- potentiated tonic current response. (F) 
Fractional response of GABA-, GABA + AP- or GABA + GX-modulated tonic current 
response due to PKCi perfusion. Each point or bar represents mean  SEM of data from 5 
to 9 cells. *p < 0.05 vs. GBZ or GABA + AP without PKCi group; 
#
p < 0.05 vs. GABA + 
GX without PKCi group; 
$






IV.1.8 Antiseizure Activity of GX in the Hippocampus Kindling Model 
To evaluate the activity of GX in protecting against hippocampus kindled seizures, fully-
kindled mice were treated with various doses of GX 15 min prior to stimulation. GX 
produced a dose-dependent reduction of behavioral seizure activity with significant 
effects on both at 5 and 10 mg/kg (Figure 17A). At the highest dose tested, behavioral 
seizures were almost entirely inhibited. GX pretreatment markedly reduced the AD 
duration in a dose-dependent manner (Figure 17B). Furthermore, the overall amplitude 
was decreased by about 50% after 5 and 10 mg/kg GX. The estimated ED50 value for 
suppression of seizure stage and AD duration is 3.2 ± 0.7 mg/kg and 3.0 ± 0.8 mg/kg, 
respectively. The time courses for behavioral seizure stage and AD duration after a 10 
mg/kg dose of GX are shown in Figure 17C and 17D, respectively. The seizure protective 
effect of GX (10 mg/kg s.c.) occurred rapidly. The protection was maximal at 15-min and 
reduced during the 240-min period after the administration as evident by its time-
dependent decrease in seizure protection (Figure 17C) and AD duration (Figure 17D). On 
the day after GX treatment, all mice exhibited stage 5 seizures with AD duration (35 ± 6 s) 
not significantly different from the control duration (38 ± 5 s), indicating that GX 
suppresses the expression of behavioral seizures but does not influence the kindled state. 
To examine the role of  subunit in GX protection against kindled seizures, the 
behavioral seizure stage and AD duration at various doses of GX in WT and  mice 
were compared. GX at 3 mg/kg displayed significantly stronger reduction in seizure stage 
(Figure 17E) and AD duration (Figure 17F) in WT mice compared to  mice, 
indicating that GX suppression of seizure activity is affected by the  subunit. These 
results are compatible with the hypothesis that GX protection is possibly due to the 
potentiation of GABA-AR-mediated inhibition that occurs rapidly within a few minutes, 






Figure 17 Antiseizure activity of GX in fully-kindled WT and KO mice. 
(A) GX dose-response curves of behavioral seizure activity and (B) afterdischarge (AD) 
duration. (C) Time courses for behavioral seizure stage and (D) AD duration with GX at 
10 mg/kg s.c. in fully kindled mice. (E) GX dose-dependent responses of behavioral 
seizure activity and (F) AD duration in WT and  mice. Each point or bar represents 





IV.1.9 GX Analogs as More Selective GABA-AR Modulators 
Structure-activity relationship studies have shown the importance of the -OH group at 
the C3 position in the binding affinity and potentiation of synaptic GABA-ARs by 
neurosteroids (Harrison et al., 1987; Mitchell et al., 2008). Additionally, the ketone group 
at the C17 and C20 position and the lipophilic properties of neurosteroids are critical for 
the potency and efficacy of receptor modulation (Kokate et al., 1994; Upasani et al., 1997; 
Covey et al., 2000; Chisari et al., 2009; Reddy and Jian, 2010; Qian et al., 2014). Our 
structure-activity relationship studies at extrasynaptic GABA-ARs also demonstrate the 
requirement of the -OH group at the C3 position for the functional activation of 
extrasynaptic receptors and the influence of alternations at the C17 and C20 position in 
the modulation efficacy and receptor binding affinity (Carver and Reddy, 2016). To 
further identify key structural features of neurosteroids that are important for the 
functional activation of extrasynaptic GABA-ARs, we compared the modulatory effects 
of GX and its analog 21-OH-GX (Figure 8) which has an additional OH group at C21 
position on whole-cell GABA-gated chloride currents and extrasynaptic GABA-AR-
mediated tonic currents. We also investigated the role of  subunit in 21-OH-GX 
potentiation of tonic inhibition. In dissociated DGGCs, 21-OH-GX allosterically 
potentiated GABA-gated currents in a concentration-dependent manner (Figure 18A). 21-
OH-GX displayed significantly greater potentiation of GABA-gated chloride currents 
(EF2-fold GABA = 0.20 M) than GX (EF2-fold GABA = 0.43 M, Figure 18B). In hippocampus 
slices, WT DGGCs displayed concentration-dependent sensitivity to 21-OH-GX-
mediated enhancement of tonic currents (0.80 ± 0.26 pA/pF at 0.1 M; 1.44 ± 0.24 
pA/pF at 0.3 M; and 3.00 ± 0.49 pA/pF at 1 M). The tonic current responses were not 
significantly different between GX and 21-OH-GX at 0.1 and 0.3 M but were 
potentiated slightly more by 21-OH-GX at 1 M (GX, 2.48 ± 0.49 pA/pF at 1 M, EF2-
fold GABA = 0. 29 M; 21-OH-GX, 3.00 ± 0.49 pA/pF at 1 M, EF2-fold GABA = 0. 23 M, 
Figure 19A, 19B). However, 21-OH-GX potentiation of tonic inhibition at 0.3 and 1 M 




0.19 pA/pF at 0.3 M; and 0.90 ± 0.15 pA/pF at 1 M, *p<0.05 vs. WT, Figure 19C –  
19E), indicating its selectivity for extrasynaptic GABA-ARs.  
 
 
Figure 18 Comparison of allosteric modulation of GABA-gated currents by GX and 
21-OH-GX in acutely dissociated DGGCs. 
21-OH-GX displayed significantly greater potentiation of GABA-gated chloride currents 
(EF2-fold GABA = 0.20 M) than GX (EF2-fold GABA = 0.43 M). (A) Representative whole-
cell current recordings in DGGCs. (B) Concentration-response curves of neurosteroid-
modulated allosteric potentiation of chloride currents in DGGCs. Neurons displayed 
concentration-dependent responses to neurosteroid potentiation of 3 μM GABA (EC10). 





Figure 19 Comparison of allosteric modulation of tonic currents by GX and 21-OH-
GX in hippocampus slices from WT and KO mice. 
21-OH-GX displayed slightly greater potentiation of tonic currents (EF2-fold GABA = 0. 23 
M) than GX (EF2-fold GABA = 0. 29 M). 21-OH-GX potentiation of tonic inhibition at 
0.3 and 1 M was significantly diminished in DGGCs from  mice. Concentration-
response curves for allosteric activation of tonic current (pA, A, D) and normalized tonic 
current density (pA/pF, B, E) by GX and 21-OH-GX in DGGCs from WT or  mice. 
(C) Representative whole-cell current recordings of DGGCs from WT or  mice. 




 grey dashed lines) was 
achieved relative to complete block by gabazine (GBZ) at 50 M. Each point represents 




IV.1.10 Antiseizure Activity of GX Analogs in the Kindling Model 
We compared the activity of GX and 21-OH-GX in protecting against hippocampus 
kindled seizures. Fully-kindled mice were treated with various doses of GX and 21-OH-
GX 15 min prior to stimulation. As shown in Figure 20, both GX and 21-OH-GX 
produced a dose-dependent reduction of behavioral seizure activity (Figure 20A) and AD 
duration (Figure 20B). However, 21-OH-GX displayed greater antiseizure activity 
compared to GX although such effect was significant at 3 mg/kg dose (Figure 20A). 
Overall, the GX analog 21-OH-GX displayed stronger potentiation in GABAergic 
chloride currents and extrasynaptic GABA-AR-mediated tonic inhibition; possibly 
conveying a stronger antiseizure effect than GX. 
 
 
Figure 20 Comparative antiseizure effects of GX and 21-OH-GX in the 
hippocampus kindling model in mice. 
(A) Dose-response curves of behavioral seizure activity and (B) afterdischarge (AD) 
duration in fully-kindled WT mice. Each point represents mean  SEM. *p < 0.05 vs. GX 




IV.2 Zinc Reduces Antiseizure Activity of Neurosteroids by Selective Blockade of 
Extrasynaptic GABA-AR-Mediated Tonic Inhibition in the Hippocampus 
IV.2.1 Concentration-Dependent Inhibition of GX Potentiation of GABA-Gated 
Currents by Zn
2+
 in Hippocampal Neurons 
We first examined the blockade of GABAergic chloride currents with Zn
2+
, a negative 
allosteric modulator of GABA-ARs (Smart et al., 1991; Kapur and Macdonald, 1997; 
Barberis et al., 2000; Carver et al., 2016). To examine the effects of subunit composition 
on Zn
2+
 inhibition of GABA-ARs, concentration-response profiles were compiled in two 
cell types: -abundant DGGCs and -sparse CA1 pyramidal cells (CA1PCs). 3 M 
GABA (EC10) was applied for 5 seconds followed by the application of Zn
2+
 for 5 
seconds (Figure 21A  21C). GABA at 3 M induced 249.5  16.5 and 538.1  34.3 pA 
of currents in DGGCs and CA1PCs, respectively. Zn
2+
 blocked inhibitory GABAergic 
chloride currents concentration-dependently in both cell types. The Zn
2+
 at 1, 3, 10, and 
30 M application blocked a mean 56.7  6.9 %, 81.6  6.4 %, 89.0  5.7 %, and 90.4  
5.6 % of GABA-induced currents in DGGCs, respectively. While the Zn
2+
 at 1, 3, 10, and 
30 M blocked a mean 64.3  11.4 %, 70.4  12.0 %, 87.3   3.6 %, and 93.1  1.6 % of 
GABA-induced currents in 2-containing CA1PCs, respectively. GABA-modulated 
currents fully returned to peak amplitude after the removal of Zn
2+
 application. The half 
maximal inhibitory concentrations (IC50) for Zn
2+
 block of 3 M GABA-induced currents 
were 0.72 and 0.70 M in DGGCs and CA1PCs, respectively. These results show a 
similar concentration-dependent profile of Zn
2+
 blockade of GABA-gated chloride 
currents in DGGCs and CA1PCs.  
Next, we studied the modulatory effects of Zn
2+
 on GX-potentiated GABA-gated currents. 
GX at 1 M was co-applied with 3 M GABA to obtain the fractional potentiation of 
GABAergic currents mediated by GX. Subsequent application of Zn
2+
 (1  30 M) 
blocked whole-cell inhibitory currents in a concentration-dependent manner (Figure 22A 
 22C). In -containing DGGCs, the IC50 for Zn
2+




currents was 0.44 M. The 1 M Zn
2+
 application blocked a mean 62.2  11.6 % of 
whole-cell current modulation by GX. The 3 M Zn
2+
 application blocked a mean 77.4  
10.5 % of whole-cell current modulation by GX. The 10 M Zn
2+
 application blocked a 
mean 86.1  4.8 % of whole-cell current modulation by GX. A 30 M concentration of 
Zn
2+
 completely blocked GABA-AR whole-cell currents, similar to that of the 
competitive antagonism of channels by bicuculline and gabazine. In -containing 
CA1PCs, the sensitivity of Zn
2+
 inhibition on GX-induced currents was modestly reduced 
compared to that of Zn
2+
 in DGGCs (Figure 22B). The IC50 for Zn
2+
 block of 3 M 
GABA + 1 M GX currents was 0.93 M, which is 2.1-fold higher than that of Zn
2+
 in 
DGGCs (0.44 M). The 1 M Zn
2+
 application blocked a mean 48.7  10.7 % of whole-
cell current modulation by GX. The 3 M Zn
2+
 application blocked a mean 58.1  11.9 % 
of whole-cell current modulation by GX. The 10 M Zn
2+
 application blocked a mean 
84.5  8.7 % of whole-cell current modulation by GX. A 30 M concentration of Zn
2+
 
blocked a mean 87.3  8.2 % of whole-cell currents. Overall, our results demonstrated 
that concentration-dependent blockade of Zn
2+
 on GX-potentiated GABA-gated chloride 









 blockade of GABA-gated currents is concentration-dependent in 
dissociated DGGCs and CA1PCs. 
(A) Representative whole-cell GABAergic current recordings from DGGCs and CA1PCs. 
Zn
2+ 
(1  30 μM)
 
inhibited GABA currents in a concentration-dependent fashion. (B) 
Fractional block of currents by Zn
2+
 (1  30 μM). (C) Inhibitory concentration response 
curves of DGGCs and CA1PCs by Zn
2+
. DGGCs IC50 = 0.72 μM; CA1PCs IC50 = 0.70 








 blockade of GX-sensitive GABA-gated currents is concentration-
dependent in dissociated DGGCs and CA1PCs. 
(A) Representative whole-cell GX-activated GABAergic current recordings from DGGCs 
and CA1PCs. Zn
2+ 
(1  30 μM)
 
inhibited GX-potentiated GABA currents in a 
concentration-dependent fashion. (B) Fractional block of currents by Zn
2+
 (1  30 μM). 
(C) Inhibitory concentration response curves of DGGCs and CA1PCs by Zn
2+
. DGGCs 
IC50 = 0.44 μM; CA1PCs IC50 = 0.93 μM. *p < 0.05 vs. control. Each bar represents 










To examine the interactions of Zn
2+
 with GX at extrasynaptic -containing GABA-ARs, 
we recorded GX-activated tonic currents from DGGCs in the hippocampus slice using 
whole-cell voltage-clamp (-65 mV) recording. At the end of each recording, 50 M 
gabazine was perfused to determine the total tonic current shift. Tonic current of each cell 
was normalized to the cell capacitance as a measure of current density (pA/pF). A 
physiological concentration of GABA (0.2 M) was used to examine GX allosteric 
potentiation (Wlodarczyk et al., 2013). Our results showed that application of 0.2 M 
GABA + 0.3 M GX resulted in a negative shift in the holding current level and an 
increase in the RMS channel conductance (Figure 25A). However, Zn
2+ 
(100 M) 
perfusion positively shifted GX-potentiated tonic currents (current density: GABA + GX, 
0.96  0.18 pA/pF; GABA + GX + Zn
2+
, 0.72  0.11 pA/pF, n = 5 cells). To further 
demonstrate the pharmacological sensitivity of Zn
2+ 
blockade of GX-induced tonic 
current potentiation, 1 M of GABA and GX were used to record tonic responses (Figure 
23A). Subsequent application of Zn
2+ 
(0.1  10 mM) induced a concentration-dependent 
blockade of tonic current density, measured as positive shift of the holding currents 
(Figure 23B). Zn
2+ 
(100 M) wash-out reversed the holding currents to the previously 




 wash-out was 
not able to eliminate the effects induced by Zn
2+
. The IC50 value for Zn
2+
 blockade of 
tonic currents was 0.186 mM (Figure 23C). The mean and the standard deviation (s.d.) of 
the tonic currents for different Zn
2+
 concentrations were plotted in Figure 23D. Higher 
the mean of tonic currents was accompanied with higher the s.d. of tonic currents. Zn
2+
 
concentration-dependently reduced both the mean and s.d. of GX-potentiated tonic 
currents. Zn
2+
 at 0.1, 1, and 10 mM caused 56.2  6.0 %, 60.8  3.0 %, and 98.3  0.7 % 
reduction of GX-potentiated tonic currents, respectively. Zn
2+
 also significantly reduced 
GX-potentiated RMS channel conductance at all concentration
 
tested (Figure 23E). Zn
2+
 




of the competitive antagonist gabazine (44.0  1.8 %). Overall, these results demonstrate 
a concentration-dependent blockade of Zn
2+ 







Figure 23 GX-potentiated tonic currents are sensitive to Zn
2+
 blockade in DGGCs in 
hippocampus slices. 
(A) Representative GABAergic Itonic recording from DGGCs in the presence of GABA + 
GX, Zn
2+
, and 50 μM gabazine (GBZ). (B) Concentration-responses of GX-modulated,  
normalized Itonic (pA/pF) to block by Zn
2+
 (0.1  10 mM). (C) Fractional responses of 
GX-modulated Itonic due to Zn
2+
 (*p < 0.05 vs. maximal block due to saturating 50 μM 
gabazine (GBZ). (D) Zn
2+
 reduced the mean and standard deviation of GX-potentiated 
tonic currents in a concentration-dependent fashion. (E) IRMS channel conductance (pA) 
and % change of Zn
2+ 
blockade of GX-dependent IRMS. GX denotes 1 μM GABA + 1 μM 
GX condition without Zn
2+
. *p < 0.05 vs. GX. Itonic denotes tonic currents. Each bar 





IV.2.3 GX Potentiation of Phasic Currents is Insensitive to Zn
2+
 Antagonism 
Next, to examine the block of Zn
2+
 on GX-potentiated phasic currents in DGGCs, we 
recorded GX-activated mIPSCs, which primarily reflect the activation of synaptic 
GABA-ARs, in the presence of the NMDA receptor antagonist (APV, 40 M), the 
AMPA receptor antagonist (DNQX, 10 M), and the sodium channel blocker (TTX, 0.5 
M) (Figure 24). Representative traces and ensemble average mIPSCs for each condition 
are shown in Figure 25A, 25B. The average mIPSC from each cell was best fit with a 
double-exponential decay curve, depicted as 1 and 2. A mean weighted decay constant 
w was also derived from 1 and 2 (see Materials and Methods). Table 6 showed the 
characteristics of mIPSCs modulated by GABA, GX, or Zn
2+
. GX significantly 
potentiated the amplitude, decay time 2, and the mean weighted decay time w of 
mIPSCs from DGGCs (Figure 24C, 24D). However, Zn
2+
 perfusion did not change GX-
modulated mean peak amplitude or decay time constant. These findings indicate that Zn
2+
 
blockade of GX-induced GABAergic currents is highly selective for extrasynaptic 






Figure 24 GX-activated mIPSCs are not sensitive to Zn
2+
 blockade. 
(A) Representative traces of mIPSCs. GABA-AR mIPSC activity was isolated by using 
TTX, APV, and DNQX, and was completely blocked by gabazine. GX (1 M) 
potentiated synaptic current but Zn
2+
 did not significantly alter the GX-potentiated 
mIPSCs. (B) Averaged mIPSCs in the presence of GX (solid line) and addition of Zn
2+
 
(dashed line). (C) Amplitudes were not significantly different between GX and 100 μM 
Zn
2+ 
(p = 0.65), or GX and 1000 μM Zn
2+
 (p = 0.70). (D) Zn
2+
did not significantly alter 
mean weighted decay kinetics (τw) of GX modulation. Data bars represent mean ± SEM 
(n = 4  9 cells per group). *p < 0.05 vs. baseline. GX denotes GABA + GX; baseline 





























1μM GABA (13) 43.1  1.5 1.1  0.1 10.6  1.3 48.0  1.9 30.2  1.4 0.56  0.08 
GABA+1μM GX (9) 65.4  6.9* 1.6  0.3 14.5  1.5 104.8  10.7* 65.5  7.9* 0.43  0.16 
GABA+GX+100μM Zn
2+ 
(5) 67.0  5.4* 1.0  0.3 22.4  4.7*
# 114.1  16.1*  87.4  15.4* 0.30  0.17 
GABA+GX+1000μM Zn
2+ 
(4) 70.5  2.0* 1.0  0.1 18.7  3.9*
# 144.9  18.9* 89.9  18.9* 0.10  0.02* 




 Chelator TPEN Reverses Zn
2+
 Blockade of GX-Sensitive Tonic 
Currents 
To further confirm the Zn
2+
 blockade of extrasynaptic GABA-ARs, we investigated 
tonic current response in the presence of a membrane-permeable, high affinity Zn
2+
 
chelator, N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN). Zn
2+ 
(100 M) 
perfusion blocked GX-potentiated tonic currents in DGGCs, resulting in a positive shift 
of tonic current density (0.24  0.09 pA/pF). Such blockade by Zn
2+ 
was prevented when 
TPEN (100 M) was added to the perfusion, and DGGCs displayed -0.27 ± 0.11 pA/pF 
negative shift in tonic current density (Figure 25). The differences between Zn
2+
-
antagonized and TPEN-enhanced tonic currents achieve statistical significance (p = 0.008, 
n = 5 cells per group). Without exogenous Zn
2+
 added to perfusion, TPEN sustained the 
negative shift of current density modulated by GX (-0.2 ± 0.08 pA/pF, n = 5 cells), 
indicating significant modulation of endogenous Zn
2+








 chelator TPEN inhibits the Zn
2+
 antagonism of GX-sensitive tonic 
currents. 
(A) Representative GABAergic Itonic recordings from DGGCs before and after the 
application of Zn
2+
 (100 M) or Zn
2+
 chelator TPEN (100 M), or in coapplication of 
both in modulation of 0.2 M GABA + 0.3 M GX. TPEN prevented Zn
2+
 blockade of 
GX-sensitive current, and Itonic exhibited significant enhancement by TPEN in 
hyperpolarization of the holding current level. Quantification of Itonic was achieved 
relative to complete block by gabazine (GBZ). Dashed lines indicate average holding 
current level throughout each drug application. (B) Itonic density shift (pA/pF) in the 
presence of Zn
2+ 
and/or TPEN, with positive values as block of GX-sensitive Itonic and 
negative values as enhancement of Itonic. Data bars represent mean  SEM (n = 5 cells per 
group). *p < 0.05 vs. GX + Zn
2+






 Antagonizes the Seizure Protective Effect of GX in 
Fully-kindled Mice 
To directly investigate the interactions of Zn
2+
 and GX on hippocampal excitability and 
seizures, we examined the antiseizure activity of GX with or without intrahippocampal 
Zn
2+ 
infusion in a mouse kindling model, in which the fully-kindled mice exhibit 
consistent, generalized stage 5 seizures. The experimental paradigm was shown in Figure 
26A. Intrahippocampal Zn
2+
 (10 – 300 M) infusion was performed 10 min before GX 
(10 mg/kg, s.c.) treatment followed by kindling stimulation. GX (10 mg/kg, s.c.) 
significantly suppressed kindling-induced seizures (Figure 26D, 26E). Zn
2+
 infusion 
blocked the antiseizure activity of GX dose-dependently, in which Zn
2+
 at 300 M 
achieves a statistical significance. The electrograph recordings of electrically-induced, 
kindling afterdischarge (AD) were shown in Figure 26B. GX-treated mice (10 mg/kg, s.c.) 
displayed significantly reduced AD durations compared to vehicle-treated mice (Figure 
26C). Despite GX treatment, 300 M Zn
2+
-infused mice exhibited significantly greater 
AD durations and higher incidence of seizures (Figure 26C  E). The reversible effect of 
Zn
2+ 
on kindling seizures was demonstrated since all animals exhibited stage 5 seizures 
after 24-hr wash-out of drug. Overall, these results suggest that Zn
2+
 plays a key role in 
the modulation of seizure susceptibility by anticonvulsant neurosteroids like GX that are 





Figure 26 Intrahippocampal Zn
2+
 infusion completely prevents the antiseizure 
effects of the neurosteroid GX in fully-kindled mice. 
(A) Experimental paradigm and infusion protocol for saline or Zn
2+
 delivery (0  300 μM) 
prior to GX (10 mg/kg, s.c.) treatment and kindling stimulation. (B) Electrograph 
recordings of electrically-induced, kindling afterdischarge (AD). The black arrow denotes 
stimulation-onset artifact. (C) AD duration of electrograph activity. Control denotes 
saline infusion (Zn
2+
-free) and vehicle injection (GX-free) condition upon kindling. (D) 
Kindling-induced behavioral seizure score after Zn
2+
 infusion. ED50 = 150 M. (E) Dose-
response curve of percent seizure protection. Anticonvulsant effect of 10 mg/kg GX was 
inhibited by 300 μM Zn
2+
. After 24 hr wash-out, mice displayed stage 5 seizures and 
similar AD duration to the control group. Data bars represent mean ± SEM (n = 5  6 
mice per group). *p < 0.05 vs. control;
 #







IV.3 Isobolographic Analysis of Extrasynaptic GABA-AR-Mediated Tonic 
Inhibition and Anticonvulsant Activity of Neurosteroid Combinations with TG and 
MDZ 
IV.3.1 Synergistic Effects of GX and TG Coapplication on Extrasynaptic GABA-
AR-Mediated Tonic Inhibition in Hippocampal DGGCs 
To characterize the interactions of neurosteroids with clinical GABAergic agent TG on 
extrasynaptic GABA-AR-mediated tonic currents, we first recorded tonic current 
potentiation by AP, GX, or TG alone (0.1 – 1 M) in DGGCs from hippocampus slices. 
Tonic currents were isolated in the presence of the NMDA receptor antagonist (APV, 40 
M), the AMPA receptor antagonist (DNQX, 10 M), and the sodium channel blocker 
(TTX, 0.5 M) in the bath solution by using whole-cell patch clamp electrophysiology. 
After application of the test drugs, a GABA-AR antagonist (gabazine, 50 M) was 
perfused to determine the total GABA-AR-mediated tonic current shift. Current density 
(pA/pF) of each cell was obtained by normalizing the tonic current shift with the cell 
capacitance. The basal level of tonic currents in DGGCs was 10.8 ± 1.6 pA, 0.31 ± 0.06 
pA/pF (Table 7). As shown in Figure 27A – 27C, AP (0.1 – 1 M), and GX (0.1 – 1 M) 
elicited direct tonic current activation in DGGCs in a concentration-dependent manner, as 
consistent with previous report (Chuang and Reddy, 2018b). The tonic current 
potentiation by TG (0.1 – 1 M), in the absence of GABA, was shown in Figure 27B, 
27C. We then co-applied GX (0.1 – 1 M) with TG at 0.1 M and recorded the 
combination effect of GX and TG on tonic inhibition. The potentiation of tonic currents 
by GX + TG was significantly greater compared to GX alone, indicating possible additive 
or synergistic effects of combination regimen (tonic current shift: 0.1 M or 0.3 M GX 
+ 0.1 M TG, p = 0.018 and 0.020, respectively; current density, 0.1 M or 0.3 M GX + 
0.1 M TG, p = 0.019 and 0.024, respectively; n = 6 – 8 cells per group). 
To elucidate the precise interaction between GX and TG, we performed the 




antagonistic, additive, or synergistic by utilizing fixed drug ratio combinations in 
preclinical studies (Tallarida, 2006, Wojda et al., 2009). We first examined the EF2-fold 
endogenous values that represent the effective functional concentration of drug (nM) required 
to double the endogenous tonic response in DGGCs (Fig. 28D – F). According to the 
concentration-response curves of GX and TG, we deduced the EF2-fold values of GX and 
TG as 250 nM and 220 nM, respectively (Fig. 28D – F). Fixed ratio drug combinations at 
1:3, 1:1, and 3:1 were tested in DGGCs to quantify the contribution of each drug to the 
overall effects. The theoretical EF2-fold (EF2-fold add) values for mixtures of GX and TG at 
three fixed ratio of 1:3, 1:1 and 3:1 are shown in Table 8. The experimental EF2-fold (EF2-
fold mix) values were derived from the tonic current modulation of each mixture. The tonic 
current shift (pA) and current density (pA/pF) exerted by each mixtures of drug 
combinations are shown in Table 7. The isobologram was plotted, and the theoretical and 
experimental EF2-fold of mixtures were compared (Figure 28; Table 8). In the isobologram, 
the EF2-fold for GX (250 nM) is plotted graphically on the X-axis, whereas the EF2-fold for 
TG (220 nM) is plotted graphically on the Y-axis. The distances between open-square 
points on the X- and Y-axes represent the 95% confidence limits (CLs) for the drugs 
treated alone. The straight line connecting these two EF2-fold values on the graph 
represents the theoretical line of additivity for a continuum of different fixed 
concentration ratios, whereas the dashed lines represent the theoretical additive 95% CLs 
of EF2-fold values. Our results showed that all three combination regimens of GX and TG 
were located drastically below the theoretical line of additivity (Figure 28B), indicating 






Figure 27 GX and TG combination significantly potentiates tonic currents in the 
hippocampal DGGCs compare to GX alone, indicating a possible synergistic 
interaction. 
(A) Representative whole-cell, voltage-clamp recordings of tonic currents in DGGCs in 
response to GX, AP, or TG. Concentration responses for tonic current shift (B) and tonic 
current density (C) in response to GX, AP, TG, or GX+TG combination in DGGCs. (D  
F) Concentration-response curves illustrating the EF2-fold values of GX, AP, and TG. *p < 




Table 7 The values of current (pA) and current density (pA/pF) potentiation by each 
mixtures of drug combinations. 
 Current shift (pA) Current density (pA/pF) Sample size (n) 
Endogenous 10.8  1.6 0.31  0.06 12 
EF2-fold endogenous 21.6  3.2 0.62  .012  
GX:TG=1:3 59.9  12.8 1.28  0.25 7 
GX:TG=1:1 61.3  10.4 1.38  0.20 7 
GX:TG=3:1 30.2  4.3 0.70   0.09 8 
AP:TG=1:3 56.5  15.5 1.37  0.30 6 
AP:TG=1:1 51.2  9.0 1.22  0.17 6 
AP:TG=3:1 129.5  32.1 3.12  0.78 6 
GX:MDZ=1:3 31.5  8.6 0.66  0.17 6 
GX: MDZ =1:1 32.0  8.4 0.66  0.18 6 
GX: MDZ =3:1 51.1  11.3 1.08  0.23 6 







Figure 28 Synergistic interactions between GX and TG of all combinations tested on 
tonic current potentiation. 
(A) Representative whole-cell recordings of tonic currents in DGGCs in response to 
combinations of GX and TG. (B) Isobologram showing interactions between GX and TG 
in tonic current potentiation in DGGCs. The EF2 for GX (250 nM) is plotted graphically 
on the X-axis, whereas the EF2 for TG (220 nM) is plotted graphically on the Y-axis. The 
distances between open-square points on the X- and Y-axes represent the 95% confidence 
limits (CLs) for the drugs treated alone. The straight line connecting these two EF2 values 
on the graph represents the theoretical line of additivity for a continuum of different fixed 
concentration ratios, whereas the dashed lines represent the theoretical additive 95% CLs 
of EF2 values. EF2 denotes concentration needed to achieve 2-fold potentiation of 
endogenous basal tonic current (10.8 ± 1.6 pA; 0.31 ± 0.06 pA/pF). The black circles 
depict the experimentally derived EF2 values (with 95% CLs as error bars) for the total 
concentration expressed as the proportion of GX and TG that produced 2-fold 
potentiation of basal tonic currents. The experimental EF2 values of the mixture of 
GX+TG for the entire fixed ratio are placed below the theoretical line of additivity, 






Table 8 Isobolographic analysis showing theoretical (EF2-fold add) and experimental 
determined (EF2-fold mix) values of GX and TG combinations on tonic current 





  GX      +     TG            =   EF
2-fold mix
 
                                            (nM) 
n
mix
   EF
2-fold add  
         =     GX     +    TG   




GX+TG 1:3 22.6 59.6 82.224.2 7 227.540.8 62.5 165 6 
GX+TG 1:1 44.1 38.8 83.018.5 7 23538.5 125 110 6 
GX+TG 3:1 134.3 39.4 173.620.5 8 242.536.3 187.5 55 6 
nadd denotes total cell numbers used to calculate the theoretical line of additivity; nmix denotes total cell 
numbers in each mixtures of drug combinations. 
 
IV.3.2 Log-Probit Dose-Response Analysis of Anticonvulsant Effects of GX and TG 
in Mice 
In seizure protection studies, GX and TG administered alone reduced seizures in a dose-
dependent fashion in both 6-Hz and kindling seizure model in mice (Figure 29A, 29C, 
29D). GX displayed a significantly faster peak response time than TG, with similar rates 
of disposition for each (Figure 29B). Administration of GX with TG at 0.25 mg/kg 
caused a leftward shift of GX dose response in the 6-Hz model; similar protection trend 
of reduced seizure stage and AD duration was noted in the kindling model, suggesting 
additive/synergistic effects of GX+TG combination in mouse seizure models (Figure 
29C – D). To study the interactions of GX with TG on seizure protection, a mouse 6-Hz 
model of epilepsy was utilized. First, we determined the median effective dose (ED50) of 
each drug by using log-probit linear regression analysis (Litchfield and Wilcoxon, 1949). 
GX was given at the increasing doses (0.5  10 mg/kg) and the percent protection against 
6 Hz-induced seizures was calculated. The dose-response relationship for GX 
administered alone was determined as y = 5.30092x + 5.30092 [r
2
 = 0.92463], where y 
denotes probit of response, x denotes logarithm of the drug dose 10, and r
2
 denotes 
coefficient of determination (Figure 29E). The ED50 value for GX was 1.46 (0.74  2.88) 
mg/kg. Similarly, TG was administered at various doses (0.1  1 mg/kg) and the percent 




was y = 4.71065x + 3.03345 [r
2
 = 0.95594]. The ED50 value for TG was 0.20 (0.10  0.39) 
mg/kg. The chi-square analysis revealed that the points creating the log-probit dose 
response relationship lines for GX and TG were not heterogeneous and thus good-to-fit 
as the experimentally denoted 
2
 values (GX = 2.370; TG = 1.193) were lower than the 
tabular 
2
 values (GX = 7.815; TG = 5.991). The parallelism test for two log-probit dose-
response curves showed that the slope function ratio was lower than the factor for the 






Figure 29 Additive and synergistic anticonvulsant interactions between GX and TG 
in acute seizure models in mice.  
(A) The percentage of seizure protection by GX, TG, or GX+TG. GX and TG reduced 
seizures in a dose-dependent fashion in the 6-Hz model. Combination therapy of GX and 
TG (0.25 mg/kg) shifted the response curve of GX toward left, indicating possible 
synergism. (B) Efficacy timeline for GX (5 mg/kg) and TG (0.25 mg/kg) in 6-Hz model. 
GX displayed significantly faster peak response time than TG, with similar rates of decay  
for each. GX and TG reduced the seizure stage (C) and afterdischarge (AD) duration (D) 
in a dose-dependent fashion in fully-kindled mice. Combination therapy of GX and TG 
(0.25 mg/kg) shifted the dose-response curves toward left, indicating possible synergism. 
(E) Log-probit dose-response relationship lines for GX and TG administered alone in the 
6-Hz-induced partial seizure model. (F) Isobologram showing interactions between GX 
and TG in the 6-Hz seizure model. The dose GX is plotted graphically on the X-axis, and 
the dosing for TG is plotted graphically on the Y-axis. The straight line represents the 
theoretical line of additivity for a continuum of different fixed concentration ratios, 
whereas the dashed lines represent the theoretical additive 95% CLs of ED50 values. ED50 
denotes dose needed to achieve seizure protection in 50% of animals. The experimental 
ED50 values of the mixture of GX+TG for fixed ratios fall at or below the theoretical line 





Figure 29 Continued. 
 
IV.3.3 Synergistic Anticonvulsant Effects of GX and TG Combinations in the 6-Hz 
Seizure Model in Mice 
In the isobolographic analysis, the theoretical ED50 add values for a mixture of GX and TG 
at three fixed ratio of 1:3, 1:1 and 3:1 were calculated as (in mg/kg) 0.514 (0.260  
1.012), 0.829 (0.420  1.634), and 1.145 (0.580  2.255), respectively (Figure 29, Table 
9). The experimental ED50 mix values were derived from the seizure protection exerted by 
each mixture at 1:3, 1:1 and 3:1 as 0.484 (0.282  0.833), 0.437 (0.219  0.870), and 
1.049 (0.535  2.057), respectively. The mixture of GX and TG at the fixed-ratio of 1:1 
exerted the greatest synergism (combination index, CI = .53, Table 10), whereas CI’s for 
the mixture of GX and TG at 3:1 and 1:3 combinations were .94 and .96, respectively. In 
addition, combinations tested between GX and TG at 1:3 and 3:1 are plotted in the 
theoretical line of additivity while the combination at 1:1 is plotted below the additive 





Table 9 Isobolographic analysis showing theoretical (EF50 add) and experimental 





  GX      +     TG      =   ED
50 mix
 




50 add  





GX+TG 1:3 0.341 0.143 0.484  
(0.282-0.833) 
32 0.514  
(0.26-1.012) 
0.365 0.149 32 
GX+TG 1:1 0.385 0.052 0.437  
(0.219-0.870) 
40 0.829  
(0.42-1.634) 
0.73 0.099 40 
GX+TG 3:1 0.999 0.05 1.049  
(0.535-2.057) 
32 1.145  
(0.58-2.255) 
1.095 0.050 32 
nadd denotes total cell numbers used to calculate the theoretical line of additivity; nmix denotes total cell 
numbers in each mixtures of drug combinations. 
 
Table 10 Combination (CI) index of the combinations of GX and TG in the 
antiseizure activity. 
ED50 GX TG CI  
alone 1.46 0.198   
GX+TG 1:3 0.341 0.143 0.96 addition/synergism 
GX+TG 1:1 0.385 0.052 0.53 synergism 
GX+TG 3:1 0.999 0.05 0.94 addition/synergism 
 
IV.3.4 Synergistic Potentiating Effects of AP and TG Coapplication on Tonic 
Currents in Hippocampal DGGCs 
To further characterize the combination interactions between neurosteroid and TG on 
tonic currents, we also examine the interactions of the endogenous neurosteroid AP and 
TG by using isobolographic analysis (Figure 30A – B). The EF2-fold endogenous value of AP 
was 288 nM (Fig. 27E). Fixed ratio drug combinations at 1:3, 1:1, and 3:1 were examined 
in DGGCs to quantify the contribution of each drug to the overall effects. The theoretical 
EF2-fold (EF2-fold add) values for mixtures of AP and TG at three fixed ratio of 1:3, 1:1 and 
3:1 were shown in Table 11. The experimental EF2-fold (EF2-fold mix) values were derived 
from the tonic current modulation of each mixtures. In the isobologram, the EF2-fold for 
AP (288 nM) is plotted graphically on the X-axis, whereas the EF2-fold for TG (220 nM) is 




TG are plotted below the theoretical line, signifying strong synergistic interactions of AP 
and TG on tonic current potentiation in DGGCs (Figure 30).  
 
 
Figure 30 Synergistic interactions between AP and TG of all combinations tested in 
the tonic current potentiation. 
(A) Representative whole-cell recordings of tonic currents in DGGCs in response to 
combinations of AP and TG. (B) Isobologram showing interactions between AP and TG 
in tonic current potentiation in DGGCs. The EF2 for AP (288 nM) is plotted graphically 
on the X-axis, whereas the EF2 for TG (220 nM) is plotted graphically on the Y-axis. The 
distances between open-square points on the X- and Y-axes represent the 95% confidence 
limits (CLs) for the drugs treated alone. The straight line connecting these two EF2 values 
on the graph represents the theoretical line of additivity for a continuum of different fixed 
concentration ratios, whereas the dashed lines represent the theoretical additive 95% CLs 
of EF2 values. EF2 denotes concentration needed to achieve 2-fold potentiation of 
endogenous basal tonic current (10.8 ± 1.6 pA; 0.31 ± 0.06 pA/pF). The black circles 
depict the experimentally derived EF2 values (with 95% CLs as error bars) for the total 
concentration expressed as the proportion of AP and TG that produced 2-fold potentiation 
of basal tonic currents. The experimental EF2 values of the mixture of AP+TG in all 
three-fixed ratio are placed below the theoretical line of additivity, indicating the 





Table 11 Isobolographic analysis showing theoretical (EF2-fold add) and experimental 
determined (EF2-fold mix) values of AP and TG combinations on tonic current 





  AP      +     TG            =   EF
2-fold mix
 
                                            (nM) 
n
mix
   EF
2-fold add  
         =     AP     +    TG   




AP+TG 1:3 27.6 63.2 90.8  28.2 6 237  35.3 72 165 6 
AP+TG 1:1 60.8 46.5 107.3  20.6 6 254  27.5 144 110 6 
AP+TG 3:1 36.1 9.2 45.3  15.6 6 271  19.8 216 55 6 
nadd denotes total cell numbers used to calculate the theoretical line of additivity; nmix denotes total cell 
numbers in each mixtures of drug combinations. 
 
IV.3.5 Log-Probit Dose-Response Analysis of Anticonvulsant Effects of AP and TG 
in Mice 
Next, we examined the interactions of AP and TG in the 6-Hz seizure model. AP was 
given at the increasing dosing of 1, 3, 5, and 10 mg/kg, and the percent protection against 
6-Hz-induced partial seizures was 10, 38.9, 60, and 99.7, respectively. The equation of 
dose response relationship for AP administered alone was determined as y = 9.28311x + 
1.69977 [r
2
 = 0.97008], where y denotes probit of response, x denotes logarithm of the 
drug dose 10, and r
2
 denotes coefficient of determination (Figure 31A). The ED50 value 
for AP was 4.20 (2.7  5.8) mg/kg. The equation for TG was y = 4.71065x + 3.03345 [r2 
= 0.95594] and the ED50 value for TG was 0.20 (0.1  0.39) mg/kg. The experimentally 
denoted 
2
 values (AP = 0.740; TG = 1.193) were lower than the tabular 
2
 values (AP = 
7.815; TG = 5.991), signifying that the log-probit curves for AP and TG were not 






Figure 31 Synergistic anticonvulsant interactions between AP and TG in the 6-Hz 
test in mice. 
(A) Log-probit dose-response relationship lines for AP and TG administered alone in the 
6-Hz partial seizure model. (B) Isobologram showing interactions between AP and TG in 
the 6-Hz seizure model. The dose AP is plotted graphically on the X-axis, and the dosing 
for TG is plotted graphically on the Y-axis. The straight line represents the theoretical line 
of additivity for a continuum of different fixed concentration ratios, whereas the dashed 
lines represent the theoretical additive 95% CLs of ED50 values. ED50 denotes dose 
needed to achieve seizure protection in 50% of animals. The experimental ED50 values of 
the mixture of AP+TG for fixed ratios fall at or below the theoretical line of additivity.  
 
IV.3.6 Synergistic Anticonvulsant Effects of AP and TG Combinations in the 6-Hz 
Seizure Model in Mice 
In the isobolographic analysis, the theoretical ED50 add values for mixtures of AP and TG 
at three fixed ratio of 1:3, 1:1 and 3:1 were determined as (in mg/kg) 1.199 (0.75  1.74), 
2.199 (1.4  3.1), and 3.2 (2.05  4.45), respectively (Figure 31B, Table 12). The 
experimental ED50 mix values were derived from the seizure protective effects exerted by 
each mixture at 1:3, 1:1 and 3:1 as 2.464 (1.70  4.06), 0.835 (0.56  1.25), and 0.436 
(0.24  0.79), respectively. All combinations tested between AP and TG showed strong 
synergistic interactions against 6-Hz-induced seizures as the combination index (CI) of 




respectively, Table 13). All combination regimens of AP and TG at 1:3, 1:1 and 3:1 are 
all plotted below the additive line (Figure 31B), indicating synergistic anticonvulsant 
interactions of AP and TG. 
 
Table 12 Isobolographic analysis showing theoretical (EF50 add) and experimental 





  AP      +     TG      =   ED
50 mix
 




50 add  





AP+TG 1:3 2.422 0.042 2.464  
(1.705-4.058) 
32 1.199  
(0.75-1.74) 
1.05 0.149 32 
AP+TG 1:1 0.797 0.038 0.835  
(0.559-1.247) 
32 2.199  
(1.40-3.10) 
2.1 0.099 32 
AP+TG 3:1 0.377 0.059 0.436  
(0.24-0.791) 
32 3.200  
(2.05-4.45) 
3.15 0.050 32 
nadd denotes total cell numbers used to calculate the theoretical line of additivity; nmix denotes total cell 
numbers in each mixtures of drug combinations. 
 
Table 13 Combination index (CI) of the combinations of AP and TG in the 
antiseizure activity. 
ED50 AP TG CI  
alone 4.2 0.198   
AP+TG 1:3 2.422 0.042 0.79 synergism 
AP+TG 1:1 0.797 0.038 0.38 synergism 
AP+TG 3:1 0.377 0.059 0.39 synergism 
 
IV.3.7 Combination Efficacy of GX and MDZ on Tonic Current Potentiation in 
Hippocampal DGGCs 
The benzodiazepine MDZ is an allosteric agonist of synaptic GABA-ARs receptors 
through sites distinct from the neurosteroid binding site (Nusser et al., 1997). Therefore, 
it is plausible that neurosteroid+MDZ exerts a synergistic response on GABA-AR 
function through a mechanism involving distinct sites and thereby may be more effective 




we tested if coapplication of neurosteroids with MDZ elicits additive or synergistic 
effects on tonic inhibition in hippocampal DGGCs (Figure 32). Like GX+TG 
coapplication experiments, we have simulated isobolograms for two allosteric drugs (GX 
and MDZ) combined. The results (Figure 32D) demonstrate that coapplication of GX and 
MDZ produces a curvilinear isobole; however, the curvature is less pronounced due to 
limited efficacy of MDZ at extrasynaptic receptors (Figure 32D). Nevertheless, 
combinations of GX and MDZ at three fixed ratio exerted synergistic potentiation of 
tonic currents as they are plotted below the theoretical line in the isobologram (Figure 
32D, Table 14). These results are highly consistent with a recent study in which the 
potentiating effect of alfaxolone resulting from the addition of a second GABAergic drug 








Figure 32 Synergistic interactions between GX and MDZ in the tonic current 
potentiation. 
(A) Representative whole-cell recordings of tonic currents in DGGCs in response to 
MDZ (0.01  0.1 M). (B) Representative whole-cell recordings of tonic currents in 
DGGCs in response to combinations of GX and MDZ. (C) Concentration response curves 
of GX and MDZ alone in the potentiation of tonic currents (pA). (D) Isobologram 
showing interactions between GX and MDZ in tonic current potentiation in DGGCs. The 
EF2 for GX (250 nM) is plotted graphically on the X-axis, whereas the EF2 for MDZ (33 
nM) is plotted graphically on the Y-axis. The distances between open-square points on 
the X- and Y-axes represent the 95% confidence limits (CLs) for the drugs treated alone. 
The straight line connecting these two EF2-fold values on the graph represents the 
theoretical line of additivity for a continuum of different fixed concentration ratios, 
whereas the dashed lines represent the theoretical additive 95% CLs of EF2 values. EF2 
denotes concentration needed to achieve 2-fold potentiation of endogenous basal tonic 
current (10.8 ± 1.6 pA; 0.31 ± 0.06 pA/pF). The black circles depict the experimentally 
derived EF2 values (with 95% CLs as error bars) for the total concentration expressed as 
the proportion of GX and MDZ that produced 2-fold potentiation of basal tonic currents. 
The experimental EF2 values of the mixture of GX+MDZ for the entire fixed ratio are 






Table 14 Isobolographic analysis showing theoretical (EF2-fold add) and experimental 
determined (EF2-fold mix) values of GX and MDZ combinations on tonic current 





  GX      +     MDZ           =   EF
2-fold mix
 
                                            (nM) 
n
mix
   EF
2-fold add  
       =     GX     +    MDZ   




GX+MDZ 1:3 43.0 17.0 60.024.0 6 87.314.9 62.5 24.8 6 
GX+MDZ 1:1 84.6 11.2 95.831.0 6 141.521.3 125 16.5 6 
GX+MDZ 3:1 79.4 3.5 82.921.7 6 195.827.6 187.5 8.3 6 
nadd denotes total cell numbers used to calculate the theoretical line of additivity; nmix denotes total cell 






IV.3.8 Anticonvulsant Activity of GX and MDZ Combination Regimens in the 6-Hz 
Seizure Model 
In the 6-Hz seizure model, MDZ was given at the increasing doses (0.05  3 mg/kg) and 
the percent protection was derived from the analysis. The dose-response relationship for 
MDZ administered alone was determined as y = 4.69735x + 6.90629[r
2
 = 0.92273], 
where y denotes probit of response, x denotes logarithm of the drug dose 10, and r
2
 
denotes coefficient of determination (Figure 33A). The ED50 value for MDZ was 0.40 
(0.11  0.69) mg/kg. The equation for GX was y = 5.30092x + 5.30092 [r
2
 = 0.92463] 
and the ED50 value for GX was 1.46 (0.74  2.88) mg/kg. The experimentally denoted 
2
 
values (GX = 2.370; MDZ = 10.118) were lower than the tabular 
2
 values (GX = 7.815; 
MDZ = 11.07), signifying that the log-probit dose-response relationship lines for GX and 
MDZ were not significantly heterogeneous and thus good-to-fit. In the isobolographic 
analysis, the theoretical ED50 add values for mixtures of GX and MDZ at three fixed ratio 
of 1:3, 1:1 and 3:1 were determined as (in mg/kg) 0.665 (0.268  1.237), 0.930 (0.624  
1.784), and 1.195 (0.538  2.330), respectively (Figure 33B, Table 15). The experimental 
ED50 mix values were derived from the seizure protective effects exerted by each mixture 
at 1:3, 1:1 and 3:1 as 0.910 (0.608  0.364), 0.550 (0.368  0.823), and 0.404 (0.259  
0.631), respectively. All combinations tested between GX and MDZ showed strong 
synergistic interactions for seizure protection as CIs of each mixture are less than 1 (CI = 
0.76, 0.59, and 0.61 at 1:1, 3:1, and 1:3 ratios, respectively, Table 16). In addition, 
combinations tested between GX and MDZ at 1:3, 1:1 and 3:1 are all plotted below the 
additive line (Figure 33B), indicating synergistic anticonvulsant interactions between GX 






Figure 33 Synergistic anticonvulsant interactions between GX and MDZ in the 6-Hz 
model in mice. 
(A) Log-probit dose-response relationship lines for GX and MDZ administered alone in 
the 6-Hz-induced partial seizure model. (B) Isobologram showing interactions between 
GX and MDZ in the 6-Hz seizure test. The dose GX is plotted graphically on the X-axis, 
and the dosing for MDZ is plotted graphically on the Y-axis. The straight line represents 
the theoretical line of additivity for a continuum of different fixed concentration ratios, 
whereas the dashed lines represent the theoretical additive 95% CLs of ED50 values. ED50 
denotes dose needed to achieve seizure protection in 50% of animals. The experimental 
ED50 values of the mixture of GX+MDZ for fixed ratios fall at or below the theoretical 






Table 15 Isobolographic analysis showing theoretical (EF50 add) and experimental 






  GX      +     MDZ      =   ED
50 mix
 




50 add  





GX+MDZ 1:3 0.834 0.076 0.910  
(0.608-0.364) 
32 0.665  
(0.268-1.237) 
0.365 0.3 32 
GX+MDZ 1:1 0.432 0.118 0.550  
(0.368-0.823) 
32 0.93  
(0.426-1.784) 
0.73 0.2 32 
GX+MDZ 3:1 0.223 0.181 0.404  
(0.259-0.631) 
32 1.195  
(0.583-2.330) 
1.095 0.1 32 
nadd denotes total cell numbers used to calculate the theoretical line of additivity; nmix denotes total cell 
numbers in each mixtures of drug combinations. 
 
Table 16 Combination index (CI) of the combinations of GX and MDZ in the 
antiseizure activity. 
ED50 GX MDZ CI  
alone 1.46 0.4   
GX+MDZ 1:3 0.834 0.076 0.76 synergism 
GX+MDZ 1:1 0.432 0.118 0.59 synergism 









V.1 The Mechanisms of Action and Structure-Activity Relationships of GX and 
Related Neurosteroid Analogs on Extrasynaptic GABA-AR-Mediated Tonic 
Inhibition and Seizure Protection 
The principal finding of this study is the demonstration of GX and its analogs as 
preferential positive allosteric modulators and direct activators of extrasynaptic GABA-
ARs in the dentate gyrus that regulate network tonic inhibition and seizures. GX and its 
analogs are highly selective for PKC-phosphorylated extrasynaptic GABA-AR-
mediated tonic inhibition in native hippocampal neurons. In addition, GX enhancement 
of tonic inhibition is diminished in mice lacking GABA-ARs. These results suggest that 
GX controls seizure susceptibility probably by potentiating GABA-AR-medicated 
synaptic and tonic inhibition though allosteric and/or direct action. Overall, these findings 
provide a mechanistic rationale for the clinical use of GX and its analog in seizure 
disorders (Reddy and Estes, 2016).  
Neurosteroids are endogenous modulators of GABA-ARs acting through an allosteric 
binding site at submicromolar concentrations and a direct activation site at micromolar 
concentrations (Hosie et al., 2007). GX is a synthetic neurosteroid with robust antiseizure 
properties (Reddy and Woodward, 2004). Unlike its natural prototype AP, GX, with its 
additional methyl group at the 3 position, is not readily metabolized to hormonally 
active 3-keto derivative (Gee et al., 1995). Therefore, GX possesses higher bioavailability 
                                                 
§§ Reprinted with permission from “3β-methyl-neurosteroid analogs are preferential positive allosteric 
modulators and direct activators of extrasynaptic δ-subunit γ-aminobutyric acid type A receptors in the 
hippocampus dentate gyrus subfield.” by S-H Chuang and DS Reddy, 2018. The journal of pharmacology 
and experimental therapeutics, 365(3): 583601, Figures 1  13, Table 1  2, Copyright ©  2018 by The 
American Society for Pharmacology and Experimental Therapeutics. All rights reserved. 
***Reprinted with permission from “Zinc reduces antiseizure activity of neurosteroids by selective blockade 
of extrasynaptic GABA-A receptor-mediated tonic inhibition in the hippocampus” by S-H Chuang and DS 
Reddy, 2019. Neuropharmacology, 148: 244256, Figures 1  7, Table 1, Copyright ©  2018 Elsevier Ltd. 




and provides a more favorable pharmacokinetic profile as a promising antiepileptic drug. 
Although GX was previously tested in recombinant 112L GABA-ARs (Carter et al., 
1997), its precise mode of action on native hippocampal neurons remained largely 
unclear. Here we demonstrated that GX is a potent allosteric modulator of both synaptic 
and extrasynaptic GABA-ARs in native hippocampal neurons. We compared the 
modulatory effects of GX with AP. GX and AP at 0.3 M allosterically potentiated tonic 
current density to 1.61 ± 0.18 pA/pF and 1.80 ± 0.18 pA/pF, respectively (Figure 12 and 
16). In seizure models including the 6-Hz test, GX exhibited improved potency compared 
with AP (Kaminski et al., 2004; Carver and Reddy, 2016). This may be attributed to its 
enhanced pharmacokinetic profile preventing its metabolism, thereby offering increased 
bioavailability.  
Like our previous structure-activity relationship study (Carver and Reddy, 2016), we 
compared the potency and efficacy of GX with its analog 21-OH-GX. Our results 
demonstrate that, with the addition of a hydroxyl group in the C21 position, 21-OH-GX 
displayed higher efficacy than GX in the augmentation of GABA currents and tonic 
inhibition. These could be related to the plausible comparable bioavailability and higher 
binding affinity to GX. In addition, both GX and 21-OH-GX displayed dose-dependent 
reduction of seizure stage and AD duration. However, 21-OH-GX exhibited significantly 
greater antiseizure potency, an effect highly selective for extrasynaptic GABA-ARs. 
Our studies confirm that 21-OH-GX possesses higher efficacy in potentiation of GABA 
currents and extrasynaptic GABA-AR-mediated tonic inhibition, possibly contributing 
to its better antiseizure activity. 
The  subunit and its expressional plasticity remain key factors in understanding 
neurosteroid sensitivity, network excitability, and seizure susceptibility (Mihalek et al., 
1999; Carver and Reddy, 2013; Whissell et al., 2015; Reddy et al., 2017; Chuang and 
Reddy, 2018a). Mice lacking the  subunit display significantly decreased sleep time in 
response to neurosteroid alphaxolone and reduced sensitivity to GX-exerted anxiolytic 




al., 2003). The -selective effect for neurosteroid modulation is also established by 
electrophysiological studies. THDOC-potentiated tonic currents and spontaneous IPSCs 
are absent in the KO mice (Vicini et al., 2002; Wohlfarth et al., 2002; Stell et al., 2003). 
AP-enhanced GABAergic currents and tonic inhibition in WT DGGCs are also 
attenuated in KO mice (Carver et al., 2014; Carver and Reddy, 2016), signifying the 
obligatory role of the  subunit in neurosteroid sensitivity. In the present study, we 
demonstrate that  subunit plays an essential role in GX’s allosteric and direct 
augmentation of tonic inhibition in native neurons. These findings are consistent with the 
emerging importance of -containing GABA-ARs to tonic inhibition and neurosteroid 
sensitivity.  
The IPSCs primarily represent the activation of synaptic GABA-ARs. To elucidate the 
extent of GX’s modulation of synaptic GABA-ARs and the role of  subunit in such 
modulation, we recorded the mIPSCs from WT and DGGCs. GX has a greater 
effect on the amplitude and the decay time of mIPSCs in WT DGGCs, an effect 
prevented by the deletion of -subunit, which indicates that GABA-ARs mediate this 
effect. Previous studies have shown the effect of  subunit on the neurosteroid-mediated 
phasic currents (Carver and Reddy, 2016). In cerebellar granule neurons, which have the 
highest expression of the  subunit, THDOC exerts strong potentiation of spontaneous 
IPSCs. However, this is significantly diminished in KO neurons (Vicini et al., 2002). In 
WT DGGCs, which have the second highest expression of the -subunit, alphaxolone 
strongly prolongs the decay time of mIPSCs, but not in those from mice (Spigelman 
et al., 2003). KO mice were observed to have a significant reduction in the expression of 
the 4 subunit and an increase in the 2 subunit (Peng et al., 2002; Spigelman et al., 
2003). This notion is with previous reports that 4-containing GABA-ARs are more 
sensitive to neurosteroid modulation (Brown et al., 2002; Wohlfarth et al., 2002). It is 
also possible that a population of perisynaptic GABA-ARs could respond to synaptic 




(Bianchi and Macdonald, 2002; Carver et al., 2014). However, another study reports that 
-containing receptors are less sensitive to GABA that could be present through synaptic 
spillover (Bright et al., 2011). Overall, these results demonstrate that  mice exhibit 
significantly attenuated responses to neurosteroid modulation of synaptic GABA-AR-
mediated phasic currents, suggesting the significance of  subunit in the neurosteroid 
sensitivity.  
Protein kinase activity influences the surface expression of GABA-ARs and the 
neurosteroid sensitivity. Several GABA-AR subunits are substrates of PKC including the 
4 and  subunits (Abramian et al., 2010; Adams et al., 2015). PKC activator potentiates 
THDOC-enhanced GABA-gated currents in recombinant receptors (Leidenheimer and 
Chapell, 1997), while inhibition of PKC reduces the THDOC and AP-prolonged decay 
time of mIPSCs in murine neurons (Fancsik et al., 2000; Harney et al., 2003). THDOC 
also promotes the phosphorylation of the S443 within the 4 subunit and the upregulation 
of 4-containing GABA-ARs in the cell membrane, leading to increased tonic inhibition 
(Abramian et al., 2010; Abramian et al., 2014). The  subunit is predominately assembled 
with the 4 and 6 subunit (Jones et al., 1997; Peng et al., 2002; Spigelman et al., 2003). 
In the present study, we demonstrate that PKC activity mediates the potentiation of tonic 
currents by AP and GX in DGGCs. The inhibition of PKC may cause the downregulation 
of 4-containing GABA-ARs in the cell membrane through reduced phosphorylation of 
4 subunits and subsequent attenuated tonic current potentiation by neurosteroids. A 
recent study indicates that sustained application of AP, but not GX, leads to increased 
phosphorylation and surface expression of the 3-containing GABA-ARs, and tonic 
current potentiation. These effects are prevented by the PKC inhibitor (Modgil et al., 
2017). Although GX does not have a metabotropic effect on GABA-AR phosphorylation 
and trafficking, inhibition of PKC still dampens the potentiation of tonic inhibition by 
neurosteroids. This is likely because sustained application of the PKC inhibitor causes 
decreased phosphorylation and subsequent internalization of receptors, and therefore, 




We confirmed that GX has potent antiseizure effect in the hippocampus kindling model 
of epilepsy, which is a well-accepted model of complex partial seizures (Albertson et al., 
1980; Sutula, 1990; Reddy et al., 2010). The comparative protective profile of GX and 
AP is outlined in Table 17. Like other neurosteroids such as AP, GX is highly effective 
against seizures induced by a variety of triggers, including chemoconvulsants, electrical 
kindling and chemical kindling (Gasior et al., 2000; Kaminski et al., 2003; Reddy and 
Woodward, 2004; Reddy and Rogawski, 2012). GX is active in the 6-Hz model, which has 
been shown to be very responsive to positive modulators of GABA-ARs (Kaminski et al., 
2004; Reddy et al., 2015). GX is developed as a rational analog of AP, which is a potent 
positive allosteric agonist of GABA-ARs (Carter et al., 1997). Since neurosteroids exhibit 
greater selectivity towards extrasynaptic receptors, the results from this study confirm 
that the antiseizure effect of GX is mostly due to its preferential interaction with GABA-
ARs besides its actions on synaptic receptors (Carver et al., 2014; Carver and Reddy, 
2016). The PK-PD correlation of key outcomes from pharmacological and 
electrophysiological studies supports this conclusion. In animal seizure models, the ED50 
value of GX ranges from 2 to 6 mg/kg (Table 17). Based on the GX plasma levels, the 
estimated threshold plasma concentration for 50% seizure protection is in the range of 
510  750 ng/ml (1.5  2.3 M) (Reddy and Rogawski, 2000). These concentrations 
exceed the range for GX allosteric potentiation in DGGCs (0.1 to 0.3 M), and 
apparently near the range for producing direct activation (1  2 M), indicating that GX 
potentiation of GABA-AR-mediated inhibition primarily contributes to its antiseizure 
activity. However, there is limited PK-PD data from clinical studies. Single oral doses of 
50 – 500 mg in healthy subjects resulted in plasma concentrations of 32  376 ng/ml 
(0.01  1.1 M) (Monaghan et al., 2013). Thus, GX and its analogs are powerful 
anticonvulsants with utility in the treatment of epilepsy and seizures in conditions with 
intact GABA-ARs, including catamenial epilepsy, status epilepticus, and chemical 




In conclusion, these results demonstrate that GX and its analogs are preferential allosteric 
modulators of both synaptic and extrasynaptic GABA-ARs in native hippocampal 
neurons. GX potentiation of tonic inhibition is  subunit-dependent and greatly 
influenced by PKC activity. These outcomes provide a strong mechanistic basis for the 






Table 17 Comparative antiseizure ED50 values of GX and AP in mouse models of 
epilepsy. 
 AP (mg/kg) GX (mg/kg) References 
Kindling Models  
Hippocampus kindling 3.5 3.5 (Carver et al., 2014; Reddy et al., 2012) 
Amygdala kindling 14 (8–23) 6.6 (5.1–9.7) (Reddy and Rogawski, 2010) 
Cocaine kindling 17.0 (ND) 17.0 (ND) (Kaminski et al., 2003) 
Pentylenetetrazol kindling ND 3.5 (2.4–5.1) (Gasior et al., 2000) 
Corneal kindling ND 4.5 (4.0–5.1) (Carter et al., 1997) 
Chemoconvulsant Models 
Pentylenetetrazol (mice) 13.7 (10.1–18.7) 3.5 (2.1–5.8) (Carter et al., 1997; Kokate et al., 1994) 
Pentylenetetrazol (rats) 2.14 (1.10–4.15) 4.3 (2.8–6.9) (Reddy and Rogawski, 2000; 2001) 
Bicuculline 12 (10–15) 4.6 (3.2–6.8) (Carter et al., 1997) 
Picrotoxin 10 (5–19) ND (Belelli et al., 1989) 
t-Butylbicycloorthobenzoate ND 11.7 (8.8–15.7) (Carter et al., 1997) 
Flurothyl (rats) ND 5.0 (ND) (Liptakova et al., 2000) 
N-Methyl-D-aspartate >40 >30 (Carter et al., 1997) 
Kainic acid >40 >30 (Carter et al., 1997) 
4-Aminopyridine >40 11.5 (8.1–16.3) (Carter et al., 1997) 
Strychnine >40 >40 (Carter et al., 1997) 
Electroshock Models 
Maximal electroshock 29 (19–44) 29.7 (25.3–34.8) (Carter et al., 1997) 
6-Hz stimulation 4.2 (2.7–5.8) 1.5  (1.3–1.7) (Carver and Reddy, 2016) 
Status Epilepticus Models 
Pilocarpine  7 (4–11)  ~6  (Briyal and Reddy, 2008; Kokate et al., 
1996) 
Kainic acid ~20 ND (Rogawski et al., 2013) 





V.2 The Influence of Zn
2+
 on Neurosteroid Activation of Extrasynaptic GABA-AR-
Mediated Tonic Inhibition and Seizure Protection 
Zn
2+
 is an extremely abundant transition metal in the synaptic vesicles of hippocampal 
glutamatergic mossy fibers and remains a key factor in the modulation of neuronal 
plasticity (Assaf and Chung, 1984). Disruption of Zn
2+
 homeostasis is associated with 
many neurological disorders, including seizures, epilepsy, and conditions with 
compromised brain functions. Previous studies show that Zn
2+
 modulates kinetics of 
synaptic GABA-ARs and alters the balance of inhibition and excitation (Barberis et al., 
2000; Lambert and Belelli, 2002). Zn
2+
 exhibits higher sensitivity to extrasynaptic 
GABA-ARs than synaptic GABA-ARs (Hosie et al., 2003; Wei et al., 2003). However, 
its inhibition on extrasynaptic receptor-mediated tonic currents and interactions with 
neurosteroids are not fully understood. Our current study shows that Zn
2+
 pretreatment 
prevents the anticonvulsant activity of neurosteroids, an effect most likely due to the Zn
2+
 
blockade of neurosteroid-potentiated extrasynaptic GABA-ARs. These receptors 
represent the main contributors in maintaining the tonic inhibition in the dentate gyrus, 
which is involved in a number of seizure and memory disorders (Carver et al., 2016).  
Positive allosteric modulators targeting extrasynaptic GABA-ARs, such as 
neurosteroids, are being evaluated as potential therapeutic agents for the treatment of 
hyperexcitable brain disorders (Reddy and Rogawski, 2001; 2010; Reddy et al., 2018; 
Younus and Reddy, 2018). GX is a neurosteroid analog developed as a more favorable 
therapeutic compound with superior bioavailability and pharmacokinetic profile 
compared to its prototype neurosteroid AP. Synthetic GX serves as a robust antiseizure 
agent as well as a powerful allosteric modulator of GABA-ARs with higher selectivity 
for extrasynaptic GABA-ARs (Reddy and Rogawski, 2000; 2010; Clossen and Reddy, 
2017a; 2017b; Chuang and Reddy, 2018b). Elucidating the neuroprotective effects of GX 
as well as its interactions with other molecules at the extrasynaptic GABA-ARs is of 
critical importance for its clinical use as an antiepileptic drug. In the present study, we 
demonstrate that Zn
2+




inhibition in DGGCs. Chelation of endogenous Zn
2+
 sustains the enhancement of tonic 
inhibition by GX. Furthermore, intrahippocampal infusion of Zn
2+
 significantly blocked 
the antiseizure activity of GX in the hippocampus kindling model of epilepsy. Zn
2+
 
selective antagonistic interactions with GX at the extrasynaptic GABA-ARs in the 
hippocampus may contribute to the blockade of GX-induced antiseizure activity by Zn
2+
; 
this drug-drug interaction provides clinical implications in the therapeutic use of GX. 
Overall, these findings are compatible with an excitability-facilitating and proconvulsant 
role of Zn
2+
 in seizure-related disorders (Cavazos et al., 1991; Buhl et al., 1996; Coulter, 
2000).   
Receptor subunit composition plays a critical role not only in neurosteroid sensitivity but 
also in Zn
2+
 inhibition on GABA-ARs (Draguhn et al., 1990; Smart et al., 1991). 
Although, in recombinant systems, Zn
2+
 inhibition on GABA-ARs exhibits similar 
sensitivity in human 432 and 43 GABA-ARs (Brown et al., 2002), Zn
2+
 
significantly shortens the decay time constant of spontaneous IPSCs as well as 
dendritically-evoked IPSCs in wildtype -rich DGGCs but not  subunit knockout 
DGGCs from hippocampus slices (Wei et al., 2003). The absence of sensitivity to Zn
2+
 
inhibition in  subunit knockout DGGCs may be due to the compensatory upregulation of 
2 subunits and thus the reduction of Zn
2+
 binding sites (Peng et al., 2002; Hosie et al., 
2003; Carver and Reddy, 2013). In the present study, we compared the sensitivity of 
GABA-induced currents and GX-potentiated GABA chloride currents to Zn
2+
 inhibition 
in native -abundant DGGCs and -sparse CA1PCs. We found increased inhibition of 
neurosteroid-potentiated GABA currents by Zn
2+
 in DGGCs compared to CA1PCs, 
displaying the selectivity of Zn
2+
 inhibition based on receptor subunit composition. In 
addition, Zn
2+
 at 30 M completely blocks GX-potentiated GABAergic chloride currents, 
similar to that of the competitive antagonist, bicuculline and gabazine. Due to its 
preferential modulation to -containing receptors, Zn
2+
 represents a potential 
noncompetitive antagonist of extrasynaptic GABA-ARs and would aid in 




In single channel studies, Zn
2+
 primarily inhibits GABA-ARs through the reduction of 
channel opening probability (Smart, 1992; Smart et al., 1994). In slice recordings, Zn
2+
 
significantly reduces phasic mIPSC event amplitude and kinetics, as well as 
desensitization kinetics (Barberis et al., 2000; Ruiz et al., 2004). However, we 
demonstrate that GX-enhanced phasic mIPSCs were unaltered by Zn
2+
. It could be that 
GX potentiation overcomes Zn
2+
 depression of synaptic receptors so that the overall 
effects of Zn
2+
 on GX-potentiated phasic currents were undetectable. However, in tonic 
current potentiation, Zn
2+
 blocks GX-potentiated tonic response concentration-
dependently in -rich DGGCs, probably due to its greater sensitivity towards -
containing receptors. Unexpectedly, Zn
2+
 prolonged the fast decay time constant 1 of 
mIPSCs in the presence of GX. One possibility might be due to the biphasic effects of 
Zn
2+
 on GABA-B receptors that tonically enhance GABA-AR currents (Turgeon and 
Albin, 1992; Khatri et. al., 2018). In addition, receptor combinations with different 
subunits respond to Zn
2+
 and neurosteroids differently. Finally, Zn
2+
 may have different 
effects on fast-closing GABA-AR subtypes (Draguhn et al., 1990; Smart et al., 1991).  
Zn
2+
 has been shown to act on multiple neurotransmission systems in the brain. In 
addition to its inhibitory effects on GABA-AR function (Smart et al., 1991;1994; 
Barberis et. al., 2000; Carver et al., 2016), Zn
2+
 also antagonizes excitatory glutamate 
NMDA receptor channels and decreases the activation and surface expression of NR2A-
contaning NMDA receptors in hippocampal neurons (Westbrook and Mayer, 1987; Vogt 
et al., 2000; Zhu et al., 2012). Additionally, Zn
2+
 enhances the activity of AMPA 
receptors (Timofeeva and Nadler, 2006) and increases glycinergic neurotransmission. 
Therefore, it is possible that the excitability-facilitating and proconvulsant role of Zn
2+
 
against GX-induced protective effects in the kindling seizure model may be resulted from 
the overall outcome of disrupted neurotransmission by Zn
2+
. Nevertheless, we have 
previously shown a critical role of extrasynaptic GABA-AR in seizure susceptibility as 
mice lacking  subunit have significantly reduced tonic currents and greater seizure 
susceptibility (Carver et al., 2014). Thus, Zn
2+




at the extrasynaptic GABA-ARs in the hippocampus may contribute to the inhibition of 





 exhibits antagonistic activity at 4- and 1-containing GABA-ARs, albeit at 
lower sensitivities than 4 subtypes (Brown et al., 2002). Specific deletion of  
subunits in 1-containing DG interneurons leads to the reduced GABAergic tonic 
inhibition and elevated firing rate of interneurons that decrease DGGC excitability and in 
vivo seizure susceptibility (Lee and Maguire, 2013). Therefore, Zn
2+
 may also contribute 
to the disinhibition of 1-containing interneurons.  
In the seizure model of hippocampal kindling, the composition and expression of GABA-
ARs in the hippocampus have been largely altered (Nishimura et al., 2005). In 
hippocampus DG, the mRNA levels of  subunit were significantly reduced with an 
increase in 2 subunits seven days after kindling completion. In CA3 pyramidal neurons, 
2 and 3 subunits were significantly upregulated after hippocampal kindling. While in 
CA1 pyramidal neurons, no significant changes of GABA-AR subunits were observed. 
As a result, the sensitivity of each cell types to Zn
2+ 
modulation may be different from 
animals without kindling, which may also involve in the Zn
2+
 antagonism of GX-induced 
seizure protection. Nevertheless, we observed the net outcome of Zn
2+
 in hippocampal 
kindling to be proconvulsant. 
Zn
2+
 increases the permeability of blood-brain barrier and proconvulsant activity in rats 
(Yorulmaz et al., 2013). Severe blood-brain barrier damage is also found in 
pentylenetetrazol-induced epileptic seizures. The Zn
2+
 level in the brain may fluctuate 
due to the contribution of peripheral Zn
2+
 that penetrates the damaged blood-brain barrier. 
Zn
2+
 concentrations are particularly high in some brain regions including hippocampus 
and amygdala, which are also the most vulnerable regions for the focal point of seizures 
(Frederickson et al., 2005). The effective concentrations of Zn
2+
 in the inhibition of GX-
potentiated tonic currents are within the levels that may occur in synaptic clefts following 
the Zn
2+






 may disrupt the neurosteroid-augmented basal inhibitory tone and hinder 
the balance of hippocampal neural circuits. In physiological condition, free zinc cations 
released from glutamatergic synapses in the hippocampus may block the inhibition of 
extrasynaptic activity of neurosteroids, hindering the antiseizure effects of neurosteroids. 
Therefore, combination therapies of neurosteroids with Zn
2+
 chelators may be potential 
avenues for the treatment of seizure-related disorders. We have attempted to examine the 
effects of Zn
2+
 chelators on the seizure activity of hippocampal kindling animals. 
However, a previous study shows that TPEN exerts notable toxic effects in in vivo animal 
studies, which was the reason these studies were not conducted further (Elsas et al., 2009). 
In Foresti et al., 2008, they used another Zn
2+
 chelator and found that pretreatment of 
Zn
2+
 chelator DEDTC (700 mg/kg) diminishes the duration of behavioral seizures and 
electrical afterdischarges, and EEG spikes, without altering seizure severity progression 
in a rat model of amygdala kindling, showing the antiseizure effects of the Zn
2+
 chelator 
(Foresti et al., 2008). Although their experiments show an antiseizure role of the zinc 
chelator, they cannot exclude the potential toxic effects of DEDTC. In their studies, they 
selected a dose that did not cause significant behavioral changes but still may be high 
enough to cause toxic effects in cellular and molecular levels since animals experienced 
severe ocular and nasal bleeding and reduced locomotor activity with the treatment of 
DEDTC. Future studies of Zn
2+
 chelators on the seizure activity are feasible when 
nontoxic Zn
2+
 chelators become available. 
The schematic diagram of the antagonistic interactions of Zn
2+
 and neurosteroids (NSs) at 
GABA-ARs is summarized in Figure 34. Neurosteroids exhibit powerful seizure 
protective effects against experimental seizures probably through the potentiation of 
synaptic and extrasynaptic GABA-AR-mediated inhibitory currents. However, Zn
2+
 
selectively hinders neurosteroid-augmented tonic inhibition but not phasic inhibition, 
which may partially contribute to the Zn
2+
 antagonism of neurosteroid-induced 
antiseizure activity. Previous studies show that Zn
2+
 blocks the frequency of mIPSCs in 
DGGCs from kindled but not controls (Buhl et al., 1996). Reduced Zn
2+
 sensitivity in 






 inhibition of GABA-AR function is also decreased in 
pilocarpine-induced status epilepticus (Banerjee et al., 1999). Overall, Zn
2+
 greatly 
contributes to the balance of neuronal excitation and inhibition in both physiological and 
pathophysiological conditions. There are many questions that remain unclear, including 
whether posttranslational modifications affect Zn
2+
 sensitivity of GABA-ARs.  
In conclusion, the present study demonstrates selective antagonistic interactions of Zn
2+ 
and GX at extrasynaptic GABA-ARs in the hippocampus. Zn
2+ 
chelation sustains the 
potentiation of tonic inhibition by GX. Furthermore, intrahippocampal infusion of Zn
2+
 
significantly blocks the antiseizure activity of GX in the mouse kindling model of 
epilepsy, indicating that Zn
2+ 
reduces the antiseizure effects of neurosteroids by selective 
blockade of extrasynaptic GABA-ARs. These pharmacodynamic interactions may have 







Figure 34 Schematic diagram of pharmacodynamic interactions of Zn
2+
 and 
neurosteroids at GABA-ARs. 
Neurosteroids exhibit powerful seizure protective effects against kindling-induced limbic 
seizures probably through the potentiation of synaptic and more preferably extrasynaptic 
GABA-AR-mediated inhibitory currents. Zn
2+
 selectively hinders neurosteroid-sensitive 
tonic inhibition but not phasic inhibition, which may partially contribute to the Zn
2+
 
antagonism of antiseizure activity of neurosteroids, including endogenous neurosteroids 





V.3 Isobolographic Analysis of Extrasynaptic GABA-AR-Mediated Tonic Inhibition 
and Anticonvulsant Activity of Neurosteroid Combinations with TG and MDZ 
The main finding of the present study is the demonstration of synergistic effects of 
neurosteroids and TG combinations in potentiating tonic inhibition in the hippocampus 
and protecting against acute seizures. This synergistic effect is likely due to a greater 
potentiation at extrasynaptic δGABA-ARs by neurosteroids through TG-induced elevated 
levels of extracellular GABA. The potential pharmacodynamic synergistic interaction 
between neurosteroids and the benzodiazepine MDZ provides better protection against 
acute seizures (Figure 35). Together, these findings provide valuable mechanistic 
rationale for synergistic therapeutic potential of neurosteroids with TG or MDZ for 







Figure 35 Molecular pathways of potential synergistic interactions between 
neurosteroids and the GABAergic drugs tiagabine or midazolam. 
GABA-ARs are pentameric GABA-gated chloride channels formed from 19 different 
subunits. Channels made from different combinations of subunits produce receptor 
subtypes with distinct functional properties. GABA-ARs are classified into two major 
groups based on their location: synaptic and extrasynaptic receptors. Synaptic (-
containing) receptors generate transient inhibitory phasic current, whereas extrasynaptic 
(-containing) receptors generate persistent inhibitory tonic currents that regulate basal 
neuronal excitability. The GABA reuptake inhibitor tiagabine-induced elevation in 
GABA levels is suggested to augment the allosteric responses of neurosteroids at synaptic 
and extrasynaptic GABA-ARs, possibly due to greater additivity of free energy for the 
open state of receptor channels. When the benzodiazepine midazolam is coadministered, 
a pharmacodynamic interaction is predicted to result in super-additive or synergism 
between neurosteroids and midazolam, possibly due to energetic additivity as they 






Neurosteroids can interact with other GABAergic drugs within the receptor milieu or at 
the receptor complex (Figure 35). The molecular mechanisms of action of neurosteroids 
on GABA neurotransmitter system include allosteric and direct agonism on GABA-ARs 
(Hosie et al., 2007). At lower nanomolar concentrations, neurosteroids bind to the 
allosteric site of GABA-ARs and potentiate the action of GABA; while at higher 
micromolar concentrations, neurosteroids can directly activate chloride channels through 
the binding of the orthosteric site. GX and AP potentiate phasic and tonic currents by 
acting at synaptic and extrasynaptic -rich receptors in DGGCs, respectively. GX and AP 
exhibit comparable allosteric and direct effects on GABA-gated chloride currents 
(Chuang and Reddy, 2018b, 2019). TG is a selective GABA transporter-1 inhibitor that 
blocks the reuptake of GABA into neurons and glial cells, resulting in the elevation of 
GABA concentration in the synaptic cleft and extracellular milieu (Czuczwar and 
Patsalos 2001). Therefore, it is predictable that combination treatment of TG and 
neurosteroids (AP or GX) exerts synergistic effects on extrasynaptic GABA-AR-
mediated tonic inhibition in dentate gyrus since the allosteric potentiating actions of 
neurosteroid on GABA-ARs were GABA dependent. It would be interesting to know if 
the combination treatment of neurosteroids and TG also synergistically potentiate 
synaptic phasic currents.  
The 6-Hz-induced partial seizure model is one of the most sensitive models for the 
evaluation of seizure protective effects of AEDs that act on GABA system (Kaminski et 
al., 2004; Reddy et al., 2015). Neurosteroids and benzodiazepines exhibit powerful 
anticonvulsant activity in the 6-Hz model. In the present study, our results show that both 
AP and GX have robust anticonvulsant effects in this model, supporting for that concept. 
Interestingly, in the combination studies, we found strong synergistic enhancement of 
anticonvulsant activity of AP when coadministered with TG. Both neurosteroids in 
combination with TG produced synergistic potentiation of tonic inhibition in the 
hippocampal dentate gyrus neurons. However, there are some striking differences 
between GX and AP. GX (ED50 = 1.46 mg/kg) exhibits higher anticonvulsant potency 




side effects than AP (Carter et al, 1997). Some pharmacodynamic differences may arise 
due to pharmacokinetic changes between GX and TG when administered simultaneously. 
Another possibility is the differences in the permeability of the drugs across the blood 
brain barrier. TG is a lipophilic agent that effectively and competitively inhibits the GAT-
1 in the brain. TG has been used in the treatment of partial seizures as an add-on drug. 
However, its utility is limited because of its adverse profile and limited spectrum of 
seizure protection. Combined treatment of neurosteroids with TG largely reduces the 
dosages of each drug, providing better therapeutic outcomes. Some previous studies have 
shown the synergistic therapeutic potentials of TG with other AEDs in other seizure 
models, including genetic epilepsy and Dravet syndrome, supporting the benefits of 
combination therapies (Luszczki and Czuczwar 2004; Madsen et al., 2009; Oakley et al., 
2013). 
The benzodiazepine MDZ is widely used for controlling acute seizures and status 
epilepticus, but it is not highly effective for delayed therapy or refractory status 
epilepticus. MDZ is an allosteric agonist of synaptic GABA-ARs through sites distinct 
from the neurosteroid binding site (Nusser et al., 1997). A previous study has shown that 
the combination of GX and MDZ exerts synergistic anxiolytic effects (Gunter et. al., 
2016). In the present study, we found that neurosteroid exerts a synergistic response with 
MDZ on GABA-ARs. The interactions between neurosteroids and MDZ on GABA-AR 
function are complex and several possible mechanisms could explain their synergistic 
effects on the antiepileptic activity. MDZ is a high-affinity, preferential positive allosteric 
agonist of synaptic -containing GABA-ARs that potentiates transient phasic IPSCs. 
Combined with low-affinity neurosteroids whose actions mainly lie on the potentiation of 
extrasynaptic -containing GABA-AR-mediated tonic currents, the overall inhibitory 
GABA neurotransmitter system in the hippocampus is strongly enhanced and thus 
contributes to greater antiseizure activity. In addition, a recent study shows a crosstalk 
between phasic and tonic inhibition in DGGCs as GABA-ARs also contribute to phasic 




MDZ also interacts with TSPO, a translocator protein that plays a crucial role in the 
synthesis of neurosteroids (Papadopoulos et al., 2006). However, MDZ at therapeutic 
dosage does not influence the level of endogenous neurosteroid AP in plasma and brain 
(Reddy et al., 2015). Therefore, it is unlikely that the synergistic effects of GX+MDZ 
stem from MDZ-induced changes in neurosteroid levels in the brain.   
The precise mechanisms underlying the synergic anticonvulsant response of 
neurosteroids are unknown. In general, the potential mechanisms underlying synergistic 
and additive effects on GABAergic tonic inhibition may result from a variety of 
pharmacodynamic effects from a combination of two drugs, including both competitive 
and noncompetitive interactions at the receptor sites (Earp et al., 2004). The recent 
analysis of GABA-AR activation by combinations of agonists acting at the same or 
distinct binding sites has led to an interesting premise for predicting the efficacy of 
GABAergic drug mixtures in combination therapy (Shin et al., 2017; 2019; Cao et al., 
2018). Coapplication of two GABAergic agents typically results in potentiation of the 
inhibitory current response. Direct activation of the GABA-AR and potentiation of 
GABA-gated receptors underlie the clinical actions of neurosteroids. The extent of 
current potentiation and thereby the in vivo anticonvulsant efficacy of a neurosteroid 
depends on the type of co-drug (indirect acting agent or direct acting allosteric agonist 
that interact with the same or different sites). Combination of two agonists acting at the 
same sites can result in potentiation due to concentration additivity based on their 
individual efficacies and concentration (Shin et al., 2019). In contrast, GABAergic drug 
combinations where the individual drugs interact with distinct sites may produce 
potentiation via energetic additivity, such as coapplication of propofol with GABA or co-
administration of alfaxolone with diazepam (Cao et al., 2018). Coapplication of two 
allosteric agonists that interact with distinct sites would result in additivity of free 
energies for the open state of receptor channels (Shin et al., 2017). Thus, neurosteroid 
combination with MDZ that interact with distinct sites may produce greater potentiation 
via energetic additivity and yield supra-additive or synergistic response, as evident from a 




synthetic neurosteroid alfaxalone enhances the GABAergic effects of etomidate (Li et al., 
2014) and diazepam (Cao et al., 2018). In the present study, we show that GX, which acts 
on the same sites as alfaxolone, exhibits synergism with MDZ on tonic current 
potentiation (Figure 32). The indirect acting agents such as TG, an orthostatic agonist, 
elevate the levels of GABA. Consequently, TG is predicted to be highly synergistic when 
combined with the neurosteroid AP (Figure 30) or GX (Figure 28) because they interact 
with distinct target sites. Such agonist combinations have significant clinical implications 
when combination therapies are desired for refractory epilepsy, pharmacoresistant status 
epilepticus, and other seizure disorders. High doses of currently used AEDs exhibit 
notable adverse effects and drug interactions. Neurosteroids provide as viable adjuncts 
for combination therapy with AEDs for both increasing seizure control and reducing 
unwanted side effects associated with high doses of AEDs.   
In conclusion, these results demonstrate robust synergistic effects of neurosteroid and TG 
combinations in potentiating tonic inhibition and protecting against acute seizures. This 
synergic efficacy is likely due to a greater allosteric agonism at extrasynaptic GABA-
ARs from TG-induced increase in GABA levels, indicating a role for tonically activated 
extrasynaptic GABA-ARs in the clinical action of AED combination regimens. These 
findings provide a mechanistic rationale for clinical potential of neurosteroid  TG 
combination for refractory epilepsy. Similarly, the synergism between GX and MDZ 
offers a viable path for their combination therapy for status epilepticus, such as the 




CHAPTER VI  
CONCLUSIONS 
Epilepsy is a chronic neurological disease characterized by repeated unprovoked seizures. 
Antiepileptic drugs (AEDs) are the mainstay for the treatment of epilepsy that affects 
nearly 65 million people worldwide. AEDs are the most effective interventions to 
suppress the occurrence of seizures; however, approximately 30% of epilepsy patients are 
unresponsive to current AEDs when used in monotherapy. Neurosteroids such as AP are 
powerful allosteric agonists of GABA-ARs and are more efficacious on extrasynaptic 
GABA-ARs that mediate tonic inhibition. There are many synthetic neurosteroids in 
trials. Synthetic GX is a robust antiseizure agent as well as a powerful allosteric 
modulator of GABA-ARs with higher bioavailability and less hormonal side effects 
compared to its prototype AP. Elucidating the mechanisms of action of GX as well as its 
interactions with other molecules at the extrasynaptic GABA-ARs and the synergistic 
therapeutic potential are of critical importance for its clinical use as an AED. This work 
investigates the mechanisms of action of GX and related neurosteroid analogs on 
extrasynaptic GABA-AR-mediated tonic inhibition and seizure protection. We also 
explore the physiological interactions between neurosteroids and zinc and the potential 
combination strategy of neurosteroids with other clinical GABAergic agents, including 
TG and MDZ. 
In studies in aim 1, we found that GX and its analogs are positive allosteric modulators 
and direct activators of both synaptic and extrasynaptic GABA-ARs in the dentate gyrus 
that regulate network tonic inhibition and seizures. The preferential potentiation of tonic 
inhibition by GX is  subunit-dependent and greatly influenced by protein kinase C 
activity. In addition, GX’s protection against hippocampus kindled seizures was 
significantly diminished in  subunit knockout mice. These results suggest that GX 
controls seizure susceptibility probably by potentiating GABA-AR-medicated synaptic 
and tonic inhibition though allosteric and/or direct action. Overall, these findings provide 




In studies in aim 2, we show that Zn
2+
 selectively blocks GX-potentiated tonic inhibition, 
but not phasic inhibition in DGGCs. Chelation of endogenous Zn
2+
 sustains the 
enhancement of tonic inhibition by GX. Furthermore, intrahippocampal infusion of Zn
2+
 
significantly blocks the seizure protective activity of GX in the hippocampus kindling 
model of epilepsy. Zn
2+
 selective antagonistic interactions with GX at the extrasynaptic 
GABA-ARs in the hippocampus may contribute to the blockade of GX-induced 
antiseizure activity by Zn
2+
; this drug-drug interaction provides clinical implications in 
the therapeutic use of GX. 
In studies in aim 3, we demonstrate strong synergistic effects of neurosteroid + TG and 
GX + MDZ combinations in potentiating tonic inhibition in DGGCs and protecting 
against acute seizures. The synergic efficacy of neurosteroid + TG is likely due to a 
greater allosteric agonism at extrasynaptic GABA-ARs from TG-induced increase in 
GABA levels, indicating a role for tonically activated extrasynaptic GABA-ARs in the 
clinical action of AED combination regimens. These findings provide a mechanistic 
rationale for therapeutic potential of neurosteroid + TG combination for refractory 
epilepsy, possibly with better efficacy and reduced side effects. Similarly, the synergism 
between GX and MDZ offers a viable path for their combination therapy for epilepsy 
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